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 The administration of pharmaceutical aerosols to infants on mechanical ventilation 
needs to be improved by increasing the efficiency of delivery devices and creating better 
ways of evaluating potential therapies.  Aerosolized medicines such as surfactants have 
been administered to ventilated infants with mixed results, but studies have shown 
improvement in respiratory function with a much lower dose than with liquid instillation 
through an endotracheal tube (ETT).  An aerosolized medicine must be transported 
through the ventilation tubing and deposit in the lungs to have the desired therapeutic 
response. 
Abstract 
 
 
 
 This work has taken a systematic approach to (i) develop new devices for the 
efficient production of small sized charged pharmaceutical aerosols, (ii) adapt a lead device 
to an infant ventilation system, (iii) develop a novel breathing infant lung (BIL) in vitro 
model capable of capturing lung delivery efficiency in an infant without the need for human 
subjects testing, and (iv) evaluate the hypothesis that small sized charged pharmaceutical 
aerosols can improve drug delivery efficiency to the lungs of a ventilated infant.  Three new 
devices were developed and screened for the efficient generation of small sized charged 
pharmaceutical aerosols, which were: wick electrospray, condensational vapor, and a 
modified vibrating mesh nebulizer in a streamlined low flow induction charger (LF-IC).   Of 
these devices, only the LF-IC produced a small [mean(SD) = 1.6(0.1) micrometers] and 
charged (1/100 Rayleigh limit) aerosol at a pharmaceutically relevant production rate 
[mean(SD) = 183(9) micrograms per minute].  The LF-IC was selected as a lead device and 
adapted for use in an infant ventilation system, which produced an increase in in vitro lung 
filter deposition efficiency from 1.3% with the commercial system to 34% under cyclic 
ventilation conditions.  The BIL model was first shown to produce a realistic pressure-
volume response curve when exposed to mechanical ventilation.  The optimized LF-IC was 
then implemented in the BIL model to demonstrate superior reduction in inspiratory 
resistance when surfactant was delivered as an aerosol compared to liquid instillation.  For 
the delivery of an aerosolized medication, the lung deposition efficiency increased from a 
mean(SD) 0.4(0.1)% when using the conventional delivery system to 21.3(2.4)% using the 
LF-IC in the BIL model, a 59-fold increase.  The charged aerosol produced by the LF-IC was 
shown to have more depositional loss in the LF-IC than an uncharged aerosol, but the 
 
 
 
charge decreased the exhaled fraction of aerosol by 17%, which needs additional study to 
achieve statistical significance.  
 Completion of this work has produced a device that can achieve lung delivery 
efficiency that is 59-fold greater than aerosols from conventional vibrating mesh nebulizers 
in invasively ventilated infants using a combination of small particle size, synchronization 
with inspiration and appropriate charge.  The BIL model produced in this work can be used 
to test clinically relevant methods of administering medications to infants and can be used 
to provide more accurate delivery estimates for development of new nebulizers and 
inhalers.  The LF-IC developed in this work could be used for controlled and efficient 
delivery of aerosolized antibiotics, steroids, non-steroidal anti-inflammatories, surfactants, 
and vasodilators. 
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The goal of this project is to improve the delivery of aerosolized medications to the 
lungs of infants receiving mechanical ventilation.  The approach taken is to use an aerosol 
that is sufficiently small to reduce deposition in the ventilation system and then enhance 
aerosol deposition within the lungs using aerosol charge.  An aerosol generator is therefore 
needed that can produce pharmaceutically relevant concentrations of highly charged 
submicrometer or sufficiently small aerosols with low device losses.  To develop an 
appropriate aerosol generation device, multiple new systems are developed and tested 
using a series of in vitro experiments.  The best performing device is then selected and 
optimized for high efficiency lung delivery.  Lung delivery of the aerosol is evaluated using 
a novel highly realistic in vitro model of a breathing infant lung connected to a clinical 
mechanical ventilation system.  Optimization of device performance is based on the 
selection of an appropriate aerosol size and charge level to maximize lung delivery, 
minimization of loss in the ventilation system, and potentially control the site of deposition 
within the lungs. 
Aerosol generation systems considered are wick electrospray (WES), condensational 
vapor (CV), and a conventional vibrating mesh nebulizer with a modified signal that is 
charged by a streamlined low flow induction charger (LF-IC).  These systems are 
constructed using 3D modeling software and further developed utilizing Computational 
Chapter 1  Specific Aims 
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Fluid Dynamics (CFD) to minimize particle loss before being constructed using rapid 
prototyping technology and evaluated experimentally.  The device development process 
will have three different particle generation options that have each been designed and 
refined before comparison and selection.   
Device implementation and optimization will involve realistic in vitro model creation 
from infant patient CT data and will result in a novel prototyped infant lung model with a 
flexible membrane that is able to reproduce in vivo lung characteristics such as inspiratory 
resistance and biophysical response to surfactant therapy.  This model can then be used to 
quantify particle deposition during respiration and allow for the optimization of the 
selected delivery device.  Upon completion of this work an optimized device will be 
available that can achieve improved lung delivery of aerosols in ventilated infants.  
Potential clinical applications include the controlled delivery of aerosolized antibiotics, 
steroids, non-steroidal anti-inflammatories, surfactants, and vasodilators. 
Objective 1: Development of an effective method for generating charged 
pharmaceutical aerosols with low depositional loss for use with invasive 
mechanical ventilation. 
The devices that currently produce charged aerosols typically do so with the 
disadvantages of high device losses, low particle charging, or the production of ozone as a 
byproduct.  These shortcomings motivate the need for a device that is able to produce a 
charged aerosol with a pharmaceutically relevant concentration of inhalable medications 
without the production and inhalation of harmful gasses like ozone. 
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The WES device is composed of a streamlined airspace that connects a counter 
electrode and a liquid reservoir containing a shaped wick submerged in a conductive 
solution at a high voltage.  The electric field causes a Taylor Cone to form at the tip of the 
wick producing a jet which breaks into highly charged droplets.  Electrospray has been 
researched extensively, and a typical setup consists of a small capillary connected to a 
syringe pump.   This capillary is held at a high voltage and a grounded target is held some 
distance away from the capillary tip.  The WES proposed utilizes a self regulating wick to 
replace the syringe pump and capillary, thereby reducing complexity and cost.  This device 
is intended for long delivery times, which is made possible by the low delivery rate that is 
common for electrospray devices.  A custom prototyped streamlined shell is used to hold 
the liquid reservoir, wick, and counter electrode while connecting to standard ventilator 
tubing. 
The CV device uses a heated capillary to vaporize a solution that is held at a high 
voltage.  Forty coils of 40 gauge electrically insulated wire are wrapped around the 30 
gauge metal needle to provide the necessary heat for change of phase.  This device has 
more components than the WES, but is able to operate with a higher aerosol output rate.  
The solution is ejected from the capillary as a vapor which condenses to form an aerosol.  
Capillary aerosol generation has previously been described; however, the CV system 
considered here is intended to form a charged aerosol. 
The LF-IC system is a commercially available AeroNeb Lab nebulizer with a 
modified driving signal to deliver one tenth of the normal aerosol mass.  A highly charged 
electrode is located below the vibrating mesh and creates a charged aerosol through 
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induction.  A streamlined shell is designed and prototyped to reduce loss in the device and 
maintain a consistent gap between the vibrating mesh and the counter electrode.  A 
controlled signal is sent to the mesh plate which has more than one thousand tapered holes 
vibrating over 128,000 times per second to produce a particular droplet production rate 
and size for a given solution.   
Each charged aerosol generation system is tested using a filter capture apparatus to 
determine the emitted dose and aerosolization rate.  Next, the particle size distribution is 
evaluated using the mini-MOUDI impactor at 2 liters per minute (LPM).  Finally, a modified 
Electrical Low-Pressure Impactor (ELPI) is used to simultaneously determine the particle 
size distribution and charge on each impactor stage at a flow rate of 30 LPM.  The best 
performing generator is then selected to be tested in an infant ventilation circuit.  Initial 
testing is done with steady flow into a filter.  The tasks that comprise objective one are 
listed below.  
Task 1.1: Develop and evaluate a wick electrospray (WES) device for generating 
charged aerosols. 
Task 1.2: Develop and evaluate a condensational vapor (CV) spray device for 
generating charged aerosols. 
Task 1.3: Develop a vibrating mesh nebulizer system (LF-IC) for generating charged 
aerosols. 
Task 1.4: Evaluate and optimize aerosol delivery through an infant ventilation 
circuit at steady state flow for the best performing charged aerosol generator. 
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Task 1.5: Evaluate the effects of cyclic ventilation on depositional loss and emission 
in the infant ventilation system. 
Objective 2: Use of charged aerosols for targeted deposition in infant 
airways. 
After a device is selected to deliver the small sized (MMAD <1.8 µm) and highly 
charged (~ 1/100 Rayleigh limit) aerosol through the infant ventilation circuit a new 
breathing infant lung model will be developed to test the airway delivery efficiency.  Infant 
CT scans will be used to reconstruct the pleural space of a 3.55 kg neonatal patient.  The 
pleural space is scaled and filled with 6mm spheres to simulate the infant alveolar region 
by the air gaps that form between the spheres.  This is connected to a previously designed 
model, Model D, of the mouth-throat down to the third airway bifurcation that has been 
scaled down to an appropriate tracheal diameter for an infant.  This model is then 
constructed using a Viper Stereolithography rapid prototyper from 3D Systems.  This 
prototyping is an additive process which cures a single layer of the computer aided design 
(CAD) model with a beam width of 0.01 inches and a layer thickness of 0.1 mm.  This model 
will first be compared to infant physiology data which documents the pressure-volume (P-
V) curve demonstrated by infant lungs.  Surfactant will then be introduced to determine the 
physiological response of the model as compared to the lungs.  Aerosolized drug will then 
be released into the ventilation circuit to determine the delivery efficiency of the selected 
generation device within this new model.  The tasks to accomplish objective two are listed 
below. 
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Task 2.1: Develop an in vitro breathing infant lung model for a full term neonate. 
Task 2.2: Evaluate targeted aerosol delivery in the breathing infant lung model. 
These tasks detail significant potential for progress in the field of aerosol therapy in 
infants.  The overarching theme of this work is to increase the understanding and 
quantification of the deposition of particulate matter in human lungs and to develop and 
compare methods of delivering therapeutic aerosols capable of improving patient 
treatment outcomes.   
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Objective 1: Development of an effective method for generating charged 
pharmaceutical aerosols with low depositional loss for use with invasive 
mechanical ventilation. 
The lungs provide a way of distributing oxygen systemically while filtering out 
particles and unwanted pollutants during respiration.  Inhaled pharmaceutical aerosols can 
be utilized to deliver medicines to the lungs (locally) or the blood (systemically) through 
the alveolar region.  For instance, asthma medication is typically administered through 
inhalation to act locally on the surface of the airways.  Systemic administration can occur 
through particle deposition in the alveolar region, which enters the blood in the capillaries 
through the alveolar epithelium (Finlay 2001).  Particles larger than 6 micrometers tend to 
deposit in the mouth-throat before they can be effective.  Particles smaller than 2 
micrometers deposit mainly in the alveolar region and provide the best systemic 
administration or are exhaled, while particles larger than 2 micrometers and smaller than 6 
micrometers are best suited to treat localized issues in the central and small airways 
(Darquenne 2012). 
The aerosol size and concentration, the patient’s breathing pattern and clinical 
disorder, the delivery device and correct usage of the device all contribute to the 
distribution of deposition within the lungs and the efficacy of an inhaled therapy (Cole 
Chapter 2  Background  
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2000).  In addition, the charge of an aerosol effects the distribution of deposition and 
reduces the exhaled fraction of particles (Bailey 1997; Bailey et al., 1998; Balachandran et 
al., 1997).  Highly charged pharmaceutical aerosols with a mass median aerodynamic 
diameter (MMAD) of 3-7 µm have high mouth-throat deposition (Azhdarzadeh et al., 
2014a; Azhdarzadeh et al., 2014b) as measured by in vitro methods.    Using in vivo 
methods, lung deposition has been greatly increased with particle charging, suggesting that 
the submicron (MMAD <1 µm)  particle sizes used imply the electrostatic effects on 
deposition are primarily within the alveolar region (Melandri et al., 1983).  High drug 
losses and high deposition variability have likely caused potentially effective medications 
to not be effective and ultimately fail clinical trials, such that they never reached patients. 
(Armangil et al., 2011; Berggren et al., 2000; Cole et al., 1999; Fink 2004; Mazela and Polin 
2011; Shah et al., 2007; Sood et al., 2004).   As a result, poor delivery efficiency is a hurdle 
to new pharmaceutical drug development.  Current aerosolized agents such as 
bronchodilators, antibiotics and surfactants need to be implemented with optimized 
delivery systems (Mazela and Polin 2011).  The goal of this work is to increase the 
efficiency of therapeutic delivery to enable superior treatment and new pharmaceutical 
drug development through the use of targeted delivery. 
Based on the study of Longest et al. (2014b), aerosols with MMADs ≤ 1.8 µm are 
expected to efficiently penetrate the infant ventilation system.  Initial estimates, calculated 
from non-dimensional quantities set forth by Finlay (2001), indicate that aerosols with a 
charge in the range of the Raleigh limit / 100 will not have significantly increased 
deposition in the large (relative to infant airways) diameter ventilation system connectors 
and will have improved retention in the lungs due to the image attraction force and 
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reduced velocities and airway diameters within the alveolar region.  Three new devices are 
developed and prototyped for in vitro aerosol characterization.  Aerosol performance 
testing is evaluated in terms of the delivered dose (and reproducibility), aerosol droplet 
size distribution (DSD), and net charge per particle.  Based on this analysis, the best 
performing device is implemented in an infant ventilation system under steady state and 
cyclic flow conditions. The purpose of this objective is to design and develop a new device 
for generating small charged particles that are suitable to maximize respiratory drug 
delivery in ventilated infants with realistically low tidal volumes.   
Task 1.1: Develop and evaluate a wick electrospray (WES) device for generating 
charged aerosols. 
Many devices currently exist which produce charged micrometer and 
submicrometer aerosols.  Corona charging is used to charge aerosols that have been 
generated from a variety of methods (Hinds 1999); however, ozone from both positive and 
negative corona makes this method incompatible with respiratory drug delivery.  
Electrospray is a thoroughly documented method for generating particles with high charge 
(Chen et al., 1995; de Juan and De la Mora 1997).  The output mass of electrospray is 
typically low compared with the needs of pharmaceutical delivery unless special 
techniques such as multiple nozzles or the use of liquid sheets are applied (Lee et al., 2011; 
Park et al., 2011).  It is not known if the highly charged aerosol associated with 
electrospray will be detrimental to the lung.  The aerosol generated by an electrospray 
device is typically discharged (Ijsebaert et al., 2001), but the corona needle used for charge 
neutralization is associated with ozone formation (Hinds 1999), which makes them 
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impractical for use in an inhaler.  Highly charged electrosprayed particles are associated 
with high device losses if they are not discharged (Fu et al., 2011). 
The development of electrospraying goes back more than one hundred years as John 
Zeleny published multiple works on the production of fine droplets from a conical 
meniscus resulting from the interaction of an electric stress on a fluid (Zeleny 1914; Zeleny 
1915; Zeleny 1917).  About fifty years later, Sir Geoffrey Taylor established the theoretical 
groundwork backed by precise experimentation, which allowed for photo documentation 
of jet formation from the tip of an oscillating conical surface near the calculated equilibrium 
of 49.3 degrees (1964).  This structure is now called a Taylor cone.  The Taylor cone spray 
regimes reviewed by Cloupeau and Prunet-Foch (1994) are still incompletely understood, 
but the most understood regime is the cone-jet mode.  In this simple and useful mode, a 
spray of charged droplets issues out of a steady jet which is emitted from the Taylor cone 
apex (de la Mora 2007).  This mode has also been used with a carbon dioxide sheath flow to 
overcome the electrical breakdown and sparking through the air and achieve electrospray 
with a sucrose solution in pure water (Chen et al., 1995).   
Noakes et al. (1998) patented the first electrospray inhaler, however, Tang and 
Gomez (1994) improved upon this design by using carbon dioxide instead of air to 
surround the capillary tip and enable spray of high surface tension liquids without electric 
breakdown and sparking.  Even though there are many academic efforts and patents, there 
are currently no commercially viable inhalation products which are electrospray based 
(Yurteri et al., 2010).  The studies of Ijsebaert et al. (2001) and Bacon et al. (2009) both 
included a needle corona discharger in their electrospray setup to neutralize the charge 
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and allow for particle penetration in the lungs.  These dischargers, unfortunately, also 
produce ozone which has been seen to cause irritation in the airways, especially of 
diseased patients (Koren et al., 1989; Stenfors et al., 2002).  
Reduction of electrospray system complexity has been achieved by removing the 
syringe pump or micro-controller.  Electrospray-based air purifiers have been built using 
small polymer wicks in place of the metal capillary to transfer charge from the charged 
spray to contaminated airstreams and act as an ozone-free precipitator (Tepper and 
Kessick 2008; Tepper et al., 2007).  In the study of Hu et al. (2011) various samples were 
analyzed using wooden tips (toothpicks) in place of capillaries to obtain the mass spectra.  
An electrospray was also formed using a paper triangle that wicks a small volume of 
solution (Liu et al., 2010).  These substitutions provided a less complicated electrospray 
system which was disposable and self regulating.  Maintaining a stable electrospray with 
solutions containing a high water content is difficult; a 25% solution of methanol in water 
was not able to produce a stable Taylor cone due to the rate of flow through the porous 
material, which is governed by the solution properties (Chiarot et al., 2012).  The use of 
chromatography paper with tips cut at increasing angles has demonstrated a continuous 
increase in ion current for increasing angle, but a significant increase in electrospray onset 
voltage from sixty degrees to ninety degrees (Yang et al., 2012).  An expected outcome of 
Task 1.1 is a testable electrospray device and a determination as to whether this aerosol 
generation method should be used to deliver a charged aerosol to a ventilated infant. 
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Task 1.2: Develop and evaluate a condensational vapor (CV) spray device for 
generating charged aerosols. 
Condensational vapor (CV) generators operate by boiling and vaporizing a pumped 
liquid vehicle and ejecting this hot vapor into a cooler gas, in which it condenses to form an 
aerosol.  An example of this design was patented by Howell and Sweeney (1998).  The 
formation of particles by homogeneous nucleation is affected by the turbulent mixing that 
occurs in the interface between the hot vapor jet and the cooler gas stream (Lesniewski 
and Friedlander 1995).  Elucidating the aerosol formation within turbulent gas jets from 
homogeneous nucleation, the study of Lesniewski and Friedlander (1998) demonstrated 
the dependence of the modality of an aerosol on the vapor mole fraction and location of 
nucleation.  CV is often referred to as CAG in the literature, and while not typically 
associated with charged aerosols, a capillary aerosol generation (CAG) is known to produce 
high fractions of submicrometer aerosols.   
The historically complex and limited CAG was simplified and expanded to generate 
stable and monodisperse aerosols with a particle size between 0.1 and 2 micrometers and a 
number concentration between 104 and 106 cm-3 over the course of several hours (Tu 
1982).  The usefulness of the CAG was expanded by investigating the heating voltage, 
vehicle water content, and solute concentration in an optimization process which produced 
a mean aerodynamically sized diameter of 0.54 +/- 0.05 micrometers and established its 
pharmaceutical use (Hindle et al., 1998).  Control of output MMAD has been demonstrated 
by controlling initial aerosol characteristics and increasing the spacer chamber holding 
time and residual volume for a CAG with direct heating of the 28-gauge stainless steel 
capillary (Hong et al., 2002).  Further control of output size was demonstrated on the PG 
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vehicle by considering the optimal thermal energy required to vaporize the formulation 
without overheating (Shen et al., 2004).  The capabilities of the CAG were further expanded 
to be able to operate with ethanol/water formulations instead of propylene glycol and it 
was also shown that the formulation could be used to control particle size (Hindle et al., 
2004).  A computational fluid dynamic (CFD) approach of simulating the multi-scale, 
multiphase numerical model allowed designers of CAG to optimize considering turbulent 
mixing and dispersion near the capillary tip (Longest et al., 2007).   
The CV process pumps a solution containing dissolved drug through a heated 
capillary producing a vapor or vapor and droplet spray, which exits a nozzle at high 
pressure and velocity (Hindle 2004; Hindle et al., 2004; Shen et al., 2004).  Condensation in 
the vicinity of the nozzle produces an aerosol with properties that depend on the 
evaporating/condensing vehicle and delivery rate.  The CV approach was later considered 
in a series of studies to better understand the underlying physics and optimize operation in 
an inhaler (Hindle and Longest 2013; Longest and Hindle 2009; Longest et al., 2007).  One 
aim of this task is to test the hypothesis that applying a high voltage to a capillary will set 
up a radial gradient with zero potential at the center of the capillary resulting in charging 
or modification of the physics of formation during vaporization.  As result of the 
completion of Task 1.2, a testable CV device will be used to determine whether this aerosol 
generation device can be used to deliver a charged aerosol to a ventilated infant in the 
current configuration. 
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Task 1.3: Develop a vibrating mesh nebulizer system (LF-IC) for generating charged 
aerosols. 
A voltage source held near a conducting object polarizes it and can induce a charge 
on it when polarized charges are not allowed to leave the object.  As opposed to many other 
methods of charging, induction charging is capable of operation without being exposed to 
the flow.  Highly tunable induction charging was developed in a vibrating orifice aerosol 
generator (VOAG) and allowed for control over the particle charge by the induction voltage 
applied (Reischl et al., 1977).  Both conducting and poorly conducting solutions 
demonstrated linear charging to a level above the field and diffusion limit, but below the 
Rayleigh limit.   Reischl’s induction charger was implemented and the elementary charges 
corresponded to the applied induction voltage linearly (Vehring et al., 1997).  The 
frequency of the VOAG was also considered at various voltages and it was shown that 
particle charge changes considerably for minor changes in frequency (Vehring et al., 1997).  
Instead of a VOAG, a collision nebulizer was used with an induction charger to carry 
biological and non-biological particles at elevated charges with the result that conductive 
non-biological particles carried charge at a much lower induction voltage (Mainelis et al., 
2002). 
Vibrating mesh nebulizers typically produce aerosols with MMADs in the size range 
of 2-6 µm (Dhand 2002), but a new mixer-heater device was developed to evaporate 
aerosol from a vibrating mesh nebulizer and produce high concentrations of 
submicrometer pharmaceutical aerosols suitable for direct inhalation(Longest et al., 2012; 
2013c).  Loss within the mixer-heater system was <10% and production of submicrometer 
aerosols required significant heating of the flow stream at the nebulizer's commercially 
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available output rate(Longest et al., 2012; 2013c).  The low flow-induction charger (LF-IC) 
was based on the same commercially available vibrating mesh nebulizer, the Aeroneb Lab, 
and used the same principle of evaporation to reduce the droplet size and add water 
content to the ventilated patient.  The nebulizer was positioned in the streamlined 
perforated T-connector (SLpT) design previously developed for high flow (Longest et al., 
2013b).  An initial design of the LF-IC has recently been developed at Virginia 
Commonwealth University to create a high flow (30 – 90 LPM) induction charger using a 
vibrating mesh nebulizer in a novel streamlined device (Golshahi et al., 2015), but the 
dimensions and operating flow rate of this device are different than the LF-IC.   
The expected outcome of Task 1.3 is the production of a third device that is capable 
of generating an aerosol for delivery to an infant patient with low flow rates (about 5 LPM).  
This device will be compared with those developed in Task 1.1 - Task 1.2 and the device 
that is able to produce the most mass with a charge of approximately 1/100th of the 
Rayleigh limit and a MMAD of approximately 1.8 μm will be chosen for further 
development and testing in an infant ventilation circuit.  
Task 1.4: Evaluate and optimize aerosol delivery through an infant ventilation 
circuit at steady state flow for the best performing charged aerosol generator. 
Infants receiving mechanical ventilation can frequently benefit from pharmaceutical 
aerosols with the goal of improving lung function while minimizing systemic exposure of 
the medication and associated side effects (Fink 2004; Mazela and Polin 2011; Rubin and 
Fink 2001).  However, the delivery of aerosolized medication to infants is a significant 
challenge with lung delivery efficiencies reported in the range of <1-14% (Dubus et al., 
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2005; Fink 2004; Fok et al., 1996; Mazela and Polin 2011; Sidler-Moix et al., 2013).  
Impediments to effective aerosol delivery include small diameter connective ventilator 
tubing, small tidal volumes, short inhalation periods (Fink 2004; Rubin and Fink 2001), and 
ventilation components that are designed for gas delivery and not aerosol administration 
(Longest et al., 2014a; Longest et al., 2014b).  Low delivery efficiency wastes valuable 
medications and makes the administration of high dose drugs very challenging.  
Furthermore, low delivery efficiency is typically associated with high variability in the 
delivered dose, which makes the use of medications with a narrow therapeutic window 
difficult.  Both low delivery efficiency and high variability are implicated as reasons for the 
clinical failure of some aerosolized medications delivered to infants (Mazela and Polin 
2011; Shah et al., 2007).  Improved dose delivery is needed for ventilated infants in order 
to maximize the clinical benefit of existing medications and to help develop new inhaled 
therapies (Brion et al., 2006; Cole et al., 1999; Fink 2004; Rubin and Williams 2014; Shah et 
al., 2007). 
Several recent studies have proposed strategies for improving pharmaceutical 
aerosol delivery to ventilated infants.  The use of vibrating mesh nebulizers and 
synchronization of nebulization with inhalation was reported to deliver approximately 12-
14% of the aerosolized dose in a macaque animal model of ventilated infants (Dubus et al., 
2005).  The study of Mazela et al. (2014) introduces a newly designed Y-connector, referred 
to as the VC connector (also known as Afectair), that separates nebulizer and ventilation 
gas bias flows thereby improving the lung delivery efficiency of a jet nebulizer when used 
with infants.  Using ventilation parameters for a premature infant, the delivery efficiency at 
a filter before an endotracheal tube (ETT) was approximately 1% or less with a commercial 
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Y-connector and increased to approximately 7% with the VC connector (Mazela et al., 
2014).  In the study of Longest et al. (2014b), optimal aerosol delivery conditions were 
evaluated for a newborn full-term infant receiving mechanical ventilation through an ETT 
using in vitro, CFD, and whole-lung modeling techniques and the predicted lung deposition 
fraction was found to range from 6.8-13.5%, which was similar to the in vivo animal model 
predictions of Dubus et al. (2005) with a lung deposition fraction range of 12.6-14%.  
Aerosol deposition in infant lungs was then optimized in the study of Longest et al. (2014b) 
for mesh nebulized aerosols with the use of a new streamlined (SL) Y-connector, delivery 
of the aerosol during only a portion of inspiration, and selection of optimal droplet sizes.  
The study of Longest and Tian (2015) evaluated the delivery of a submicrometer excipient 
enhanced growth (EEG) aerosol in a port on top of a new streamlined Y-connector.  With 
appropriate timing of delivery, a maximum tracheobronchial deposition fraction of 56% 
was achieved and a method of growing an initially small dry powder aerosol was 
demonstrated (Longest and Tian 2015).  
A new strategy to target the deposition of pharmaceutical aerosols within the lungs 
of ventilated infants is the use of small charged droplets generated from an initial solution 
or suspension liquid formulation.  In this approach, the droplet size is sufficiently small to 
allow for effective penetration through the delivery system and upper infant airways 
without significant depositional drug loss, which likely requires an aerosol mass median 
aerodynamic diameter (MMAD) of approximately 1.8 µm or less (Longest et al., 2014b).  As 
described in the study of Longest et al. (2014b), exhalation of the aerosol dose is a 
significant problem with ventilated infants.  To reduce the exhalation of large dose 
fractions, charge on the pharmaceutical aerosol will foster deposition within the lung 
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airways and potentially allow for targeting the site of delivery.  An optimal level of charge is 
required to minimize deposition in the delivery system or extrathoracic airways, where 
velocities are relatively high, and then maximize deposition in the tracheobronchial and/or 
alveolar airspace.  While a number of studies in adults have considered the use of aerosol 
charge to target deposition in the lungs (Bailey 1997; Bailey et al., 1998; Balachandran et 
al., 1997; Chan et al., 1978), previous studies have not applied this approach to infants and 
have not attempted to use initially small particles to minimize extrathoracic or ventilation 
system deposition.  Additionally, the run time will be varied to examine the effect of static 
charge accumulation on electrically insulated components under steady-state flow 
conditions.   
The expected outcomes of Task 1.4 include the measured deposition fraction in the 
ventilation system through the 3 mm endotracheal tube, the impact of runtime on charged 
aerosol delivery, and the comparison of LF-IC device efficiency in streamlined components 
as compared to the commercial mesh nebulizer in commercial components. 
Task 1.5: Evaluate the effects of cyclic ventilation on depositional loss and emission 
in the infant ventilation system. 
The extent to which poor delivery efficiency of aerosolized medicines limits 
treatment options for ventilated infants has been highlighted in Task 1.4.  Increasing the 
lung delivery efficiency of pharmaceutical aerosols creates opportunities for improved 
clinical effects of existing medications and will likely expand the number of aerosol 
therapies available for infants.  Aerosol delivery during mechanical ventilation is 
considered less efficient compared with spontaneously breathing delivery as highlighted in 
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the study of MacIntyre et al. (1985), who clinically demonstrated 2% nominal lung 
deposition in intubated adult subjects on mechanical ventilation and 12% in non-intubated 
adult subjects using a nebulizer which generated an aerosol with a mass median 
aerodynamic diameter between 1 and 5 µm.  In this study, seven patients over the age of 49 
with various reasons for being connected to mechanical ventilation received aerosolized 
treatment through a 7 mm endotracheal tube (ETT), while 3 healthy volunteers received 
aerosolized treatment through a mouthpiece (Macintyre et al., 1985).  Transport of aerosol 
through gas delivery tubing, connection components and patient interface device is a 
significant challenge during mechanical ventilation because ventilation components are 
typically designed for gas delivery and not aerosol administration (Longest et al., 2014a; 
Longest et al., 2014b).  In addition to this, the nebulizer type, nebulizer location within the 
ventilation circuit, gas flow, and mode of nebulizer operation are important considerations 
for increasing aerosol delivery efficiency during mechanical ventilation (Fink and Ari 
2013). 
During mechanical ventilation in infants, aerosol delivery efficiencies in the range of 
<1-14% are common, even considering more recent vibrating mesh nebulizer devices 
(Dubus et al., 2005; Fink 2004; Fok et al., 1996; Mazela and Polin 2011; Sidler-Moix et al., 
2013) .  Using a jet nebulizer in an in vitro model of a ventilated premature infant, with a 
new connector to separate nebulizer and ventilation gas bias flow, Mazela et al. (2014) 
increased albuterol sulfate delivery efficiency from 1% or less through the commercial Y-
connector to a maximum of approximately 7% with the improved connector, before the 
ETT or mask.  Additional aerosol losses are known to occur in the infant ETT, which can 
have an internal diameter as small as 2.5 mm.  A new streamlined Y-connector was 
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implemented with synchronized delivery and reduced droplet sizes (~ 1.8 µm) to optimize 
aerosol deposition in the infant lungs using in vitro, whole lung, and CFD modeling (Longest 
et al., 2014b).  For a full term (3.6 kg) infant and 3 mm ETT, maximum total lung delivery 
efficiency of a polydisperse aerosol with a mass median aerodynamic diameter (MMAD) of 
1.78 µm reached 45.2%.   
In Task 1.5, depositional losses in a commercial infant ventilation circuit are 
determined using a commercial mesh nebulizer and the previously determined (Task 1.3) 
best performing charger design, the low-flow induction-charger (LF-IC).  The ventilation 
circuit is driven by a cyclic air-flow provided by an infant ventilator and the estimated lung 
delivered dose is collected on a filter at the end of a curved 3 mm (ID) ETT and quantified 
using a validated HPLC method.  The drug remaining in the nebulizer, LF-IC, Y-connector, 
and a 3 mm ETT are collected and compared to the lung delivered dose.  The performance 
of the delivery system is also quantified in terms of time as the delivery rate of drug to the 
lung.  The reduced mass output of the LF-IC compared to a commercial nebulizer is 
expected to have a lower drug delivery rate to the lung, but the increased efficiency is 
intended to minimize drug waste and reduce intersubject variability in cases where 
adequate delivery times are available, as with mechanical ventilation.  The LF-IC is 
designed to target the deposition of pharmaceutical aerosols in ventilated infants by 
reducing the particle size to penetrate the delivery system with the addition of an induced 
charge on the droplets to foster lung deposition and reduce exhalation of the inhaled dose 
(Task 1.3).  An aerosol mass median aerodynamic diameter that is smaller than typically 
delivered, i.e., approximately 1.8 µm or less, is necessary to reduce depositional loss in the 
delivery system at typical flow rates used with a neonate (Longest et al., 2014b).   The LF-IC 
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is redesigned to minimize device volume for use with cyclic flow conditions and to allow 
for the inclusion of a ventilator flow meter in the ventilator circuit, a new common feature 
in mechanical ventilation systems that has not adequately been considered in previous 
studies.  This redesigned LF-IC also incorporates a breath actuated nebulizer to increase 
delivery of aerosolized drug to the patient and reduce the exhaled dose.   
The purpose of Task 1.5 is to compare the performance of the previously developed 
LF-IC with a commercially available nebulizer in an infant ventilation circuit under cyclic 
flow conditions.  The LF-IC and commercial device performances are evaluated by the 
quantification of model drug mass using HPLC in the following system components: 
exhalation filter, in-line  ventilator flow meter, ventilator components (commercial or 
streamlined Y-connector), nebulizer and connectors (Aeroneb Lab, commercial T-
connector, LF-IC), endotracheal tube, and lung filter. 
Objective 2: Use of charged aerosols for targeted deposition in infant 
airways 
Efficient delivery of pharmaceutical aerosols to infants has not been achieved due to 
high variability and low pulmonary deposition, resulting in unclear clinical results (Longest 
and Tian 2014).  In vitro models have been used to represent infant patients, but none of 
these models simulate realistic exhalation of aerosol (Fink 2004).  Considering an in vitro-
in vivo parallel study with two jet nebulizers, a smaller initial MMAD was more efficient in 
vitro, but that did not lead to improved delivery to the patient in vivo (Watterberg et al., 
1991). Comparing a metered dose inhaler and an ultrasonic nebulizer, a neonatal test lung 
was used to obtain delivery results that were similar to the simultaneously obtained 
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clinical delivery results for intubated infants (Grigg et al., 1992).  Both of these studies 
highlight the benefits and difficulty of using an in vitro model to predict device losses and 
patient delivery before conducting an in vivo study and perfectly motivate the creation of a 
superior model for testing device, drug, or delivery methods in pre-clinical studies.   
Task 2.1: Develop an in vitro breathing infant lung model for a full term neonate. 
In vitro experiments are important to establish parameters for the safe delivery of 
aerosol therapies before commencing in vivo studies (Byron et al., 2010; Carrigy et al., 
2014; Martin and Finlay 2014).  For instance, in the study of Finer et al. (2010), an in vitro 
infant model was used to determine the maximum possible delivered dose using a 
vibrating mesh nebulizer and a 2% synthetic surfactant solution, assuming that none of the 
aerosol that reached the patient was exhaled.  These types of studies provide exposure 
limits for protecting patients during in vivo studies but are not representative of the actual 
dose delivered to the lung because they do not currently account for drug exhalation and 
often do not include realistic upper airway anatomies and breathing physiology.  In vitro 
testing of mean, small, and large models of the mouth and upper airways has been used to 
produce an in vitro-in vivo correlation to predict in vivo aerosol drug deposition using an in 
vitro test method for dry powder inhalers (Delvadia et al., 2013; Delvadia et al., 2012).  
However, most in vitro models do not account for the drug distribution within the lungs.  It 
is well known that drug distribution within the lungs can have a significant impact on 
therapeutic benefit (Usmani et al., 2003). 
Healthy lungs expand evenly due to work done by the diaphragm to increase volume 
in the chest cage, resulting in inhalation.  After inhalation, the diaphragm relaxes and the 
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pressure returns to its original value, causing the lungs to contract in an elastic manner 
thereby driving exhalation and a  return to a resting volume (Drake et al., 2005).  At the end 
of inspiration or expiration in a healthy patient there is no airflow and the intrapleural 
pressure does not reflect forces associated with airflow, only the elastic recoil forces (West 
2012).  Compliance is a metric of the lung’s elastic recoil and is measured as the change in 
volume per unit change in pressure across the lung.  If the compliance of the lungs was only 
due to elastic tissue forces, it would be graphed on a pressure vs. volume plot as a single 
straight line connecting maximum and minimum lung volume points.  However, airway 
resistance and changes in surface tension cause the volume response to an applied 
pressure to deviate from a linear relationship during inhalation vs. exhalation.  In this 
chapter, the Pressure-Volume (P-V) graph was used to determine realistic response of the 
BIL model to mechanical ventilation because it is known that patient inhalation will deviate 
from a linear compliance due to the pressure needed for gas flow through narrow resistive 
airways (Walsh and DiBlasi 2010).  The pressure difference between the alveoli and the 
mouth divided by the airflow is defined as the airway resistance and the area under the 
linear compliance line but bounded by the P-V curve is the work required to overcome 
airway and tissue resistance (West 2012).   
In healthy individuals, the lungs are able to control the surface tension of the 
alveolar region by adjusting the amount of surfactant present on the surface.  Patients with 
insufficient surfactant have alveoli that tend to collapse during normal tidal breathing, 
frequently leading to respiratory failure if not treated with surfactant replacement therapy 
(Willson 2015).  In a multicenter randomized trial, dramatic oxygenation improvement 
occurred within 5 minutes, mortality decreased from 51% to 31%, and the mean time 
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patients were on mechanical ventilation was 35% less with instilled surfactant therapy 
(Collaborative European Multicenter Study 1988).  According to the American Academy of 
Pediatrics, “…the optimal method of surfactant administration in preterm infants has yet to 
be clearly proven” and additional data is needed to recommend a method such as 
aerosolized surfactant delivery (Polin et al., 2014).  Considering non-invasive aerosol 
delivery of synthetic lung surfactant in rabbits, surfactant deficiency was effectively 
relieved, but large portions of the surfactant were not nebulized and more than 40% of the 
aerosolized surfactant was lost in the ventilation circuit (Walther et al., 2014). 
The upper tracheobronchial airways of the breathing infant lung (BIL) model were 
scaled from a previously constructed adult mouth-throat model (Walenga et al., 2013) and 
digitally joined to a new model of the infant pleural space before being prototyped.  Model 
D extends from the mouth through three generations of bifurcating geometries and was 
constructed from a single CT scan that was consistent with mean airway dimensions of 
adults (Walenga et al., 2013).  An average infant height of 50 cm was used with the 
morphological correlation from Phalen (1985) to determine a mean (SD) infant outlet 
diameter of generation three as 2.59 (0.37) mm, which was used to scale model D.  
Ventilation parameters for a 3.55 kg infant were selected from Walsh & DiBlasi (2010), 
which represents 50th percentile conditions at full term delivery.   The chosen functional 
residual capacity (the amount of air left in the lung after exhalation) was based on the 
youngest ICRP (1994) model, a 3 month old Caucasian infant.  The pleural cavity was 
modeled from a CT scan of an infant, prototyped, and filled with plastic spheres having a 
diameter of 6 mm.  The characteristic diameter of the smallest possible gap between three 
adjacent spheres was 1.36 mm and provided an initial approximation of the expected 
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alveolar airway outer diameter of 0.54 mm (Khajeh-Hosseini-Dalasm and Longest 2014).  
The expected surfactant pool (amount of surfactant) in healthy lungs is approximately 4 
mg/kg (Rebello et al., 1996).  However, it is known that a small amount of surfactant (0.5 
mg lipid/kg) delivered to the lungs via aerosol can have a large impact on physiological 
response in surfactant deficient airways (Lewis et al., 1993). 
Common methods of surfactant delivery include liquid bolus administration 
(referred to as instillation of single or multi-dose), continuous infusion (or continuous 
instilation), and aerosolization.  Special consideration needs to be given to the patient to 
prevent transient oxygen desaturation and severe airway obstruction which have been 
seen more frequently in extreme low birth weight infants with more severe lung disease 
when surfactants are instilled (Tarawneh et al., 2012).  The instillation process involves the 
insertion of an endotracheal tube, which carries a number of risks, pouring between 1.25 
ml/kg and 5.8 ml/kg (Polin et al., 2014) of surfactant solutions down the endotracheal tube 
into the patient’s lungs (or approximately 4 ml), and application of mechanical ventilation, 
which is also associated with lung injury and infection risks.  Instillation of surfactant in 
infants has caused airway obstruction immediately following administration in multiple 
studies (Miedema et al., 2011; Wheeler et al., 2009).  Although instillation is currently the 
only approved method for surfactant administration it requires an artificial airway and 
some positive pressure ventilation, which may be harmful to any  patient, especially infants 
(Willson 2015). 
In Task 2.1, inspiratory resistance and compliance were determined in the 
breathing infant lung (BIL) model across three methods of surfactant administration: 
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instilled, commercial, and modified-charged.  A low flow-induction charger, capable of 
delivering a charged aerosol with a mass median aerodynamic diameter (MMAD) < 1.8 µm 
(Golshahi et al., 2015; Holbrook et al., 2015), was developed and characterized in Task 1.3.  
The LF-IC was redesigned in Task 1.5 to utilize a lower charging voltage, a smaller device 
volume, breath synchronized delivery, and relocation of the nebulizer proximal the patient.  
These changes allowed for implementation in an infant ventilation circuit under cyclic 
ventilation and provided an in vitro inhaled dose for “commercial” (CM) and “modified and 
charged” (M-C) delivery.  The maximum efficiencies and delivery rates from Task 1.5 only 
measure the drug mass inhaled and do not measure the fraction exhaled, as is widely done 
in the literature (Dhand 2008; Fink and Ari 2013; Fink 2004; Guerin et al., 2008).  Results 
from Tasks 1.3 – 1.5 are used to estimate the fraction delivered to the newly developed BIL 
model and provide standard methods and protocols to be used in Task 2.2 and future 
studies.  
In general, aerosolized delivery of medication to infants and adults suffers from high 
variability and low delivery efficiency (Brion et al., 2006; Cole et al., 1999; Fink 2004; Rubin 
and Williams 2014; Shah et al., 2007).  Considering instilled and aerosolized delivery of 
surfactant to rats with acute lung injury, a highly inefficient device delivered a dose at least 
4-fold lower than the instilled dose (100 mg/kg) to produce an equivalent increase is 
oxygenation and decrease in breath rate (Sun et al., 2009).  New technologies provide an 
opportunity to efficiently deliver aerosolized surfactant with a low total administered dose 
and enhanced homogeneity of distribution (Pillow and Minocchieri 2012).  The 
improvement of lung function with minimal systemic exposure can be accomplished by 
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administering pharmaceutical aerosols to infants receiving mechanical ventilation (Fink 
2004; Mazela and Polin 2011; Rubin and Fink 2001).   
The purpose of Task 2.1 was to develop a BIL model that will respond in 
physiologically consistent ways and capture both deposited and exhaled dose in future 
studies.  Conventional and modified aerosol delivery techniques with a vibrating mesh 
nebulizer were considered and compared against an instilled surfactant case.  After 
creating a realistic BIL model that is capable of distinguishing between three surfactant 
administration methods, the BIL model is suggested for use with the developed LF-IC from 
Task 1.5 to deliver a model drug such as albuterol sulfate to determine the exhaled fraction 
and the delivery rate to the lung, which is evaluated in Task 2.2.  In vitro testing of the BIL 
model is developed to enable testing of next generation medications, increase the efficiency 
of current inhaled therapies, and test surfactant administration techniques.   
Task 2.2: Evaluate targeted aerosol delivery in the breathing infant lung model. 
Inertia, gravity, diffusion, interception, and electrostatic forces cause particles to 
deposit in the lung airways (Hinds 1999).  Each of these forces presents a potential 
opportunity to target deposition in the airways, but the focus of this work is on deposition 
enhancement by electrostatic forces. Electrostatics affect deposition by the space charge 
effect and an image attraction force with a conducting surface; the space charge effect is a 
repulsion of similarly charged particles within an aerosol that causes better dispersion and 
the image force is an attractive force to the lung wall (Koolpiruck et al., 2004).  Since the 
wall of the airway is lined with electrically conductive mucus, a charged particle nearing 
the wall will experience an attractive force that increases by a power of two as the distance 
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to the wall decreases.  Deposition due to electrostatic forces is therefore extremely 
important in the alveolar region where the distance to the wall is small (Kwok and Chan 
2009). 
Charged aerosols have been shown to have the potential for controlling deposition, 
particularly in reducing the exhaled fraction of particles (Bailey 1997; Bailey et al., 1998; 
Balachandran et al., 1997).  Highly charged pharmaceutical aerosols have high mouth-
throat deposition when the particle size is large (3-7 micrometers)(Azhdarzadeh et al., 
2014a; Azhdarzadeh et al., 2014b).    Melandri found that the charge on inhaled particles 
greatly increased deposition in vivo and suggested that the submicron particle sizes used in 
his study imply the electrostatic effects on deposition are primarily within the alveolar 
region(Melandri et al., 1983).   The impact that particle charging has on lung deposition of 
particles is unclear; the polarity and magnitude of the charge still need to be considered in 
future human subjects testing(Wong et al., 2013). 
The BIL model designed and constructed for Task 2.1 was evaluated with the 
modified and charged delivery system of Task 1.5 to determine the amount of drug 
delivered to and retained in the lungs.  Development of aerosol delivery protocols often 
relies on in vitro studies to determine the mass of drug delivered to the lung.  However, 
these in vitro studies are not able to account for the reduction in lung deposition caused by 
exhalation.  In vitro models over estimate the dose to a patient because they use an 
absolute filter which cannot simulate drug loss due to exhalation (Dhand 2008; Fink and 
Ari 2013; Fink 2004; Guerin et al., 2008), as was applied in Task 1.5.  For example, a novel 
connector has been developed to bypass the bias-flow and increase delivery of a jet 
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nebulized aerosol, but the improvement was measured before the ETT, without an inline 
flow meter, and not considering exhalation (Mazela et al., 2014).  Large particles are often 
filtered out by ventilation circuitry such that the aerosol MMAD after an infant ventilation 
circuit and a 3 mm ETT was measured as 1.4 µm for a vibrating mesh and a jet nebulizer 
which generated aerosols with MMADs of 4.6 and 4.8 µm, respectively (Dubus et al., 2005).  
Inefficient delivery and exhalation of inhaled aerosol therapy has been addressed by 
reducing aerosol MMAD to < 1.8 µm, as suggested by Longest et al. (2014b), and inducing a 
charge on the aerosol to increase deposition in the lung (Holbrook et al., 2015).   
In Task 2.2, depositional losses and delivery efficiency were determined in the BIL 
model using the same techniques described in Task 1.5.  A modified signal was supplied to 
a vibrating mesh nebulizer to reduce the output rate and initial momentum of the 
generated aerosol (described in Task 1.3 – Task 1.5).  This modified output was sprayed 
into a streamlined induction charger that has been previously optimized (Task 1.5) to 
deliver aerosol efficiently under cyclic ventilation conditions in an infant ventilation circuit.  
The experiments of Task 1.5 demonstrated a 26-fold increase in delivery efficiency, but a 
reduction in the rate of delivered mass to the inhalation filter. The systems designed and 
implemented in Task 1.3 – Task 1.5 will be applied to a test case of aerosolized albuterol 
sulfate (a model drug commonly used as a bronchodilator) to determine the impact of 
charging on the exhalation of an aerosol < 1.8 µm (MMAD) and test the ability of the BIL 
model to simulate the exhalation of inhaled aerosol.  The lung deposition in this study is 
expected to be lower than the filter data collected in Task 1.5 (34%), but the difference 
between the commercial system and the modified and charged delivery system is expected 
to be greater than the 26-fold increase demonstrated in Task 1.5. 
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An in vitro model of an infant capable of realistically capturing the lung dose of an 
administered pharmaceutical aerosol under actual ventilation conditions would clearly be 
a beneficial tool for testing inhaled therapies with expensive drugs or significant side 
effects.  Development of inhaled therapies for infants has been hindered by low delivery 
efficiency (high waste) and high variability (uncontrolled dose) (Mazela and Polin 2011; 
Shah et al., 2007).  Surfactants are very expensive, steroids need low variability because of 
adverse side effects, and antibiotics need to be delivered in high and consistent doses to 
prevent bacteria from surviving (Lehne and Rosenthal 2014).  Bronchodilators such as 
albuterol sulfate (AS) are typically inexpensive, have low side effects, and don't require a 
large dose.  AS was selected as a marker to determine the depositional loss and delivery 
efficiency of the LF-IC in the novel BIL model.  Implementation of the BIL model in Task 2.2 
will quantify the depositional reduction due to aerosol exhalation using an in vitro 
experiment. 
The purpose of Task 2.2 was to compare the performance of the previously 
implemented LF-IC with a commercially available nebulizer under realistic flow conditions 
in a BIL model (Task 2.1) designed to capture both deposited and exhaled dose.  
Conventional and modified aerosol delivery techniques with a vibrating mesh nebulizer 
were considered and suggestions are given for method of administration.  The expected 
outcome of Task 2.2 is an in vitro method of testing lung deposition of aerosol therapy 
without assuming perfect capture within the lungs as compared to Task 1.5. 
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Preface: This chapter has been published as a research article in Journal of Aerosol Science, 
October 2015, Vol. 88, 35-47. 
Abstract.  The delivery of pharmaceutical aerosols to infants receiving mechanical 
ventilation is extremely challenging due to small diameter flow passages, low tidal 
volumes, and frequent exhalation of the aerosol.  The use of small charged particles is 
proposed as a novel method to prevent deposition in ventilator components and foster 
deposition in the lower infant airways.  The objective of this study was to compare the 
performance of multiple new devices for generating small charged particles that are 
expected to maximize respiratory drug delivery in ventilated infants.  Criteria used to select 
a leading device included production of a charged aerosol with a mass median aerodynamic 
diameter (MMAD) ≤ approximately 1.8 µm; low device depositional loss of the aerosol 
(<20%); particle charge in the range of the Rayleigh limit/100; and high drug output with 
low performance variability.  Proposed new devices were a wick electrospray (WES) 
system with accelerated cross-flow air; a condensational vapor (CV) system with a charged 
solution and strong field gradient; and a low flow - induction charger (LF-IC) designed to 
operate with a modified commercial mesh nebulizer.  Based on infant ventilation 
conditions, flow rates through the devices were in a range of 2-5 L/min and the devices 
were assessed in terms of depositional drug loss and emitted drug mass; droplet size 
Chapter 3 Generating Charged Pharmaceutical Aerosols 
Intended to Improve Targeted Drug Delivery in Ventilated 
Infants 
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distribution (DSD) using a Mini-MOUDI; and DSD and net charge with a modified ELPI.  
Considering the WES, primary limitations were (i) low and variable aerosol production 
rates and (ii) high device depositional losses.  The CV device produced a high quality 
aerosol with a MMAD of 0.14 µm and a drug delivery rate of 25 µg/min.  However, the 
device was excluded because it failed to produce a charged aerosol.  In contrast, the LF-IC 
produced a 1.6 µm aerosol with high net charge, low device depositional loss (<15% based 
on recovery), and low variability.  In the ELPI size fraction bin nearest the MMAD, the LF-IC 
produced >100 elementary charges per particle, which was an order of magnitude increase 
compared to the case of zero charging voltage.  In conclusion, the LF-IC was selected as a 
leading system that is expected to improve aerosol delivery efficiency in ventilated infants 
through the use of small charged particles. 
3.1 Introduction 
Infants receiving mechanical ventilation can frequently benefit from pharmaceutical 
aerosols with the goal of improving lung function while minimizing systemic exposure of 
the medication and associated side effects (Fink 2004; Mazela and Polin 2011; Rubin and 
Fink 2001).  However, the delivery of aerosolized medication to infants is a significant 
challenge with lung delivery efficiencies reported in the range of <1-14% (Dubus et al., 
2005; Fink 2004; Fok et al., 1996; Mazela and Polin 2011; Sidler-Moix et al., 2013).  
Impediments to effective aerosol delivery include small diameter connective ventilator 
tubing, small tidal volumes, short inhalation periods (Fink 2004; Rubin and Fink 2001), and 
ventilation components that are designed for gas delivery and not aerosol administration 
(Longest et al., 2014a; Longest et al., 2014b).  Low delivery efficiency wastes valuable 
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medications and makes the administration of high dose drugs very challenging.  For 
example, surfactant delivery with a mesh nebulizer was reported in one study to require a 
3 hour period for the administration of a 72 mg dose (Finer et al., 2010).  Furthermore, low 
delivery efficiency is typically associated with high variability in the delivered dose, which 
makes the use of medications with a narrow therapeutic window difficult.  Both low 
delivery efficiency and high variability are implicated as reasons for the clinical failure of 
some aerosolized medications delivered to infants (Mazela and Polin 2011; Shah et al., 
2007).  Improved dose delivery is needed for ventilated infants in order to maximize the 
clinical benefit of existing medications and to help develop new inhaled therapies (Brion et 
al., 2006; Cole et al., 1999; Fink 2004; Rubin and Williams 2014; Shah et al., 2007). 
Several recent studies have proposed strategies for improving pharmaceutical 
aerosol delivery to ventilated infants.  The use of vibrating mesh nebulizers and 
synchronization of nebulization with inhalation was reported to deliver approximately 12-
14% of the aerosolized dose in a macaque animal model of ventilated infants (Dubus et al., 
2005).  Mazela et al. (2014) describes a newly designed Y-connector, referred to as the VC 
connector (also known as Afectair), that separates nebulizer and ventilation gas bias flows 
thereby improving the lung delivery efficiency of a jet nebulizer when used with infants.  
Based on an in vitro model of ventilated premature infants, Mazela et al. (2014) reported 
delivery efficiency at the exit of a commercial Y-connector to be approximately 1% or less 
vs. a maximum of approximately 7% with the VC connector.  In a previous study, Longest et 
al. (2014b) evaluated optimal aerosol delivery conditions for a newborn full-term infant 
receiving mechanical ventilation through an endotracheal tube (ETT) using in vitro, CFD, 
and whole-lung modeling techniques.  With a mesh nebulizer, commercial Y-connector, and 
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a 3 mm ETT, the predicted lung deposition fraction was found to range from 6.8-13.5%, 
which was similar to the in vivo animal model predictions of Dubus et al. (2005) with a lung 
deposition fraction range of 12.6-14%.  Aerosol deposition in infant lungs was then 
optimized by Longest et al. (2014b) for mesh nebulized aerosols with the use of a new 
streamlined (SL) Y-connector, delivery of the aerosol during only a portion of inspiration, 
and selection of optimal droplet sizes.  The study of Longest and Tian (2015) evaluated the 
delivery of a submicrometer excipient enhanced growth (EEG) aerosol in a port on top of a 
new streamlined Y-connector.  With appropriate timing of delivery, a maximum 
tracheobronchial deposition fraction of 56% was achieved and a method of growing an 
initially small dry powder aerosol was demonstrated. 
A new strategy to target the deposition of pharmaceutical aerosols within the lungs 
of ventilated infants is the use of small charged droplets generated from an initial solution 
or suspension liquid formulation.  In this approach, the droplet size is sufficiently small to 
allow for effective penetration through the delivery system and upper infant airways 
without significant depositional drug loss, which likely requires an aerosol mass median 
aerodynamic diameter (MMAD) of approximately 1.8 µm or less (Longest et al., 2014b).  As 
described by Longest et al. (2014b), exhalation of the aerosol dose is a significant problem 
with ventilated infants.  To prevent the exhalation of large dose fractions, charge on the 
pharmaceutical aerosol will foster deposition within the lung airways and potentially allow 
for targeting the site of delivery.  An optimal level of charge is required to minimize 
deposition in the delivery system or extrathoracic airways, where velocities are relatively 
high, and then maximize deposition in the tracheobronchial and/or alveolar airspace.  The 
ability to tune the charge level is an important design factor of the delivery technology.  
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While a number of studies in adults have considered the use of aerosol charge to target 
deposition in the lungs (Bailey 1997; Bailey et al., 1998; Balachandran et al., 1997; Chan et 
al., 1978), previous studies have not applied this approach to infants and have not 
attempted to use initially small particles to minimize extrathoracic or ventilation system 
deposition. 
A number of devices are available for the production of charged micrometer and 
submicrometer aerosols.  Corona charging is frequently used to provide high charge to 
existing aerosols (Hinds 1999); however, ozone from both positive and negative corona 
makes this method incompatible with respiratory drug delivery.  Electrospray is a well 
known method to generate particles with high charge (Chen et al., 1995; de Juan and De la 
Mora 1997).  However, output mass is typically low compared with the needs of 
pharmaceutical delivery unless advanced techniques such as the use of liquid sheets or 
multiple nozzles are applied (Lee et al., 2011; Park et al., 2011).  Furthermore, it is not 
known if the high charges associated with electrospray aerosols will be detrimental to 
efficient lung delivery.  The use of corona needles for electrospray discharge (Ijsebaert et 
al., 2001) is associated with ozone formation (Hinds 1999), making them impractical for 
use in inhalers.  Vibrating orifice charged particle generators are limited by very low mass 
output (Azhdarzadeh et al., 2014a; Azhdarzadeh et al., 2014b; Reischl et al., 1977). 
While not typically associated with charged aerosols, devices known to produce high 
doses of submicrometer aerosols are capillary aerosol generation (CAG) and vibrating 
mesh nebulizers coupled with evaporation-type devices.  The CAG process pumps a 
solution containing dissolved drug through a heated capillary producing a vapor or vapor 
and droplet spray, which exits a nozzle at high pressure and velocity (Hindle 2004; Hindle 
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et al., 2004; Shen et al., 2004).  Condensation in the vicinity of the nozzle produces an 
aerosol with properties that depend on the evaporating/condensing vehicle and delivery 
rate.  The CAG approach was later considered in a series of studies to better understand the 
underlying physics and optimize operation in an inhaler (Hindle and Longest 2013; 
Longest and Hindle 2009; Longest et al., 2007). 
Vibrating mesh nebulizers typically produce aerosols with MMADs in the size range 
of 2-6 µm (Dhand 2002).  Longest et al. (2012; 2013c) demonstrated the use of a new 
mixer-heater device to evaporate these aerosols and produce high concentrations of 
submicrometer pharmaceutical aerosols suitable for direct inhalation.  Loss within the 
mixer-heater system was <10% and production of submicrometer aerosols required 
significant heating of the flow stream at the nebulizer's commercially available output rate. 
A recent advance of electrospray aerosols is the introduction of inexpensive and 
disposable spray elements to feed the liquid solution and produce the Taylor cone (Tepper 
and Kessick 2008; Tepper and Kessick 2009; Tepper et al., 2007).  Electrosprays have been 
produced with polymer wicks, toothpicks, and shaped paper  (Hu et al., 2011; Liu et al., 
2010; Tepper and Kessick 2009; Yang et al., 2012).  An advantage of this approach is the 
replacement of the expensive spray pump control unit with a self-feeding and disposable 
unit.  Considering condensational aerosols, Ouyang (1995) has previously demonstrated 
the production of charged condensational aerosols with the addition of high voltage 
charging. 
The objective of this study is to compare the performance of multiple new devices 
for generating small charged particles delivered at flows that are that are suitable to 
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maximize respiratory drug delivery in ventilated infants.  Evaluation criteria of the devices 
include: 
1. Production of a charged aerosol with a MMAD ≤ approximately 1.8 µm; 
2. Low device depositional loss of the aerosol (< 20%); 
3. Net Particle charge in the range of the Rayleigh limit / 100; and 
4. High drug output ( >10 µg)  with low performance variability (<10% 
coefficient of variation for emitted dose). 
Based on the study of Longest et al. (2014b), aerosols with MMADs ≤ 1.8 µm are expected 
to efficiently penetrate the infant ventilation system.  Initial estimates, calculated from non-
dimensional quantities set forth by Finlay (2001), indicate that aerosols with a charge in 
the range of the Raleigh limit / 100 will not have significantly increased deposition in the 
large diameter ventilation system connectors and will have improved retention in the lungs 
due to the image attraction force and reduced velocities and airway diameters within the 
alveolar region.  Furthermore, high drug output is required for the delivery of high dose 
medications like inhaled surfactants and antibiotics.  Three new devices are developed and 
prototyped for in vitro aerosol characterization.  Aerosol performance testing is evaluated 
in terms of the delivered dose (and reproducibility), aerosol droplet size distribution 
(DSD), and net charge per particle.  Based on this analysis, the best performing device is 
selected for future study in terms of emitted dose from an infant ventilation system and 
infant lung delivery. 
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3.2 Methods 
3.2.1 Overview of Devices 
In this study, three new devices for the production of charged small (≤1.8 µm) 
pharmaceutical aerosols are developed and compared.  Each device begins with an existing 
aerosol generation platform and includes significant modifications in order to attain the 
desired aerosol characteristics.  Each of the devices is operated at air flow rates consistent 
with infant ventilation conditions (2-5 LPM) to deliver aerosol out of the device. The first 
device implements the paper wick electrospray platform (Figure 3.1a), which has the 
advantages of low cost and no moving parts.  However, low aerosol emission is expected 
due to the high charging field.  Modifications include the addition of a narrow flow channel 
intended to accelerate the cross-flow air and remove the aerosol from the electrical field 
region prior to deposition on the charged electrode.  The second device employs the CAG 
approach and is termed the condensational vapor (CV) device (Figure 3.1b).  In this 
method, a drug solution is pumped through a heated capillary to produce a vapor.  Nearly 
complete vaporization of the solution is used to eliminate the need for a nozzle at the 
capillary tip, which may reduce the potential for device clogging.  A high voltage charge is 
also applied to the capillary, which is electrically isolated from the heating element.  The 
space inside the metal capillary represents a region of high field gradient with zero field 
strength at the center of the capillary in the evaporation zone.  This high field gradient is 
expected to potentially charge the evaporating liquid filaments and droplets.  It was not 
known if this potential charge would influence the evaporation or condensation processes 
and potentially produce a charged aerosol, as with the condensational vapor strategy of 
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Ouyang et al. (1995).  Modifying the size of a recovered condensational aerosol or 
producing a charged aerosol by charging the base solution was seen as a potentially 
advantageous development.  Finally, a commercial mesh nebulizer (Aeroneb Lab; Aerogen, 
Galway, Ireland) was employed as a convenient aerosol source in the low flow - induction 
charger (LF-IC; Figure 3.1c).  Modifications included altering the vibration amplitude to 
reduce liquid output, thereby enabling evaporation to near submicrometer size at the low 
flow rates required for infant ventilation, and including a charged electrode positioned 
below the mesh to charge the aerosol by induction charging.  Other studies have used 
induction charging with single orifice plates (Azhdarzadeh et al., 2014a; Azhdarzadeh et al., 
2014b), but the application of induction charging to a vibrating mesh system with low 
airflow is a new advancement.  Further details in device development and experimental 
testing methods for these new systems are described in the following sections.  
A schematic of the three experimental setups that were employed to generate 
albuterol sulfate (Spectrum Chemicals, New Brunswick, NJ; model drug commonly used as 
a bronchodilator) aerosols is provided in Figure 3.2.  To quantify performance, options 
considered for each system were assessing aerosol depositional drug loss in the device, 
collection of the emitted drug mass on an aerosol filter, determination of aerosol droplet 
size distribution (DSD) with the Mini-MOUDI (MSP Corp., Shoreview, MN) at a flow of 2 
LPM, and determination of net charge on separate aerosol size fraction bins and DSD with a 
modified electrical low pressure impactor (ELPI; Dekati, Finland) at a flow rate of 30 LPM.  
Separate flow rates were required by the Mini-MOUDI and ELPI based on internal 
3.2.2 Overview of test systems 
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calibrations by the respective manufacturers.  Sampling at 2 LPM provides for an accurate 
view of the aerosol DSD emitted from the device because makeup air is not required.  In 
contrast, sampling at 30 LPM will result in some evaporation of aerosol droplets; however, 
the ELPI device allows for quantification of the net aerosol charge within 12 different 
aerosol size fraction bins.  In a bipolar aerosol, the ELPI measures the net charge of the 
combined positive and negative charges for a given size bin.  Selection of an appropriate 
series of tests depended in part on operation of the individual devices. 
Both the WES and LF-IC contain internal flow passages such that depositional drug 
loss was evaluated.  In these experiments, the device was operated for a specified amount 
of time and then disassembled.  Device components were washed in distilled deionized 
water.  Drug mass recovered was quantified using a previously validated High Performance 
Liquid Chromatography (HPLC) method for albuterol sulfate (AS).  Device deposition was 
not assessed for the CV system (only delivered dose was determined) because an enclosure 
housing was not constructed.  This was because, as described later, this device was not 
selected for future study and an enclosure system was not required.   
Delivered dose testing was conducted by operating the device at its specified flow 
rate and collecting the delivered dose on a high-efficiency respiratory filter (Pulmoguard II; 
Quest Medical, Brockton, MA).  An airflow of 10 LPM was maintained through the filter 
using a vacuum pump.  HPLC analysis was again used to determine the drug mass delivered 
to the filter.  If the filter drug mass was below a typical infant drug delivery mass (10 µg for 
albuterol sulfate) or had a coefficient of variation greater than 10% , then the device was 
considered not to be a viable option and testing with additional methods was not pursued.   
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Impactor measurements consisted of employing either the Mini-MOUDI or modified 
ELPI at the manufacturer specified flow rates of 2 or 30 LPM, respectively.  The aerosol 
generation devices operated in a flow rate range of 2-5 LPM.  During sampling of the 
aerosol, room-condition makeup air was used to satisfy the various flow rate requirements 
of the generation devices and impactors.  The Mini-MOUDI was implemented as received 
from the manufacturer and drug mass on each stage was determined by washing with 
deionized water before HPLC analysis quantified AS recovery.  The ELPI was operated in a 
modified mode as described by Kotian et al. (2009) in order to determine both aerosol size 
and net charge.  In this approach, the corona charger of the ELPI was removed.  Drug mass 
deposition on individual stages was determined by HPLC analysis and used to determine 
the DSD at 30 LPM.  The electrical reading of each stage was used to determine the net 
aerosol charge within each respective size fraction bin.  Further details of these testing 
methods describing how they were applied to each aerosol generation system are provided 
in the following sections. 
Table 3.1 provides a comparison of device parameters selected for the performance 
characterization experiments.  Considering the number of possible variables with three 
charged aerosol generation systems, device optimization can be a daunting task.  To 
address this issue, preliminary screening experiments were conducted to guide parameter 
selection and maximize device performance.  As a result, the devices selected for 
comparison and the parameters defined in Table 3.1 represent the end product of a large 
amount of preliminary optimization work.  For example, the minimum stable operating 
voltage for an electrospray was found to be 6 kV with the WES system.  In contrast, the LF-
IC system was found to effectively emit charged aerosols with a charging voltage of 1 kV.  
 
 
42 
The CV system was limited to 1 kV applied voltage due to the dielectric material coating the 
heating wire breaking down at higher voltages.  Aerosolization rates in Table 3.1 report 
liquid volume emitted from each system determined by weighing the devices before and 
after use.  Due to the low aerosolization rate of the WES (µL/hour), compared with the CV 
and LF-IC (mL/hour), the drug concentration in the WES device was increased to 5%w/v, 
which resulted in a highly conductive solution and enhanced electrospray performance.  In 
contrast, producing small aerosols with CV and LF-IC require using <1% w/v solution 
concentration.  WES was enhanced with a surfactant (0.02% w/v poloxamer 188 (Leutrol 
F68) donated from BASF Corporation, Florham Park, NJ) to reduce surface tension of the 
solution, whereas NaCl (Sigma Chemical Company, St. Louis, MO) was used as a charging 
excipient in the CV and LF-IC devices.  Finally, typical inhalation waveforms used with full 
term neonates have a mean tracheal flow rate of approximately 2-5 LPM (Walsh and 
DiBlasi 2010).  The lower end of this range was found to generate a sufficiently small 
aerosol with the WES and CV systems.  In contrast, a combination of 5 LPM flow and 
modification of the nebulizer output signal were important to produce a near 
submicrometer aerosol with the LF-IC device, as described further in Section 2.5. 
The WES device was composed of a streamlined airspace that connects a grounded 
electrode and a liquid reservoir containing a triangular tipped paper wick submerged in 
the drug solution at a high voltage, as seen in Figure 3.1a.  In the device, the grounded 
electrode is positioned above the paper wick.  The paper wick is made of Whatman Grade 
3MM Cellulose Chromatography Paper cut to a width of 5 mm, a length of 15 mm and a 60 
3.2.3 Wick electrospray (WES) 
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degree angle tip was formed to emit the electrospray.  Air flows over the top of the wick, 
perpendicular to the direction of the electrical field and aerosol spray.  The intent of this 
design was to create a highly charged aerosol via electrospray and then remove the aerosol 
from the electrostatic field using a crossing airflow before the droplets deposit on the 
grounded electrode.  The distance between the paper wick tip and the grounded electrode 
was a constant 3 mm.  Filtered air was connected to the inlet of the WES shell and regulated 
to flow at 2 LPM as confirmed upstream by an inline flow meter.   
The formulation drug solution used was 5%w/v AS and 0.2% w/v Poloxamer 188 in 
distilled water as shown in Table 3.1.  Poloxamer 188 is a surfactant that was added to 
reduce the surface tension of the solution and improve spraying.  The solution was 
sonicated for at least thirty minutes to ensure complete dissolution.  The solution was then 
pipetted into the WES reservoir to the maximum fill line of 400 microliters after the wick 
was inserted vertically with the sharp tip oriented toward the grounded electrode.   
A high voltage power supply (CZE1000R; Spellman High Voltage Electronics 
Corporation, Hauppauge, NY, USA) operating in negative mode was connected to the wick 
reservoir, while the ground of the power supply was connected to the electrode.  The high 
voltage power supply can be limited by either current or voltage.  To operate in current 
limiting mode, the voltage limit was set to a value higher than the measured voltage.  The 
current limit was set to 3 microamperes and slowly decreased to 0.6 microamperes to 
maintain the desired operating current with an appropriate voltage.  An electrical resistor 
was used in series with the grounded electrode to determine the functionality of the device 
and the mode of electrospray achieved.  Voltage across this resistor was recorded once per 
second for each experiment using a digital multimeter (Fluke Corporation, Everett, WA) 
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with data-logging software.  The voltage across the resistor was observed during the run to 
determine the electrospray current and operating mode of the system.  After the one hour 
run time was completed, the high voltage power supply was discharged by turning off the 
power supply and then connecting the high voltage lead to ground. 
For assessing device drug deposition and drug delivery, a 30 cm length of 10 mm 
(diameter) ventilator tubing was connected to the WES device. The aerosol generated at a 
flow rate of 2 LPM was collected on a Pulmoguard II filter that was positioned at the outlet 
of the tubing.  An airflow of 10 LPM airflow was maintained through the filter using a 
vacuum pump.  The increased filter flow rate was used to ensure complete entrainment 
and capture of the aerosol exiting the tubing.   
Performance of the electrospray system was assessed by quantifying the drug 
deposition in each relevant component of Figure 3.2a.  To determine drug deposition in the 
WES system, the counter electrode, tubing and filter were all washed in deionized water 
and the AS concentrations of the resulting solutions determined by a validated HPLC 
method.  Recovered drug mass was determined by multiplication of AS concentration by 
the dilution volume. In order to determine the percentage AS recovery, known volumes of 
the formulation solution were also diluted to accurately quantify the concentration of the 
formulation.  
The CV device was expected to function similar to CAG with an aqueous drug 
solution formulation (Longest et al., 2007) but with differences of (i) increased energy per 
volume of solution to achieve near full vaporization, (ii) use of a straight tip capillary, and 
3.2.4 Condensational Vapor (CV) 
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(iii) charging of the solution prior to vaporization and condensation.  Increased energy 
input was intended to fully vaporize the solution and form a more consistent nano-scale 
condensational aerosol.  Drug molecules are expected to be contained in hydrated ion 
clusters or un-evaporated nano-droplets. By providing sufficient energy to vaporize the 
solution, the capillary nozzle can be eliminated, which was a source of significant spray 
momentum (Longest et al., 2008) and potentially system clogging and malfunction.  
Charging the solution is expected to create a charged aerosol or charged evaporated 
droplets during the vaporization process through conduction charging (Zhao et al., 2005).  
In the vicinity of vaporization, high charge is expected on the walls of the capillary and fluid 
phase with zero charge in the vaporized core.  The gradient between the charged and 
unchanged regions during liquid boiling-breakup was expected to create charged discrete 
droplet elements.  The evaporation of these charged droplets could then produce charged 
ions.  Both the presence of charge and generated ions could influence the evaporation and 
condensation processes altering the final aerosol size and/or producing charged 
condensational droplets. 
Control of the capillary temperature was adjusted and monitored using electrically 
insulated heating wire and a thermocouple.  40 gauge (0.0031 inch) NiCr heating wire with 
DuPont’s heavy polymide 240C enamel insulation was obtained from WireTronic Inc. 
(Volcano, CA).  The wire was wrapped around the capillary approximately 35 times to form 
the heating element, as shown in Figure 3.1b.  The resistance of this heating wire was 
measured before and after each experiment and replaced when it was not between 10 – 20 
ohms.  A thermocouple temperature probe was placed on the capillary approximately 1 cm 
away from the tip to measure the capillary wall temperature.  A DC power supply 
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(HY3005F-3, Mastech, San Jose, CA) provided approximately 1.5 Watts to the 40 gauge 
heating wire to obtain heating that varied the capillary temperature (1 cm from the tip) 
between 100 and 160 oC. Control experiments were also performed in the absence of 
charging to determine the effect on both DSD and net particle charge.  
The formulation drug solution used in the CV system was 0.25% w/v AS and 
0.25%w/v  NaCl in distilled water as shown in Table 3.1.  The solution was sonicated for at 
least thirty minutes to ensure complete dissolution.  0.7 mL of solution was loaded into a 1 
mL syringe and connected to the heated capillary.  A syringe pump (NE – 300, New Era 
Pump Systems Inc. Farmingdale, NY) was used to pump the solution to the heated capillary 
at a constant flow rate of 0.6 mL/hour.  The loaded syringe was inverted, tapped, and 
depressed to ensure there were no air bubbles in the syringe before each experiment.   
The DSD was determined for the CV device using the Mini-MOUDI impactor for a 20 
minute run. A vacuum pump provided the pressure drop needed to sample 2 LPM through 
the Mini-MOUDI impactor (Figure 3.2b).  A flow meter was attached to the inlet of the 
impactor prior to aerosol generation to verify 2 LPM through the Mini-MOUDI and 
removed before generating an aerosol.  Potential losses were minimized by spraying 
directly from the heated capillary to the impactor inlet to avoid deposition in connecting 
tubing. 
The DSD and net particle charge were determined simultaneously using the ELPI at 
30 LPM for a 20 minute sample time.  The aerosol was sprayed directly into a streamlined 
connector (Figure 3.3 ) attached to the inlet of the ELPI.  A downstream vacuum pump was 
used to draw 30 LPM of room-condition air containing the aerosol through the impactor.  
 
 
47 
Drug aerosol deposition was recovered by washing the inlet and each stage of the impactor 
and quantified using a validated HPLC technique. 
With the ELPI, electrometer current data was collected for each of the 12 stages and 
recorded to a .CSV file using Dekati software.  Using the midpoint method, this data was 
then numerically integrated with respect to time to give the net charge collected per stage.  
The HPLC-determined drug mass per stage was used with the midpoint diameter between 
the corresponding stages’ cut sizes to determine the number of particles depositing on each 
stage. The net stage charge was then divided by the total number of particles per stage to 
determine the average number of charges per particle. 
3.2.5 Low flow-induction charger (LF-IC) 
The LF-IC was based on the commercially available Aeroneb Lab vibrating mesh 
nebulizer.  The nebulizer was positioned in the streamlined perforated T-connector (SLpT) 
design previously developed by Longest et al. (2013b) as shown in Figure 3.1c.  This 
connector was shown to reduce depositional loss by a factor of 4.5x compared with the 
commercial design of the T-connector.  Two modifications of this system include adjusting 
the driving signal of the mesh nebulizer and the addition of a charged electrode.  As 
described below, the driving signal of the mesh nebulizer was adjusted to reduce the mass 
output by a factor of 10x in order to allow for evaporation of the aerosol.  The desired 
target was evaporation to a 1.8 µm MMAD with 5 LPM of gas flow.  The charged electrode 
was positioned below the mesh on the opposite side of the SLpT (distance of 47.6 mm) to 
produce a charged aerosol by induction charging at an applied voltage of 1 kV.  Induction 
charging with a vibrating orifice generator was previously described by Reischl et al. 
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(1977) and implemented by Azhdarzadeh et al. (2014a; 2014b).  Our group (Golshahi et al., 
2015) has recently developed an induction charger with a mesh nebulizer that operates at 
high flow rates (30-90 LPM).  This study is the first to report the functioning of a low flow 
(5LPM) induction charger system with a mesh nebulizer.  Use of the mesh provides a 
substantial increase in output compared with vibrating single orifice devices, such that 
pharmaceutically relevant doses of medication can be delivered. 
One tenth of the aerosol output by mass with the Aeroneb Lab nebulizer was 
achieved by reducing the amplitude of the applied sinusoidal driving voltage while 
maintaining the commercial frequency of 128.2 kHz.  A Rigol DG10220 function waveform 
generator (Beaverton, OR) produced the desired signal and was amplified using a TS200 
modulated power supply from Accel Instruments (Irvine, CA).  This signal was 
continuously monitored using a Tektronix TDS 210 oscilloscope (Beaverton, OR).  This 
reduced output should enable adequate drying at 5 LPM as opposed to the study of 
Golshahi et al. (2015), where a flow rate of 90 LPM was required to dry the aerosol.  5 LPM 
of filtered air was directed through the LF-IC, drying and entraining the charged aerosol 
before it was exposed to atmospheric pressure and directed to a collection filter or an 
impactor. Control experiments were also performed in the absence of charging using 0 kV 
to determine the effect on both DSD and net particle charge. 
Dose variability and device deposition were determined directly from the impactor 
studies.  In all cases, the device was operated for 5 minutes.  To determine device 
deposition, the system was disassembled after the aerosol generation time period and 
components were washed with deionized water.  As with the previous systems, drug mass 
was determined with a validated HPLC method. 
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The nominal dose of each run was calculated by determining the mass of 
formulation nebulized.  After each run, the inner wall of the nebulizer was wiped before 
being weighed and subtracted from the initial mass of the nebulizer.  A solution density of 1 
g/cm3 was assumed and the difference between the measured masses was multiplied by 
the formulation AS concentration to calculate the nominal mass of AS that was aerosolized. 
To determine the DSD from the LF-IC, 2 LPM of the 5 LPM airstream from the LF-IC 
was sampled into the Mini-MOUDI.  A streamlined connector used for sampling the 5 LPM 
flow stream and providing 2 LPM to the impactor is displayed in Figure 3.3 a.  This 
connector interfaces with the SLpT, the Mini-MOUDI, and a Pulmoguard II filter that was 
used to capture excess flow.  Mass of drug on the connector, inlet, and each stage of the 
impactor was determined using washings and HPLC analysis.   
To calculate charge per particle, the ELPI was again employed as with the CV device.  
The 5 LPM airstream from the LF-IC was directed into the streamlined connector added to 
the ELPI (Figure 3.3 b), which also pulled in 25 LPM of makeup room-condition air based 
on operation of a downstream vacuum pump.  Current measurement data was recorded 
using the ELPI’s electrometers and software for 30 seconds prior to aerosol generation.  
The nebulizer and the induction charger were turned on simultaneously.  After the run the 
current data was recorded for 30 seconds beyond when the generator was turned off.  For 
each experiment, the generator and charger were both operated for 5 minutes.  The 
collected current data was processed as with the CV device.  Only the current that was 
collected during the generation/charging time was included in the calculation of charge per 
particle. 
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Droplet particle sizing with the ELPI was expected to report smaller droplet size 
compared with the Mini-MOUDI due to particle evaporation at a higher airflow rate.  
However, evaporation is not expected to alter the charging profile.  It is assumed that 
droplets do not evaporate beyond a critical Rayleigh limit, which would cause breakup due 
to electrostatic effects.  Measured net charge on the droplets can then be used to 
approximate charge on the aerosol exiting the LF-IC device at 5 LPM. 
3.3 Results 
3.3.1 Wick electrospray 
The WES emitted mass results captured on the filter showed high variability and 
high device losses within a group of four replicate experiments.  As shown in Table 3.2, the 
WES device aerosolized a mean of about 27 µg of drug in the 1 hour period, of which about 
12 µg was deposited on the device and this was associated with high variability (coefficient 
of variation = 106%). Device deposition ranged from approximately 1 to 25 µg of drug. 
Similar variability was observed for the emitted dose (109%) with the mean emitted dose 
of 15 ug in 1 hr. This variability was too great considering that the system needs to provide 
safe, reproducible, and reliable drug delivery.  Also, the mean delivery rate of 15 µg per 
hour to the filter was a hindrance to further development because it is lower than typical 
electrospray systems with micropump controllers and the system was observed to not be 
stable over the long delivery times that would be necessary for pharmaceutical use.  The 
measured current provided by the electrospray was observed to decrease over time, which 
indicated a change in spray mode.  The paper wick was also observed to be physically 
damaged after approximately 20 minutes of spraying.  This was likely because of high 
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temperatures associated with corona effects at the sharp wick tip as well as spraying 
fragments of paper.  As a result of these observations, the WES approach was determined 
to not be effective for respiratory drug delivery to ventilated infants and was not 
considered further. 
3.3.2 Charged vapor 
Unlike the WES device, in which the delivered dose was determined by the wick 
characteristics, the delivered dose from the pump controlled CV device was determined 
and controlled by the pump flow rate.  Given these fixed delivery conditions, the emitted 
dose of the CV device was determined using the impactor testing rather than the filter 
capture apparatus. With the Mini-MOUDI system, the mean (standard deviation; SD) drug 
mass emitted from the device and deposited in the impactor (including the inlet) was 257.6 
(24.6) µg over a period of 20 minutes.  The expected dose based on the pumping rate and 
solution concentration was 500 µg, which indicates that some drug mass remained in the 
capillary or escaped from the impactor inlet.  Variability was lower than observed with the 
WES device, with a coefficient of variation of 9.5%, which was expected with this pump 
based system. The mean (error bars are SD) DSD of the CV aerosol measured with the Mini-
MOUDI is illustrated in Figure 3.4 with a mean (SD) MMAD of 0.14 (0.015) µm.  Based on 
measurements in the ELPI, the aerosol had a negligible amount of net charge.  For example, 
experiments were performed with and without the high voltage charge being applied, there 
was only a small difference observed in the charged and uncharged elementary charge 
units on Stage 3 (cut size midpoint = 0.13 µm), with values of  0.21 e and 0.5 e, respectively.  
Furthermore, both the aerosols generated with and without the application of high voltage 
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had an MMAD of approximately 0.14 µm.  As a result, it was observed that charging the 
solution had no effect on formation of the condensation aerosol.  Due to the generation of 
relatively unchanged particles that would easily be exhaled due to their small size, the CV 
device was not selected for further evaluation. 
3.3.3 Low flow-induction charger 
For the LF-IC operated with 1 kV for 5 minutes, aerosol characterization with the 
Mini-MOUDI resulted in a mean (SD) emitted dose of 913.8 (45.1) µg.  Considering the run 
time of 5 minutes, the LF-IC could potentially deliver 182.8 µg/min of charged AS particles 
to a patient with low emitted dose variability with a coefficient of variation of 4.9%. Based 
on a nominal dose of 1065.8 (38.4) µg, the mean (SD) depositional loss in the nebulizer and 
device was 14.3 (1.7)%.  The overall recovery of drug was 96.9 (2.7)% of the nominal dose 
indicating good mass balance in this study. The mean DSD for the LF-IC is displayed in 
Figure 3.5 based on the Mini-MOUDI measurements and results in a mean (SD) MMAD of 
1.57 (0.1) µm.  This result demonstrates that an appropriate amount of evaporation was 
achieved at the airflow rate of 5 LPM with the modified nebulizer signal.  Using the ELPI, 
the measured mean DSD is displayed in Figure 3.6. The measured MMAD was 0.88 (0.08) 
µm, indicating that the aerosol was composed of droplets at a flow rate of 5 LPM and that 
further size reduction of the aerosol was possible when the aerosol was exposed to the 
higher flow rate employed with the EPLI. 
For particles with a mean size of 0.79 µm (midpoint size of Stage 7 which is nearest to 
the MMAD of the aerosol when sampled at 30 LPM), the uncharged LF-IC (0 kV) was shown 
to provide an average of 13.17 elementary charges for every particle collected based on 
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ELPI measurements.  This small amount of charging is expected within a mesh nebulizer 
due to the difference between positive and negative ion mobility within the solution.  
Distilled water is expected to have a net negative charge of a similar magnitude for this 
reason (Finlay 2001).  Increasing the induction voltage to 1 kV increased the charge by a 
factor of 12.9x, resulting in 169.94 elementary charges per particle.  The charge per particle 
vs. charging voltage results are summarized in Table 3.3 along with results from other 
stages in the ELPI.  It is observed on stages with a majority of aerosol drug mass deposition 
(Stages 5-10), charging at 1 kV produces conditions similar to the Rayleigh limit / 100, 
which can be considered a high level of charge that will have an effect on lung deposition.  
Net charges on other stages in Table 3.3 were excluded because of deposition on these 
stages was below the limit of detection for the HPLC assay, it is estimated that this mass 
represents < 3% of the drug deposited in the impactor. 
3.4 Discussion 
This study has developed and compared three new systems intended to produce 
charged small aerosols with the ultimate goal of integrating a lead device into an infant 
ventilation system and significantly improving lung delivery efficiency.  The developed 
devices were compared in terms of emitted dose, aerosolization characteristics, and net 
aerosol charge.  Selection criteria for the best performing device were described in the 
introduction.  Based on these evaluations, strengths and weaknesses of each device have 
emerged leading to the selection of a system for further testing. 
Considering the WES device, primary limitations were (i) low and variable aerosol 
delivery rates and (ii) high device depositional losses.  This study considered the new 
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approach of inexpensive spray elements to replace the micropump controller.  It was 
anticipated that known low aerosol production rates with electrospray could be 
counteracted by longer spray times or continuous delivery.  Furthermore, controlled slow 
delivery of the inhaled medication may be advantageous for immature infant lungs.  
Unfortunately, the paper spray elements quickly broke down and had highly variable 
aerosol production.  More robust elements like polymer wicks (Tepper and Kessick 2008; 
Tepper and Kessick 2009; Tepper et al., 2007) may spray for a longer time, but high 
variability is still expected.  Electrospray delivery could be improved through the use of a 
traditional micropump controlled system.  However, the second major limitation of this 
approach is the very strong electrical field compared with the available air flow rate to 
remove the particles at 2-5 LPM.  Spraying required an initializing voltage of 6 kV for a 
stable ion current.  It is known that the typical charge on electrospray droplets is very near 
the Rayleigh limit (Ganan-Calvo et al., 1997).  Insufficient airflow is available to reduce 
deposition of this aerosol on the charged electrode without deionization.  As described, use 
of a corona needle is not acceptable for inhalation systems.  Fu et al. (2011) described the 
use of radioactive spot ionizers in an electrospray system.  However, insufficient space is 
available in the system to include these units.  Increasing the device volume is not practical 
due to the limited tidal volume used in infant ventilation.  Based on these observations, it 
now appears that the WES system or electrospray in general may not be effective at 
improving lung delivery efficiency in a ventilated infant system. 
Considering the CV device, a high quality submicrometer and almost nanometer scale 
aerosol was formed with low variability.  Heating of the capillary effectively produced a 
condensation aerosol with some residue of drug remaining on the capillary walls.  By 
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increasing the energy input per solution volume compared with previous CAG systems, the 
need for a capillary nozzle was removed and a submicrometer aerosol was formed with an 
aqueous solution.  The thermocouple near the tip of the capillary was used to ensure 
temperature in the range of 100-160 oC, which may be damaging to some therapeutic 
molecules.  However, previous analysis has indicated that a number of common respiratory 
medications have low thermal degradation when aerosolized using the CAG device (Hindle 
et al., 2004).  The primary disadvantage of CV was the absence of charge on the condensed 
aerosol.  Previous studies have demonstrated conduction charging with sprays (Zhao et al., 
2005) and effects of ions on condensational aerosol formation (Ouyang et al., 1995).  
However, the charging approach that was selected in the CV study failed to produce a 
charged aerosol or alter the final aerosol size.  This is likely because the system failed to 
provide an effective field gradient in the region of phase change or the direction of droplet 
separation.  Furthermore, 100 nm particles lack sufficient Brownian motion (Xi and 
Longest 2008) to foster deposition over the short infant inhalation times.  Primarily due to 
the failure to produce a charged aerosol, the CV device was not selected for further 
consideration. 
The previous study of Golshahi et al. (2015) demonstrated that induction charging 
coupled with a mesh nebulizer was effective at high flow rates.  In this study it was 
determined that (i) the mesh nebulizer output rate could be reduced to allow for 
evaporation and formation of a 1.6 µm aerosol and (ii) high delivery efficiency could be 
achieved at a flow rate of 5 LPM through the device with a charging voltage of 1 kV.  Device 
depositional losses were <15% based on recovered dose, which includes losses on the 
nebulizer body, SLpT, and charger counter electrode.  Perhaps as important, the variability 
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associated with the delivered aerosol dose was low, with a coefficient of variation of only 
4.9%. The previous study of Longest et al. indicated that a 1.8 µm aerosol had only minor 
losses in a 3 mm endotracheal tube at a flow rate of 5 LPM; however, particle charge effects 
were not considered in that study.  Considering the analysis of Finlay (2001) on 
electrostatic effects in the lungs, 100 elementary charge units on a 1 µm particle is expected 
to have a significant impact on deposition.  The LF-IC produced >100e with a charging 
voltage of 1 kV, whereas in the absence of the charging voltage, spray charging from the 
nebulizer produced only ~10e. 
While the LF-IC produces the targeted aerosol size and charge, integration into an 
infant ventilation system will require addressing several additional challenges.  Infant 
ventilation requires very small tidal volumes.  As a result, dead volume in the system may 
need to be reduced together with connection of the SLpT very near the Y-connector.  
Inspiration only occurs over approximately 0.5 s with a 1 or 2 s exhalation.  Therefore, 
synchronization of aerosol generation with inspiration will also be necessary.  Safety of the 
system can be ensured by covering the charged counter electrode with a plastic film.  
Common dielectric materials block electrical conduction but permit the passage of 
electrical fields. 
In conclusion, the LF-IC system was found to produce a targeted aerosol size of 
approximately 1.6 µm with low device loss, low variability in emitted dose and what is 
expected to be the correct net particle charge to enhance lung deposition and reduce 
exhalation of the dose.  In contrast, the WES system had both poor emitted dose and high 
variability.  The CV device provided a high quality submicrometer aerosol but negligible net 
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particle charge.  Future studies are needed to integrate the LF-IC device into the infant 
ventilation system, evaluate aerosol transmission through the endotracheal tube and 
assess lung deposition and delivery.  Selection and development of the LF-IC is a first step 
toward using small charged aerosols to enhance the delivery of inhaled pharmaceuticals to  
infants in future studies. 
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Table 3.1 Experimental parameters of the three aerosol generation systems.  A voltage 
of 6kV was required to generate an aerosol with the WES system, but could be reduced to 
1kV with the CV and LF-IC systems.  Concentration of albuterol sulfate (AS) was maximized 
in WES to address the expected low aerosolization rate.  Excipients were selected to 
maximize aerosolization and charging performance of each system.  The range of supply air 
flowing through the devices and to the infant for effective ventilation was 2-5 LPM. 
Parameters WES CV LF-IC 
Charging Voltage 6 kV  1 kV  1 kV  
Aerosolization Rate 0.54 µL/hour*  0.6 mL/hour  2 mL/hour 
Formulation 5% w/v AS  0.25%
 w
/v AS  0.25%
 w
/v AS  
Excipients 0.02% w/v Poloxamer 188  0.25%
 w
/v NaCl  0.25%
 w
/v NaCl  
Supply Air  2 LPM 2 LPM  5 LPM 
*For the specific wick and solution combination  
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Table 3.2 Summary of the AS aerosol delivery characteristics for the WES device (n = 
4) with 1 hour of operation.  WES Device and Emitted Dose represent the mass of drug in 
micrograms remaining in the device flow pathway and emitted from the device, 
respectively.  For the WES, AS device loss was greater than the emitted dose.  Moreover, 
high coefficients of variation in both WES device deposition and emitted dose indicate 
highly variable performance. 
 Mean AS mass (µg) Coefficient of Variation (%) Range (µg) 
WES Device  
11.80  106.0  0.90 – 25.2 
Emitted Dose 15.05  109.1  0.71 - 29.9 
Total Recovered Dose 26.85 107.4 1.87 – 55.1 
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Table 3.3 Elementary charges (e) per particle produced by the LF-IC device and 
measured in the ELPI.  Drug deposition on other stages (not shown) were below the HPLC 
assay limit of detection. 1 kV charging was observed to increase the net charges per particle 
for all stages (sizes) beyond Stage 4.  At the aerosol MMAD (~0.79 µm in the ELPI), 1kV 
charging increases e by a factor of 12.9x.  Furthermore, 1kV charging produces values 
consistent with Rayleigh limit charging / 100, which is viewed as advantageous for 
enhanced lung deposition. 
ELPI 
Midpoint 
Diameter (µm) 
e_Rayleigh/100 1 kV(e) 0 kV(e) 
Stage 4 0.21 43.55 2.13 14.82 
Stage 5 0.33 83.43 25.91 0.94 
Stage 6 0.50 159.88 79.88 12.93 
Stage 7 0.79 313.59 169.94 13.17 
Stage 8 1.29 653.72 513.83 34.61 
Stage 9 2.02 1280.96 1590.35 126.82 
Stage 10 3.23 2590.08 9646.40 1822.96 
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Figure 3.1 Pharmaceutical Aerosol Generators 
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Figure 3.2 Summary of Critical System Components 
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Figure 3.3 Streamlined Impactor Connectors 
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Figure 3.4 Mini-MOUDI Sizing of CV at 2 LPM and 1 kV (MMAD = 0.14 +/- 0.015 µm; 
n = 3) 
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Figure 3.5 Mini-MOUDI Sizing of LF-IC at 2 LPM and 1 kV (MMAD = 1.57 +/- 0.10 
µm; n = 3) 
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Figure 3.6 ELPI Sizing of LF-IC at 30 LPM and 1 kV (MMAD = 0.882 +/- 0.078 µm; n 
= 3) 
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4.1 Introduction 
The extent to which poor delivery efficiency of aerosolized medicines limits 
treatment options for ventilated infants has been highlighted in previous chapters.  
Increasing the lung delivery efficiency of pharmaceutical aerosols creates opportunities for 
improved clinical effects of existing medications and will likely expand the number of 
aerosol therapies available for infants.  Aerosol delivery during mechanical ventilation is 
considered less efficient compared with spontaneously breathing delivery as highlighted in 
the study of MacIntyre et al. (1985), who clinically demonstrated 2% nominal lung 
deposition in intubated adult subjects on mechanical ventilation and 12% in non-intubated 
adult subjects using a nebulizer which generated an aerosol with a mass median 
aerodynamic diameter between 1 and 5 µm.  In this study, seven patients over the age of 49 
with various reasons for being connected to mechanical ventilation received aerosolized 
treatment through a 7 mm endotracheal tube (ETT), while 3 healthy volunteers received 
aerosolized treatment through a mouthpiece (Macintyre et al., 1985).  A significant 
challenge to aerosol delivery during mechanical ventilation is passing the aerosol through 
the gas delivery tubing, connection components and patient interface device.  Ventilation 
Chapter 4 Charged Pharmaceutical Aerosols in Invasive 
Mechanical Ventilation 
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components are typically designed for gas delivery, not aerosol administration (Longest et 
al., 2014a; Longest et al., 2014b).  In addition to this, the nebulizer type, location within the 
ventilation circuit, gas flow, and mode of nebulizer operation are important considerations 
for increasing aerosol delivery efficiency during mechanical ventilation (Fink and Ari 
2013). 
During mechanical ventilation in infants, aerosol delivery efficiencies in the range of 
<1-14% are common, even considering more recent vibrating mesh nebulizer devices 
(Dubus et al., 2005; Fink 2004; Fok et al., 1996; Mazela and Polin 2011; Sidler-Moix et al., 
2013) .  In addition to very low aerosol delivery efficiencies, high variability is also a likely 
reason for clinical failure when infants receive aerosolized medicines (Mazela and Polin 
2011; Shah et al., 2007).   Small diameter connective ventilator tubing, short inhalation 
periods, and small tidal volumes all contribute to ineffective aerosol delivery to ventilated 
infants (Fink 2004; Rubin and Fink 2001).   Much work is still needed to improve aerosol 
delivery efficiency and reduce variability in mechanically ventilated infants, such that the 
clinical benefit of existing medications can be maximized and new inhaled therapies can be 
developed (Brion et al., 2006; Cole et al., 1999; Fink 2004; Rubin and Williams 2014; Shah 
et al., 2007). 
Through the use of mesh nebulizers and new ventilation connection components, 
aerosol delivery efficiency has recently been improved for ventilated infants.  A macaque 
animal model of a ventilated infant was used to demonstrate 12 – 14% of the aerosolized 
dose through a 3 mm infant ETT using a vibrating mesh nebulizer synchronized with 
inspiration and without bias flow (Dubus et al., 2005).  Using a jet nebulizer in an in vitro 
model of a ventilated premature infant, with a new connector to separate nebulizer and 
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ventilation gas bias flow, Mazela et al. (2014) increased albuterol sulfate delivery efficiency 
from 1% or less through the commercial Y-connector to a maximum of approximately 7% 
with the improved connector, before the ETT or mask.  Additional aerosol losses are known 
to occur in the infant ETT, which can have an internal diameter as small as 2.5 mm.  Similar 
to the 12.6-14% in vivo model deposition fraction range predictions of Dubus et al. (2005),  
Longest et al. (2014b) used in vitro, whole lung, and CFD modeling techniques to predict 
the lung deposition fraction for a newborn full-term infant under mechanical ventilation 
through an ETT using commercial connection components (6.8 – 13.5%).  A new 
streamlined Y-connector was then implemented with synchronized delivery and reduced 
droplet sizes (~ 1.8 µm) to optimize aerosol deposition in the infant lungs (Longest et al., 
2014b).  For a full term (3.6 kg) infant and 3 mm ETT, maximum total lung delivery 
efficiency of a polydisperse aerosol with a mass median aerodynamic diameter (MMAD) of 
1.78 µm reached 45.2%.   
In this chapter, depositional losses in a commercial infant ventilation circuit are 
determined using a commercial mesh nebulizer and the previously determined (Chapter 3) 
best performing charger design, the low-flow induction-charger (LF-IC).  The ventilation 
circuit is driven by a steady-state air-flow of 5 LPM and the estimated lung delivered dose 
is collected on a filter at the end of a curved 3 mm (ID) ETT and quantified using a validated 
HPLC method.  The drug remaining in the nebulizer, LF-IC, streamlined Y-connector, and a 
3 mm ETT are collected and compared to the lung delivered dose.  The performance of the 
delivery system is also quantified in terms of time as the delivery rate of drug to the lung.  
The reduced mass output of the LF-IC is expected to have a smaller drug delivery rate to 
the lung, but the increased efficiency is intended to minimize drug waste and reduced 
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intersubject variability in cases where adequate delivery times are available, as with 
mechanical ventilation.  Additionally, the run time will be varied to examine the effect of 
charge accumulation on electrically insulated components under steady-state flow 
conditions.  The LF-IC is designed to target the deposition of pharmaceutical aerosols in 
ventilated infants by reducing the particle size to penetrate the delivery system with the 
addition of an induced charge on the droplets to foster lung deposition and reduce 
exhalation of the inhaled dose (Chapter 3).  An aerosol mass median aerodynamic diameter 
that is smaller than typically delivered, i.e., approximately 1.8 µm or less, is necessary to 
bypass the delivery system with acceptable losses at typical flow rates used with a neonate 
(Longest et al., 2014b).    
The objective of this study is to compare the performance of the previously 
developed LF-IC with a commercially available nebulizer in an infant ventilation circuit 
under steady-state and cyclic flow conditions.  The LF-IC and commercial device 
performances are evaluated by the quantification of albuterol sulfate (AS; model drug) 
mass recovered using HPLC in the following system components (Figure 4.1): 
1. Exhalation filter; 
2. Ventilator components (commercial or streamlined Y-connector); 
3. Nebulization device and connectors (Aeroneb Lab, commercial T-connector, 
LF-IC); 
4. Endotracheal tube; and 
5. Lung filter. 
After implementing the previously developed LF-IC in an infant ventilation circuit 
experiencing steady-state air-flow, the LF-IC is redesigned to minimize device volume for 
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use with cyclic flow conditions and to allow for the inclusion of a ventilator flow meter, a 
new common feature in mechanical ventilation systems that has not adequately been 
considered in previous studies.  This redesigned LF-IC also incorporates a breath actuated 
nebulizer to increase delivery of aerosolized drug to the patient and reduce the exhaled 
dose. 
4.2 Systems & Methods 
4.2.1 Overview of Systems 
In this study, commercial and modified aerosol delivery systems were compared for 
full term neonates receiving invasive mechanical ventilation.  Both systems utilized a 
vibrating mesh nebulizer to produce an aerosol.  The commercial system included a 
commercial T-connector, commercial Y-connector, and a continuous nebulization signal 
(Figure 4.1a).  Modifications to the systems included: a reduced nebulizer signal, 
synchronized nebulizer timing, introduction of a low flow-induction charger, and a 
streamlined Y-connector (Figure 4.1b).  Two flow conditions were evaluated with each 
system, steady state and cyclic ventilation.  Steady state flow conditions allow for simplified 
experiments to be conducted at the same flow rates of previous characterization studies 
(Chapter 3).  The cyclic flow condition provided a better comparison with clinical use and 
in vivo studies.  To avoid running a full matrix of experiments, selected cases were defined 
and presented in Table 4.1.  An additional case was considered to evaluate the effects of 
extended run times and the potential for static charge buildup on insulated ventilation 
circuitry.  Elements of the delivery systems and flow conditions are described in the 
following paragraphs.   
 
 
72 
As described in Chapter 3, the driving signal of the vibrating mesh nebulizer 
(Aeroneb Lab; Aerogen Limited, Galway, Ireland) was altered to reduce the momentum of 
the aerosol stream and to reduce the water mass in the system.  The reduced momentum 
was expected to reduce depositional loss in the LF-IC.  The reduced water mass allowed for 
evaporation of the nebulized droplets to achieve a small size (MMAD) and this was 
expected to reduce losses in the ventilator components and 3 mm ETT (Teleflex Medical; 
Research Triangle Park, NC).  Drug mass deposition in system components and on the lung 
filter (Pulmoguard II filter; Quest Medical; Brockton, MA) were quantified for the 
commercial and modified systems using high performance liquid chromatography (HPLC) 
to determine albuterol sulfate concentrations (Spectrum Chemicals, New Brunswick, NJ; 
model drug commonly used as a bronchodilator).  Nominal dose was determined by 
weighing the nebulizer after loading the nebulization solution and after nebulization.  The 
difference was multiplied by the concentration of AS in the solution (0.25%) and the 
nominal sprayed mass of AS was determined.  The methods for fabrication and use of the 
original LF-IC with an albuterol sulfate and sodium chloride nebulization solution can be 
found in Chapter 3.  LF-IC methods presented in this chapter refer to changes in the 
redesigned LF-IC for cyclic ventilation. 
To expand upon previous evaluations with steady state flow conditions, the current 
study also included analysis during cyclic ventilation.  The cyclic ventilation flow condition 
was generated by a Galileo ventilator (Hamilton Medical Inc; Reno, NV) and a Model 1601 
Adult/Infant Training/Test Lung (Michigan Instruments; Grand Rapids, MI) to simulate the 
breathing cycle (inhalation, exhalation, and breath pause).  Expansion to cyclic ventilation 
required two new components in the flow circuit, which are ventilator flow meter and the 
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exhalation filter.  Both of these necessary components provide additional sources of 
aerosol loss that must be analyzed and minimized in this study. 
The working principles of the inline flow meters that are common to many current 
generation ventilators are: hot wire anemometry, variable orifice, screen 
pneumotacograph, and ultrasonic (Schena et al., 2015).  The impact of these flow meters, 
which are required for most modern ventilators to properly function, on aerosol delivery to 
ventilated patients has not been adequately assessed.  Many ventilators, such as the one 
used in the current study, utilize an embedded inline flow meter containing a screen with 
small holes which cannot be removed from the ventilator circuit due to feedback controls 
and patient alarms.  These flow meters are needed due to the importance of monitoring the 
ventilated volume to reduce the incidence of ventilator induced lung injury (Slutsky 2015).  
(Kacmarek 2011).   
During cyclic ventilation, the redesigned LF-IC (Figure 4.2) utilizes a reduced device 
volume and a breath synchronized nebulization phase to increase delivery efficiency.  This 
synchronization is controlled by two electrical relays that are triggered by the breathing 
pattern of the infant ventilator.  Further details of LF-IC redesign and experimental testing 
methods for these systems are described in the following sections and summarized in 
Table 4.1. 
4.2.2 Steady State Flow Condition 
Aerosol delivery during 5 LPM steady state flow is quantified in an infant ventilation 
circuit, System 1.1, by washing individual components in deionized water and determining 
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the concentration of drug mass by HPLC using validated techniques as described in Chapter 
3.   Depositional accumulation of droplets on the walls of the nebulizer in the commercial 
system caused dripping from the nebulizer into the T-connector, necessitating the grouping 
of nebulizer and T-connector in the wash.  To retain consistency across the systems, this 
procedure was also followed for the LF-IC, even though the aerosol did not accumulate in 
the nebulizer and drip into the LF-IC.  The aerosol first enters the commercial neonatal T-
connector (Aerogen Limited) where it is entrained in the 5 LPM supply air (relative 
humidity < 10%).  It then passes into a commercial Y-connector (included in a neonatal 
conventional ventilation circuit, (Teleflex Medical; Research Triangle Park, NC)) that has 
the exhalation port sealed.  The base of the Y-connector connects directly to an uncuffed 
ETT curved through a 90 degree bend with a 3 cm radius of curvature, representing 
passage through the infant oropharyngeal region (Longest et al., 2014b).  The sterile ETT 
has an inner diameter of 3 mm and an outer diameter of 4 mm, consistent with use in a full-
term neonate.  The outlet of the ETT is positioned inside the Pulmonguard II filter and is 
less than one centimeter from the filter surface inside the filter plastic housing.  The 
connection between ETT and filter is open to atmosphere to allow different airflow through 
the ventilation components and the filter.  5 LPM was pushed through the system using a 
compressed gas source, as with invasive mechanical ventilation, while 20 LPM was pulled 
through the filter using a downstream vacuum pump intended to capture the aerosol 
exiting the ETT during the 0.5 minute experiment.  A summary of the critical components 
in System 1.1 is shown in Figure 4.3a. 
To improve aerosol delivery, streamlining, induction charging, and reduced 
nebulization output (modified system) were evaluated under steady state flow conditions 
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in System 1.2.  The experimental setup for System 1.2 was the same as Figure 4.3 a, but 
with streamlining to reduce depositional loss and the replacement of the commercial T-
connector with the LF-IC.  The modified Aeroneb nebulizer operates on a sinusoidal signal 
with an amplitude of 32.4 volts peak-to-peak (VPP) and a frequency of 128.2 kHz to reduce 
the emitted mass and the initial momentum of the nebulized aerosol.  Since the modified 
system has a mass output that is 1/10th the commercial system, the runtime for System 1.2 
was increased from 0.5 minutes to 1 minute to keep the minimum mass concentration 
values within the same range for the HPLC calibration curve.  In addition to comparing 
commercial nebulization with the LF-IC under steady state conditions, the 1 minute 
operation of System 1.2 was increased to 30 minutes to consider the buildup of charged 
droplets depositing on the insulated components over time (System 1.3).  HPLC washing 
and drug mass calculation methods are unchanged from Chapter 3.   
4.2.3 Commercial Delivery System during Cyclic Ventilation  
The Galileo ventilator provides pressure controlled constant mandatory ventilation 
(P-CMV).  Positive end-expiratory pressure (PEEP) is set to 5 cm H20 and Pcontrol is set to 15 
cm H20 resulting in a peak inspiratory pressure (PIP) of 20 cm H20.  The rise time for 
pressure in a pressure controlled setting, Pramp, is set to 100 ms.  The number of breaths per 
minute is set to 30.  Each 2 second breath is composed of 0.6 seconds of inspiration and 1.4 
seconds of expiration, giving an I:E ratio of 1:2.3.  These choices are consistent with target 
infant parameters for a 3.55 kg infant from Walsh & DiBlasi (2010) and are summarized in 
Table 4.2. 
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The Galileo ventilator has a bias-flow to remove the exhaled gas and reduce patient 
rebreathing of CO2.  The ETT is inserted and sealed into a Pulmoguard II filter with the filter 
housing outlet attached to the training test lung (TTL) operating in infant mode.  The 
resistance and compliance of the TTL are selected to have values of 20 cm H20/L/sec 
(Rp20) and 0.002, respectively.  Resistance and compliance value selection is based on the 
study of Abbasi et al. (2012).  The cyclic flow conditions have an additional filter at the 
exhalation outlet of the Y-connector to capture the exhaled dose as shown in Figure 4.3b.  
The commercial cyclic ventilation setup, System 2.1, is run for one minute with continuous 
nebulization (Table 4.1).   
4.2.4 Modified Delivery System During Cyclic Ventilation 
To reduce the loss of drug due to bias flow, the commercial system was modified by 
changing the location of the nebulizer (Figure 4.3c).  The nebulizer was moved from the 
inspiratory line to after the Y-connector.  The LF-IC is redesigned for use in System 2.2 due 
to the relocation proximal to the patient.  The redesigned LF-IC has a reduced internal 
volume to overcome the low tidal volume of air available which passes through the ETT 
and into a ventilated infant.  The original LF-IC with the 45 mL air space was acceptable in 
the inspiratory line because the bias-flow prevented re-breathing of exhaled gasses.  The 
new LF-IC shown in Figure 4.2 is streamlined to seamlessly connect the ventilator flow 
meter, Aeroneb Lab nebulizer, and the 3 mm ETT.  The internal volume of the LF-IC has 
been reduced from an acceptable 45 mL (Chapter 3) positioned upstream of the Y-
connector, to 6.7 mL.    This reduced downstream volume is necessary to minimize re-
breathing, a 45 mL device placed after the Y-connector would prevent effective ventilation 
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of a 3.55 kg infant having a tidal volume of approximately 28 mL.  The distance between the 
induction electrode and the nebulizer’s mesh surface is decreased from 47.6 to 46.0 mm.  
The induction charging voltage is also decreased from 1 kV to 0.5 kV because the 
depositional losses in the LF-IC were too great in preliminary experiments (data not 
shown).  The increased losses were due to the reduced air flow during the periods of 
synchronized nebulization in the cyclic breathing condition.  This reduction in charging 
voltage is expected to lessen the impact the charged aerosol has on the exhaled fraction 
when the system is implemented in a breathing lung.  This and other system parameters 
are tabulated and grouped in Table 4.1. 
In addition to this reduced volume, breath synchronized nebulization is utilized to 
reduce the amount of aerosol that is being lost before inhalation.  The Galileo ventilator has 
an internal relay that can be used to trigger an external nebulizer for delivery of aerosol 
during inspiratory flow or expiratory flow.  A standard external Multifunction Timer Relay 
(Finder Relays, INC.; Suwanee, GA) was operated in On-Delay mode and connected in series 
with the internal relay to allow for a delayed trigger from the beginning of inspiration or 
expiration (Figure 4.4).  The time delay was adjusted to trigger the nebulizer 1.29 seconds 
after the beginning of expiration, and that is 0.11 seconds before inspiration (Figure 4.5).  
The duration of nebulization was 0.11 seconds.  These values were based on a preliminary 
optimization study (data not reported) that considered both the length of nebulization and 
the best nebulization start time evaluated at multiple time points in the inhalation and 
exhalation breathing periods.  A 20 volt DC signal is supplied by a laboratory DC power 
supply (Tenma Test Equipment; Springboro, OH) to the internal Galileo relay such that 
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during expiration, the 20 volt signal is supplied to the on-delay relay, and during 
inspiration no signal is present at the on-delay relay. 
Another important difference between the commercial and modified system is the 
relocation of the nebulizer from before the flow-meter to after.  The flow-meter embedded 
in the Hamilton Galileo ventilator is a variable orifice meter which has a plate that will open 
like a flap to create a variable resistance with respect to flow rate and a lower pressure 
drop across the device.  Modern ventilation systems cannot be properly operated without 
their embedded flow-meters due to the required volume-control feedback circuit.  These 
flow-meters have undocumented effects on aerosol delivery.   
4.3 Results 
4.3.1 LF-IC Performance during Steady State flow 
The LF-IC (System 1.2) is compared with the commercial setup (System 1.1) under 
steady-state conditions to determine aerosol mass balance, locations of aerosol deposition, 
and delivery rate of drug to the filter.  To establish mass balance, the recovered drug mass 
was divided by the nominal dose for Systems 1.1 and 1.2, resulting in 97.3 (2.6)% and 95.2 
(2.7)% recovery during steady-state flow, respectively.  The commercial nebulizer and T-
connector contained 59.9 (1.5)% of the deposited AS, while the modified system had 22.2 
(5.3)% of the deposited aerosol in the LF-IC (nebulizer and streamlined T-connector).  
Aerosol deposition in the commercial Y-connector was 12.7 (3.0)% of the albuterol sulfate 
mass recovered.  The streamlined Y-connector connected to the LF-IC contained 4.9 (0.7)% 
of the deposited aerosol.  In both systems, about 17% of the drug mass was recovered in 
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the ETT.  The commercial setup, System 1.1, achieved 10.0 (2.6)% delivery of the albuterol 
sulfate solution to the lung filter, while the LF-IC in System 1.2  achieved 48.9 (6.4)% 
deposition of the charged aerosol on the lung filter (Table 4.1).  These findings are shown 
graphically in Figure 4.6, where error bars represent +/- 1 SD.  
Having determined the deposition locations of the aerosolized albuterol sulfate, the 
total mass recovered and rate of delivery to the filter are reported for Systems 1.1 and 1.2.  
The mean (SD) total masses of albuterol sulfate recovered (n = 3) in the commercial and 
modified setups were 976.4 (56.9) µg and 128.7 (14.4) µg, respectively.  The commercial 
system demonstrated a drug delivery rate of 156.0 (52.0) µg/min to the lung filter with a 
coefficient of variation (CV) of 33.3%.  The LF-IC’s drug delivery rate in the modified 
system was 67.7 (10.5) µg/min to the lung filter at 5 LPM steady state flow, resulting in a 
CV of 15.5%.  Therefore, the LF-IC had approximately 50% of the commercial setup drug 
delivery rate to the lung filter, but improved delivery efficiency to the lung filter by a factor 
of 5 and reduced variability in terms of the delivery rate CV 2-fold. 
4.3.2 Delivery Time Comparison in Electrically Insulated Connectors 
The LF-IC was run for 30 minutes at the same steady state air flow rate of 5 LPM 
using the same drug solution as considered in Section 4.3.1 to examine the effect of static 
charge buildup associated with increased runtime (i.e., System 1.3).  With the 30 minute 
run, the mean (SD) drug mass as a percentage of total recovery in the nebulizer and T-
connector was 24.2 (12.3)%.  Under the 30 minute run conditions, the streamlined Y-
connector had 5.9 (1.6)% of the recovered drug mass.  The ETT captured 21.7 (17.0)% of 
the recovered drug mass.  The efficiency of the LF-IC in delivering drug to the filter was 
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48.2 (17.2)% over the 30 minute run compared to 48.9 (6.4)% for the same conditions and 
a 1 min run.  The drug delivery rate to the filter was 67.5 (25.8) µg/min over 30 minutes 
with a total recovered mass of 4182.6 (175.9) µg in the system.  The overall recovery of 
drug was 99.0 (0.9)% of the nominal dose indicating excellent mass balance as reported in 
Table 4.3.  The results examining the impact of runtime on deposition in the steady state 
circuit are summarized graphically in Figure 4.7.  Based on these findings, there does not 
appear to be a build-up of static charge over a 30 minute run that can influence 
depositional loss in the system. 
4.3.3 LF-IC Performance during Cyclic Ventilation 
As with Systems 1.1 – 1.3, System 2.1 and System 2.2 are evaluated to determine 
mass balance, aerosol deposition location, and rate of drug delivery to the inhalation filter.  
Recovered drug normalized by nominal dose, mean (SD), for the commercial system was 
94.1 (3.3)% and  for the modified and charged system was 101.2 (2.4)% of the nominal 
dose under cyclic ventilation conditions.  Evaluation under realistic cyclic flow conditions 
allows for measurement of the albuterol sulfate that is exhaled before it enters the patient, 
in the commercial [16.2 (3.7)%] and the modified [18.6 (1.7)%] systems.  The mean (SD) 
commercial loss of drug in the Y-connector is 7.9 (3.5)% of the recovered dose.  This is in 
contrast to the loss in the Y-connector using the LF-IC, which was only 1.2 (0.5)%.  The 
infant ventilator’s flow meter captured 4.8 (3.9)% of the drug in the commercial system 
and 4.0 (0.4)% of the drug in the modified system.  The nebulizer and T-connector 
contained 67.6 (4.4)% of the recovered albuterol sulfate in the commercial system, while 
25.2 (2.8)% was in the nebulizer and T-connector in the modified system.  Drug mass 
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recoveries in the ETT for the commercial and modified systems were 1.7 (1.7) and 17.1 
(1.0)%, respectively.  The lung filter captured 1.3 (0.6)% of the recovered albuterol sulfate 
in the commercial system and 34.0 (1.7)% of the recovered albuterol sulfate in the charged 
and modified system.  These results are displayed in Figure 4.8.  The delivery efficiencies of 
Systems 1.1 through 2.2 are summarized in Table 4.4 and used to compared efficiencies 
across all the systems in the discussion. 
During a runtime of 1 minute, the commercial system delivered 25.6 (10.6) µg of 
albuterol sulfate to the lung filter under cyclic ventilation conditions (System 2.1).  The 
coefficient of variation (CV) of drug mass delivered for System 2.1 was 41.4%.  The 
modifications applied to the LF-IC caused the modified setup (System 2.2) to deliver 70.4 
(2.6) µg total or 3.52 (0.13) µg/min of albuterol sulfate to the lung filter during the 20 
minute run.  The CV of the drug mass delivered for the modified system was 3.7%.  2043.5 
(253.0) µg of albuterol sulfate was recovered in the commercial system under cyclic 
ventilation.  207.4 (9.1) µg albuterol sulfate was recovered in the modified system under 
cyclic ventilation.  As a result, for realistic cyclic ventilation condition, the modified system 
reduced drug delivery rate by a factor of 7-fold, but improved drug delivery efficiency to 
the lung filter by a factor of 26-fold. 
4.4 Discussion 
In Chapter 3, a novel aerosol generation system was designed and selected to produce a 
charged aerosol with a mass median aerodynamic diameter (MMAD) in the range of 1-2 
µm.  This approximate size was chosen to minimize deposition in the ventilation circuitry 
and ETT, while the charge was added to reduce the exhalation of the small aerosol inhaled 
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by the patient, which will be evaluated in later chapters.  In vitro testing of the novel LF-IC 
system in mechanical ventilation circuits was determined to be necessary to verify the 
reduction in losses due to reduced MMAD and ensure the induced charge on the aerosol did 
not counteract the benefits associated with smaller particle size and streamlined designs.   
The total losses in System 1.2 were about one half (Table 4.4) of the losses in the 
commercial system under steady state flow (System 1.1). As expected, the reduced 
momentum of the aerosol stream in System 1.2 caused the constant 5 LPM airflow to clear 
the aerosol more effectively than in System 1.1.  In the commercial system, 40% of the 
aerosol exits the device, while nearly double the amount (78%) of charged aerosol exits the 
device in the modified system with the induction charger located in the T (LF-IC) under 
steady state conditions (Table 4.4).  Because the droplet size of the commercial device is so 
large and the commercial connector has abrupt 90° changes of flow direction, 12.7% of the 
generated aerosol is lost in the Y-connector in System 1.1.  This is in contrast to the 1.6 µm 
aerosol navigating the streamlined-Y and losing 4.9% in System 1.2.  In Table 4.4, the 
fractions lost in the ETT appear to be equal, but this is deceiving because System 1.2 has a 
larger fraction entering the ETT than System 1.1 (72.9% vs. 27.4%).  If the recovered 
fraction in the ETT is normalized by the amount entering, then System 1.1 will have 64% of 
the remaining dose deposit in the ETT, while System 1.2 will only lose 24% of the 
remaining dose in the ETT.  The reduction of MMAD and introduction of charge on the 
aerosol reduces the depositional losses on the ventilation circuit as proposed in Chapter 3 
and leads to a 5X improved dose to the lung filter (48.9% vs. 10.0%) under steady-state 
flow conditions. 
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Having characterized the LF-IC and evaluated it against a commercial device under 
steady-state flow conditions, a realistic cyclic ventilation setup was necessary to compare 
the LF-IC to clinical studies and examine the impact of new components and parameters.  
For the commercial system under cyclic flow (System 2.1), the periods of no flow with 
continuous nebulization increased the amount of drug lost on the nebulizer and T-
connector from 59.9% to 67.6% (Table 4.4).  The fraction remaining after exiting the T-
connector is 32.4% of the nebulized fraction.  Half of this (16.2%) is lost to the exhalation 
filter because of the continuous nebulization and bias flow.  Three quarters of the 
remaining fraction is then lost in the Y-connector and flow meter.  This leaves about 3% of 
the aerosol to either be lost in the ETT or inhaled by the patient.  More than half of the 
aerosol that reaches the ETT is lost there.   This leaves only 1.3% of the nebulized aerosol 
available to the patient to be inhaled (with an additional high fraction likely exhaled).   
This result of 1.3% deposition in the inhalation filter with a high quality mesh nebulizer 
using a commercial setup is much lower than the 12.6% deposition reported in the study of 
Dubus et al. (2005), which considered deposition of an aerosol produced by a synchronized 
vibrating mesh nebulizer in four intubated macaques.  One major difference is in the study 
of Dubus et al. (2005) the ventilator used did not have an embedded in-line flow meter or a 
bias flow to overcome.  All of the 25 ventilators (from 10 different manufacturers) 
reviewed by Schena (2015) contain embedded inline flow-meters.  Future mechanical 
ventilators will likely continue the current trend of increasing patient monitoring and 
feedback controlled based on various meters allowing for improved ventilation synchrony 
(Kacmarek 2011).  The Galileo ventilator used in this study is more consistent with current 
and likely future mechanical ventilation practice than previous studies which often do not 
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include flow meters or bias-flow, and is therefore an accurate assessment of mesh 
nebulizer performance in current clinical scenarios. 
This study maximized delivery during cyclic flow using a new LF-IC positioned 
downstream of the Y-connector with a modified signal and synchronized with breathing.   
For the modified system under cyclic flow, System 2.2, a charged aerosol is generated in a 
region with an electric field and zero airflow, 0.11 seconds prior to inhalation producing 
25.2% deposition of the nebulized aerosol in the charging region.  The remaining 74.8% is 
then transported by the inhalation flow through the ETT, where a fraction of the aerosol 
deposits, reducing the potential inhaled fraction to about 58% (based on how much is lost 
in the ETT during inhalation in System 2.2).  34% of the aerosol is deposited in the lung 
filter, leaving the remaining 24% that does not reach the filter to be exhaled through the 
ETT and deposited on the exhalation filter (Table 4.4).  In the results of Longest et al. 
(2014b), approximately 60% delivery efficiency to the lung was possible using numerical 
modeling; but nebulizer and T-connector deposition was neglected.  If nebulizer and T-
connector deposition is added to the lung filter deposition for system 2.2, 59.2% deposition 
is estimated.  This excellent agreement highlights the need for future studies to further 
reduce T losses.  The nebulizer relocation, signal modification, and synchronization with 
delivery contributed to a 26 fold increase in inhaled dose in the modified system (34% vs. 
1.3%). 
Initial experiments (not reported here) showed very low inhaled dose when the LF-IC 
was upstream of the Y-connector under cyclic ventilation.  Redesigning and moving the LF-
IC downstream of the Y-connector and the flow-meter reduced the number of potential 
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deposition sites during inspiration and decreased the dead volume to increase efficiency 
and demonstrate the large influence of nebulizer positioning within the circuit.  The 
charged aerosol in this study likely decreases the amount delivered to the inhalation filter, 
but in future studies that consider exhalation, a charged aerosol is expected to enhance 
deposition.  Initial experiments (not reported here) also showed large influence of 
nebulization delivery timing as various durations and starting times of nebulization were 
explored before selecting 0.11 seconds prior to inhalation.  The exhaled fraction can be 
viewed as the fraction of drug that could be gained by reducing dead volume or improving 
synchronization of nebulization.  Additional optimization of synchronization timing may 
increase the delivery rate, perhaps without decreasing the delivery efficiency.  Future work 
will need to consider timing aerosol generation to begin during exhalation, but continue 
into the beginning of inspiration.  This will require better ventilator control of the attached 
nebulizer or additional hardware such as a “true-off/on delay” to implement.  This 
additional hardware would allow for control of the activation and duration of nebulization 
as opposed to only controlling the onset or activation of the nebulizer and using the change 
of breath phase to turn off the device.  Potential optimization is still available to deliver 
more aerosol in a shorter amount of time.  The maximum delivery rate under cyclic 
conditions derived from the modified system under steady state conditions is 20.31 
µg/min. 
The device volume has been reduced through redesign, but the filter still provides a 
large dead volume of air that is expected to artificially reduce the capabilities of both the 
commercial and LF-IC systems.  The dead volume of the filter and the ventilator 
components mean that generated aerosol will still be in the line after inhalation and 
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remaining mass will be exhaled.  Clinically, dead volume is a critical quantity that must be 
minimized to reduce the amount of re-breathing of exhaled gas a patient incurs. 
Commercial delivery rate decreased from 156 µg/min to 25.6 µg/min due to the cyclic 
breathing profile, ventilator flow meter deposition, and bias flow (System 1.1 vs. 2.1).  The 
delivery rate of the LF-IC decreased from 67.7 µg/min to 3.52 µg/min, primarily due to the 
reduced spraying time of the synchronized nebulizer, 0.11 seconds spray for every 2 
second breath.  Based on the maximum delivery rate from System 1.2, 67.7 µg/min, and the 
ratio of inspiration to total breathing cycle, 0.3 (Tinsp/ TBreath), the maximum delivery rate 
expected is 20.3 µg/min using the current setup.  The commercial system delivers 7.27-fold 
more drug to the inhalation filter in one minute than the modified system does; however, if 
the modified system is run for long enough to deliver the equivalent mean mass as the 
commercial system, approximately 7.3 minutes, the standard deviation is 0.95 µg as 
compared to the commercial standard deviation of 10.6 µg.  This 10 X decrease is equally 
demonstrated in the 11.2 fold reduction of CV from 41.4% to 3.7% for commercial and 
modified delivery rate of inhaled dose, respectively.  As described above, the main 
advantage of the modified system is a 26-fold improvement in delivery efficiency of the 
nebulized aerosol to the lungs.  This improvement is critical for providing efficient and 
reproducible lung delivery of therapeutic aerosols. 
In designing this system for delivering aerosolized drugs, drugs that have high cost and 
significant side effects are being primarily considered.  Surfactants are very expensive, 
steroids need low variability due to adverse side effects, and antibiotics need to be 
delivered in high and consistent doses to prevent survival.  Albuterol Sulfate is inexpensive, 
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has low side effects, doesn't require a large dose, and is therefore acceptable using the 
inefficient and highly variable devices that are currently available.  The LF-IC is then ideally 
positioned to deliver drugs such as surfactants, antibiotics, and steroids (as well as others) 
because the emphasis of design is on efficiency rather than speed.  Even with the reduced 
drug mass delivery rate of the LF-IC, the reduction in variability allows for equivalent 
dosing with reduced variability when the patient is treated for a longer time.  Some 
medications, like surfactants, are very expensive.  Clinical trials of surfactants have had 
inconclusive or mixed outcomes likely due to high variability and poor lung delivery 
efficiency (Berggren et al., 2000; Finer et al., 2010). 
The steady state system uses room temperature air to flow through the system at 5 
LPM, while the cyclic system utilizes a heater to maintain an approximately 35° Celsius 
inspiratory line.  A humidifier was not connected in the cyclic ventilation system; rather the 
patient is reliant on the liquid content of the evaporating aerosolized droplets in the heated 
line to prevent the cooling and drying of the airways by dry and cold ventilation gas.  Dubus 
et al. (2005), who provides the current benchmark of in vivo delivery in macaques with 3 
mm ETTs,  did not use a system with added heated or humidity.  Additionally, the ventilator 
that was used did not have bias flow or an in-line flow meter (Dubus et al., 2005).  Among 
others, bias flow, humidity, and position of aerosol device in the circuit,  have been shown 
to be important factors for improving mechanically ventilated aerosol delivery efficiency 
(Ari and Fink 2015).  The system considered in this study delivers humidity through the 
nebulization of an aqueous solution because removal of humidity from the inspiratory line 
is not recommended for the patient’s well being and safety (Ari and Fink 2015).   Using a 
heated and humidified line, Mazela et al. (2014) delivered 6.6% of a nominal albuterol 
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sulfate dose to the end of the Y-connector in a mechanical ventilation system; however, an 
ETT was not considered.  This system used a novel VC connector to bypass bias flow and 
improve delivery of a jet nebulizer to a delivery rate of 2.9 µg/min (Mazela et al., 2014). 
In conclusion, the LF-IC system was found to increase the lung delivery efficiency 
during steady state ventilation from 10.0% to 48.9% and during cyclic ventilation from 
1.3% to 34.0%.  This 26-fold improvement in the lung dose efficiency of the LF-IC over the 
conventional nebulizer is expected to be even higher in clinical trials due to reduced 
efficiency of the conventional system resulting from the increased model accuracy of 
predicting exhalation of inhaled pharmaceutical aerosols.  The induced charge on the 
aerosol from the LF-IC is expected to enhance deposition in the small diameters of the 
infant airways, while the commercial aerosol which reaches the lungs will likely be exhaled 
at a higher fraction.  The CV of the lung dose using commercial delivery under steady state 
flow (System 1.1) was 26% and decreased to 13% in the modified system under steady-
state flow (System 1.2).  In the cyclically ventilated systems, the CV decreased from 46.2% 
in the commercial system (System 2.1) to 5% in the modified system (System 2.2).  
This study has implemented, with progressively more realistic flow conditions, the 
previously developed and characterized LF-IC.  The LF-IC produces a charged aerosol with 
a mass median aerodynamic diameter (MMAD) of 1.6 µm and was designed to decrease 
losses in the device and breathing circuit while increasing efficiency of delivery to the lung.  
Successful integration of the LF-IC into an invasive mechanical ventilation circuit was 
achieved through volume reduction, streamlining, synchronization and nebulizer 
placement within the breathing circuit.  The tested systems were compared in terms of 
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mass efficiency of delivery and time of therapy efficiency.  Based on the superior efficiency 
performance (26 fold improvement of inhaled dose) and the reduced variability (11-fold 
reduced CV of delivery rate) of the LF-IC system over the commercial system under cyclic 
flow conditions, further testing and implementation of the new LF-IC in clinical or highly 
realistic in vitro models is suggested. 
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Table 4.1 Systems examined to evaluate aerosol transmission (steady airflow) and the 
effects of cyclic ventilation. 
System Charging Voltage 
(kV) 
Runtime 
(min) 
Air-flow 
Conditions 
Nebulization 
Signal 
Nebulization Timing 
1.1 0 0.5 Steady Commercial Continuous 
1.2 1 1 Steady 32.4 VPP* Continuous 
1.3 1 30 Steady 32.4 VPP* Continuous 
2.1 0 1 Cyclic Commercial Continuous 
2.2 0.5 20 Cyclic 32.4 VPP* 0.11 (s) before inhale 
*VPP – Peak-to-Peak Voltage 
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Table 4.2 Ventilation parameters to represent invasive mechanical ventilation of a full 
term neonate (3.55 kg) based on Walsh & DiBlasi (2010). 
Ventilation Parameters 
Pcontrol 15 cm H20 
Peep 5 cm H20 
Pramp 100 ms 
Ventilation Mode P-CMV 
Breath/Min 30 
Tinsp 0.6 s 
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Table 4.3 Total drug mass recovered (standard deviation) as a percentage of estimated 
nebulized drug [n = 3].  Values near 100% indicate that the washing process was thorough 
and aerosol was not lost from the system. 
System Recovery (% Nominal) 
1.1 97.3 (2.6) 
1.2 95.2 (2.7) 
1.3 99.0 (0.9) 
2.1 94.1 (3.3) 
2.2 101.2 (2.4) 
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Table 4.4 Drug mass deposited in each system component as a percentage of nebulized 
dose.  Exhaled drug mass and deposition in the Y, flow meter, Neb + T, and ETT all 
represent sources of drug loss.  Lung filter deposition represents an approximation of the 
drug delivery efficiency to the lungs.  This assumption neglects loss from aerosol that 
enters the lung and is then exhaled. 
System 1.1 1.2 1.3 2.1 2.2 
Exhaled N/A N/A N/A 16.2 (3.7)% 18.6 (1.7)% 
Y 12.7 (3.0)% 4.9 (0.7)% 5.9 (1.6)% 7.9 (3.5)% 1.2 (0.5)% 
Flow Meter N/A N/A N/A 4.8 (3.9)% 4.0 (0.4)% 
Neb + T 59.9 (1.5)% 22.2 (5.3)% 24.2 (12.3)% 67.6 (4.4)% 25.2 (2.8)% 
ETT 17.5 (4.1)% 17.4 (2.2)% 21.7 (17.0)% 1.7 (1.7)% 17.1 (1.0)% 
Lung Filter 10.0 (2.6)% 48.9 (6.4)% 48.2 (17.2)% 1.3 (0.6)% 34.0 (1.7)% 
Total Loss* 90.0 (5.3)% 44.4 (5.8)% 51.8 (21.0)% 98.2 (7.9)% 66.0 (3.5)% 
*Defined as the aerosol depositing on components other than the lung filter.  
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Figure 4.1 Aerosol delivery through a.) Commercial delivery system and b.) 
Modified delivery system.  Both the T-connector and the Y-connector are 
streamlined in the modified delivery system before delivery through an infant 
endotracheal tube under steady state flow conditions (exhalation and monitoring 
outlets closed).  
  
 
 
95 
 
Figure 4.2 Streamlined low flow induction charger with reduced dead volume 
located after flow meter. 
  
 
 
96 
 
Figure 4.3 Connection configuration for the (a) aerosol delivery under steady-
state flow, (b) commercial aerosol delivery under cyclic ventilation, and (c) modified 
aerosol delivery under cyclic ventilation 
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Figure 4.4 Electrical wiring diagram for the modified LF-IC system under cyclic 
ventilation conditions (System 2.2). 
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Figure 4.5 Flow profile resulting from specified control pressure (Pcontrol = 15, 
Peep = 5, Pramp = 100 ms) with timing of aerosol generation (synchronized 
nebulization) 0.11 seconds prior to inhalation. 
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Figure 4.6 Drug mass deposition (i.e. % recovered) in ventilator circuit under 
steady-state flow during operation of System 1.1, commercial, and System 1.2, 
streamlined & 1 kV charged (n = 3 for each system; error bars represent standard 
deviation). 
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Figure 4.7 Effect of operating time on drug mass deposition (i.e. % recovered) in 
ventilator circuit under steady-state flow during operation of streamlined & 1 kV 
charged LF-IC systems 1.2 and 1.3 (n = 3 for each system; error bars represent 
standard deviation). 
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Figure 4.8 Drug mass deposition (% recovered) for System 2.1 and 2.2 under 
cyclic flow conditions.  Run time is reduced for the commercial system to 0.5 
minutes, increased for the modified system to 20 minutes and charging is reduced to 
0.5 kV for the modified System 2.2 (error bars represent standard deviation). 
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5.1 Introduction 
Healthy lungs expand evenly due to work done by the diaphragm to increase volume 
in the chest cage, resulting in inhalation.  After inhalation, the diaphragm relaxes and the 
pressure returns to its original value, causing the lungs to contract in an elastic manner 
thereby driving exhalation and a  return to a resting volume (Drake et al., 2005).  At the end 
of inspiration or expiration in a healthy patient there is no airflow and the intrapleural 
pressure does not reflect forces associated with airflow, only the elastic recoil forces (West 
2012).  Compliance is a metric of the lung’s elastic recoil and is measured as the change in 
volume per unit change in pressure across the lung.  If the compliance of the lungs was only 
due to elastic tissue forces, it would be graphed on a pressure vs. volume plot as a single 
straight line connecting maximum and minimum lung volume points.  However, airway 
resistance and changes in surface tension cause the volume response to an applied 
pressure to deviate from a linear relationship during inhalation vs. exhalation.  In this 
study, the Pressure-Volume (P-V) graph was used to determine realistic response of the 
BIL model to mechanical ventilation because it is known that patient inhalation will deviate 
from a linear compliance due to the pressure needed for gas flow through narrow resistive 
Chapter 5  Development of a Breathing Infant Lung (BIL) 
Model for a Full Term Neonate to Enable In Vitro Testing of 
Surfactant Administration and Physiological Lung Response 
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airways (Walsh and DiBlasi 2010).  The pressure difference between the alveoli and the 
mouth divided by the airflow is defined as the airway resistance (West 2012).  The area 
under the linear compliance line and bounded by the P-V curve is the work required to 
overcome airway and tissue resistance.   
In healthy individuals, the lungs are able to control the surface tension of the 
alveolar region by adjusting the amount of surfactant present on the surface.  Patients with 
insufficient surfactant have alveoli that tend to collapse during normal tidal breathing, 
frequently leading to respiratory failure if not treated with surfactant replacement therapy 
(Willson 2015).  In a multicenter randomized trial, dramatic oxygenation improvement 
occurred within 5 minutes, mortality decreased from 51% to 31%, and the mean time 
patients were on mechanical ventilation was 35% less with instilled surfactant therapy 
(Collaborative European Multicenter Study 1988).  According to the American Academy of 
Pediatrics, “…the optimal method of surfactant administration in preterm infants has yet to 
be clearly proven” and additional data is needed to recommend a method such as 
aerosolized surfactant delivery (Polin et al., 2014).  Considering non-invasive aerosol 
delivery of synthetic lung surfactant in rabbits, surfactant deficiency was effectively 
relieved, but large portions of the surfactant were not nebulized and more than 40% of the 
aerosolized surfactant was lost in the ventilation circuit (Walther et al., 2014). 
Common methods of surfactant delivery include liquid bolus administration 
(referred to as instillation of single or multi-dose), continuous infusion (or continuous 
instilation), and aerosolization.  Special consideration needs to be given to the patient to 
prevent transient oxygen desaturation and severe airway obstruction which have been 
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seen more frequently in extreme low birth weight infants with more severe lung disease 
when surfactants are instilled (Tarawneh et al., 2012).  The instillation process involves the 
insertion of an endotracheal tube, which carries a number of risks, pouring between 1.25 
ml/kg and 5.8 ml/kg (Polin et al., 2014) of surfactant solutions down the endotracheal tube 
into the patient’s lungs (or approximately 4 ml), and application of mechanical ventilation, 
which is also associated with lung injury and infection risks.  Instillation of surfactant in 
infants has caused airway obstruction immediately following administration in multiple 
studies (Miedema et al., 2011; Wheeler et al., 2009).  Although instillation is currently the 
only approved method for surfactant administration it requires an artificial airway and 
some positive pressure ventilation, which may be harmful to any  patient, especially infants 
(Willson 2015). 
In general, aerosolized delivery of medication to infants and adults suffers from high 
variability and low delivery efficiency (Brion et al., 2006; Cole et al., 1999; Fink 2004; Rubin 
and Williams 2014; Shah et al., 2007).  Considering instilled and aerosolized delivery of 
surfactant to rats with acute lung injury, a highly inefficient device delivered a dose at least 
4-fold lower than the instilled dose (100 mg/kg) to produce an equivalent increase is 
oxygenation and decrease in breath rate (Sun et al., 2009).  New technologies provide an 
opportunity to efficiently deliver aerosolized surfactant with a low total administered dose 
and enhanced homogeneity of distribution (Pillow and Minocchieri 2012).  The 
improvement of lung function with minimal systemic exposure can be accomplished by 
administering pharmaceutical aerosols to infants receiving mechanical ventilation (Fink 
2004; Mazela and Polin 2011; Rubin and Fink 2001).   
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In this chapter, inspiratory resistance and compliance were determined in the 
breathing infant lung (BIL) model across three methods of surfactant administration: 
instilled liquid, commercial (CM) aerosol generation, and modified-charged (MC) aerosol 
generation.  A low flow-induction charger, capable of delivering a charged aerosol with a 
mass median aerodynamic diameter (MMAD) < 1.8 µm (Golshahi et al., 2015; Holbrook et 
al., 2015), was developed and characterized in Chapter 3.  The LF-IC was redesigned in 
Chapter 4 to utilize a lower charging voltage, a smaller device volume, breath synchronized 
delivery, and relocation of the nebulizer proximal the patient.  These changes allowed for 
highly efficient implementation in an infant ventilation circuit under cyclic ventilation and 
provided an in vitro inhaled dose for “commercial” (CM) and “modified and charged” (M-C) 
aerosol delivery.  From the nebulizer development testing of Chapter 4, The M-C aerosol 
system had a lung filter delivery efficiency of 34% and a delivery rate of 3.5 µg/min.  The 
CM system demonstrated a lung delivery efficiency of 1.3% and a delivery rate of 25.6 
µg/min (Chapter 4).  These are maximum efficiencies and delivery rates, as they only 
measure the drug mass inhaled and do not measure the fraction exhaled.  The 
measurement of maximum efficiencies and delivery rates use a filter to capture the lung 
dose, as is widely done in the literature (Dhand 2008; Fink and Ari 2013; Fink 2004; Guerin 
et al., 2008).  These previous chapters are used to estimate the fraction delivered to the 
newly developed BIL model and provide standard methods and protocols to be used in the 
current and the following chapter. 
The object of this study was to develop a BIL model that will respond in 
physiologically consistent ways and capture both deposited and exhaled dose in future 
studies.  Conventional and modified aerosol delivery techniques with a vibrating mesh 
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nebulizer were considered and compared against an instilled surfactant case.  After 
creating a realistic BIL model that is capable of distinguishing between three surfactant 
administration methods, the BIL model is suggested for use with the developed LF-IC from 
Chapter 4 to deliver a model drug such as albuterol sulfate to determine the exhaled 
fraction and the delivery rate to the lung, which is evaluated in Chapter 6.  In vitro testing of 
the BIL model is developed to enable testing of next generation medications, increase the 
efficiency of current inhaled therapies, and test surfactant administration techniques.   
5.2 Methods 
 The ventilation parameters selected for use in the BIL model were representative of 
a 3.55 kg infant (Walsh and DiBlasi 2010), which represents 50th percentile conditions at 
full term delivery.  These are the same conditions used in the filter deposition study of 
Chapter 4.  The inspiratory line of the ventilation circuit used a heater to maintain an inlet 
temperature of approximately 35 °C.  A pressure controlled peak inspiratory pressure (PIP) 
of 20 cm water and a breathing rate of 30 breaths per minute were used for all 
experiments.  An inspiratory time of 0.6 seconds was used which resulted in an 
approximate expiratory time of 0.5 seconds and a pause of 0.9 seconds.  The only 
adjustable parameter for the mode of ventilation used (infant mode) was inspiratory time, 
the other timing parameters were not separately adjustable.  The positive end-expiratory 
pressure (PEEP) was set to 5 cm of water and the pressure and tidal volume were 
measured after loading the spheres for a verification case of no liquid in the lungs and a 
case with 12 mL water in the pleural space to more closely approximate real lung 
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conditions.  The resistance measured in the BIL should increase when the water is added to 
the lung.   
The Galileo ventilator (Hamilton Medical Inc; Reno, NV) enables the measurement of 
inspiratory resistance and quasi-static compliance (Arnal et al., 2015).  These 
measurements were repeated with administration of a commonly used syntheticsurfactant 
(instilled and aerosolized).   Sodium Dodecyl Sulfate (SDS; Amresco Inc., Solon, OH) was 
selected for use as the surface acting agent to reduce the surface tension of the liquid in the 
BIL model due to low cost and availability in these preliminary experiments.  The 
inspiratory resistance and compliance were measured before and after surfactant 
administration using the built-in monitoring capacity of the Galileo ventilator during 
invasive mechanical ventilation.  The conductivity of the 0.05%(w/v)   Sodium Chloride 
(NaCl; Sigma Chemical Company, St. Louis, MO) solution, representing the airway surface 
liquid, was measured using an EC400 conductivity meter (Extech Instruments, Nashua, NH) 
and found to have a conductivity of 5000 µs/m.  The ventilation circuit and connectors 
used were the same as described in Chapter 4.   
5.2.1 Model Design and Construction 
5.2.1.1 Upper Airways 
The upper tracheobronchial airways of the breathing infant lung model were scaled 
from a previously constructed adult mouth-throat model (Walenga et al., 2013).  Model D 
(Figure 5.1) extends from the mouth through three generations of bifurcating geometries 
and was constructed from a single CT scan that was consistent with mean airway 
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dimensions of adults (Walenga et al., 2013).  To properly scale the model to infant 
dimensions, the areas of the eight outlets at generation three were averaged and assumed 
to be circular to obtain an average (SD) diameter of 6.1 (1.2) mm for Model D.  An average 
infant height of 50 cm was used with the morphological correlation from Phalen (1985) to 
determine a mean (SD) infant diameter of generation three as 2.59 (0.37) mm.  The 
approximate lower end of this acceptable range was selected, 2.3 mm, to provide a length 
scaling ratio of 0.377 (2.3 mm/6.1 mm).  As such, Model D was scaled down to 37.7% of the 
starting adult size to match the average segmental bronchiole diameter of a newborn of 
average length and connected to the pleural space as described in the next section.  The 
shape of the scaled glottis was modified to ensure a 4.2 mm (outer diameter) endotracheal 
tube would pass through the rigid model without constriction.   
5.2.1.2 Lower Airways 
The pleural space was digitally constructed from an infant CT scan using Mimics 
14.0 (Materialise; Belgium) and 3-Matic (Materialise; Belgium) software resulting in a 
volume of 0.2 liters in the pleural region.  The FRC was based on the youngest ICRP (1994) 
model, a 3 month old Caucasian infant.  The chosen FRC from ICRP, 150 mL, was greater 
than another possible choice, 110 ml (Lumb 2012), because the fluid added to the model 
replaces the airspace and reduces the FRC.  For this reason, the pleural space was scaled up 
from 0.2 to 0.42 liters to achieve an FRC of 150 mL when packed with two thousand two 
hundred fifty spheres at an approximate close random volume packing density of 0.641, 
without any added fluid.  
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The BIL (Figure 5.2a and 2b) was prototyped using a Viper SLA Rapid Prototyper 
with Accura 60 resin (3D Systems; Valencia, CA).  The minimum resolution of the 
prototyper was 0.1 mm, which was sufficient to resolve the geometry.  The appropriate 
number of spheres was then loaded to fill the pleural cavities while leaving room for 
expansion between the spheres during inhalation.  A balance was used to determine the 
number of spheres loaded into each cavity before every experiment.  To prevent bulk 
motion of the spheres an outlet cover (Figure 5.2c) was designed and attached after the 
spheres were loaded into the pleural cavity.  After attaching the outlet cover to the BIL 
model a flexible membrane was used to close the system.  The flexible membrane was a 
102 µm thick sheet of nitrile (Protégé, Aurelia; Aurora, IL) that was stretched over the 
outlet cover and fixed with hot glue.  The seal on the flexible membrane was checked by 
inflating the BIL model with approximately 40 mL of air while holding the model under 
water to identify potential leaks in the system.  As described in Chapter 4, the ventilator 
circuit was connected to the 3 mm ETT using either a commercial Y-connector or a 
streamlined connector (LF-IC).  The ETT bypassed the modified glottis and its outlet was 
placed near the bottom of the trachea of the prototyped model. 
Two thousand two hundred fifty spheres with a 6 mm diameter reduced the air 
volume in the pleural cavities by 254 mL, making necessary a scaling of the pleural space.  
The spheres used were 6 mm and plastic (Crosman Corporation; Bloomfield, NY) with a 
mass of 0.12 grams per sphere.  An effective alveolar diameter was calculated by 
determining the area of a triangle between three tangential circles of equal diameter 
(Figure 5.3).  This triangle is an equilateral triangle with side length 6 mm.  The area of 
intersection between the triangle and a single circle is calculated by the equilateral angle, 
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60° of a 360° circle of radius 3 mm.  This area is the same in all three circles, and can thus 
be multiplied by 3.  The area of intersection is subtracted from the area of the triangle to 
calculate the area between three tangential circles.  This area is then assumed to be circular 
to calculate an effective diameter, resulting in a characteristic diameter of 1.36 mm (Figure 
5.3).  This diameter of 1.36 mm provides an approximation of the expected alveolar airway 
outer diameter of 0.54 mm (Khajeh-Hosseini-Dalasm and Longest 2014).  Preliminary 
experiments (not shown here) determined the maximum volume of fluid to be instilled 
without visible pooling of the injected liquid to be 12 mL, which is consistent with the 
expected airway surface liquid in pediatric airways of 6-20 mL.  The system was 
disassembled and the spheres were discarded after each experiment to remove the 
possibility of surfactant contamination on the spheres between runs. 
5.2.2 Surfactant Administration  
The BIL model developed in the previous sections was used to test surfactant 
therapy when administered during invasive ventilation as an instilled liquid bolus, an 
aerosol generated with a commercial nebulizer, or using the modified aerosol generation 
system developed in Chapter 4.  For the instilled liquid bolus, the BIL model was 
disconnected from ventilation and four milliliters of water with 0.05%(w/v) NaCl were 
injected in each pleural cavity by rotating and positioning the model, and the system was 
shaken to distribute the solution.  The BIL was reconnected to the ventilator for 
measurement of inspiratory resistance and compliance.  This surfactant free system is 
representative of an extreme case of lung surfactant dysfunction or deficiency.  During 
instilled surfactant treatment, the BIL model was disconnected from ventilation and 2 mL 
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of a 1.73%(w/v) SDS solution was delivered as a liquid bolus injection down the 3 mm ETT 
with the BIL model turned toward the right lung.  The model was then rotated toward the 
left lung and another 2 mL of 1.73%(w/v) SDS was instilled.   After injection, this solution 
mixed with the 8 mL of 0.05%(w/v) NaCl solution to create a 20 mM SDS solution with a 
surface tension of 37 mN/m as measured by a bubble pressure tensiometer (BP2; Krüss, 
Hamburg, Germany).  The instillation administration technique was designed to deliver 
enough SDS to reduce the surface tension of the water in the BIL model to approximately 
half that of water (72 to 37 mN/m).  After liquid bolus administration of surfactant, the BIL 
model was reconnected to the ventilator circuit for measurement of resistance and 
compliance during active ventilation after 20 minutes. 
The instilled surfactant experiment was followed by nebulized delivery of surfactant 
using a commercial (CM) and a modified and charged (M-C) aerosol delivery system with 
an Aeroneb Lab nebulizer (Aerogen, Galway, Ireland).  Preliminary results of the BIL model 
from Chapter 6 demonstrated delivery efficiency of the CM and M-C systems of 0.4 and 
20%, respectively.  For the CM system a concentration of 0.31%(w/v) SDS was chosen for 
delivery over 1 minute because the spraying of the surfactant solution was hindered by the 
generation of bubbles on the reservoir side of the nebulizer's mesh for higher 
concentrations.  Commercial nebulization parameters were consistent with those tested in 
Chapter 4.  The charged and modified system was then implemented to deliver the 
nebulized surfactant to the BIL model using the same solution concentration used for the 
CM system and 20 minutes of synchronized delivery (best case conditions as described in 
Chapter 4).   
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5.2.3 Data Capture and Processing  
Quasi-static compliance and resistance of the BIL model were measured using a 
Galileo ventilator connected through the serial port to a computer running the Galileo data 
collection software.  This software records the breathing profiles, parameters, and lung 
properties every 2.5 seconds and records them to a .txt file.  A second file was saved 
containing the pressure and volume information that was used to create the characteristic 
loops and visualize the lung mechanics recorded every 0.032 seconds to a .txt file.  The pre-
administration inspiratory resistance (ResistancePre) and compliance (CompliancePre) 
values immediately preceeding administration are read from the recorded file during 
processing.  Similarly, the post-administration values (ResistancePost and CompliancePost) 
are recorded at the end of treatment. 
To make the data more comparable, the impact of the surfactant administration on 
resistance is assessed as the change in resistance divided by the initial resistance, 
%Resistance.  These values are calculated using the pre and post administration 
resistances.  Similarly, the impact of the surfactant administration on compliance is the 
change in compliance divided by the initial compliance, %Compliance.  These processing 
equations are displayed below. 
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It is important to note that the pre-administration values in the instillation technique 
correspond to a liquid lung volume of 8 mL, while the nebulization technique has a liquid 
lung volume of 12 mL.  When used, the coefficient of variation (CV) was calculated as the 
standard deviation (SD) divided by mean.  An increased compliance and a decreased 
inspiratory resistance are both clinically desirable changes that will likely reflect improved 
oxygenation.  The P-V curve generated by the BIL should resemble a typical infant 
breathing curve with normal distention as seen in the study of Fisher et al. (1988). 
5.3 Results 
 5.3.1 Demonstration of a Characteristic P-V Curve 
The generation of a realistic pressure-volume curve was the first test of the model 
and the foundation of a useful in vitro model of lung mechanics.  The inspiratory resistance 
of the model was examined with a liquid volume of 0 mL and the largest volume of liquid 
that could be added without visible pooling, i.e., 12 mL.  Three replicate experiments were 
conducted to determine the response and standard deviation of each volume of liquid to 
the pleural space.  The mean (CV) resistance increased from 25 (0%) cm H20/L/s at 0 mL 
liquid to 31 (5.9%) cm H20/L/s for 12 mL of liquid, an increase of 24%.  Two sets of three 
replicate experiments show the mean (CV) compliance increasing from 1.75 (3.3%) to 1.85 
(3.1%) mL/cm H20 for 12 mL of airway liquid.  The increased compliance is clearly visible 
as the increased slope of the straight line connecting max inhalation to max exhalation in 
the case of 0 mL airway liquid, Figure 5.4a, and the case of 12 mL airway liquid, Figure 5.4b.  
The P-V curve shown in Figure 5.5 is compared with clinical results for infants and does not 
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exhibit the characteristic “beak” shape of over-distention, but rather the properly 
ventilated shape.  
5.3.2 Surfactant Administration Response 
To further establish the BIL model’s capabilities, the response to instilled and 
aerosolized surfactant administration was assessed.  After ventilation on the 35°C line for 
20 minutes prior to administration, the model was removed from the circuit and the 
instillation of 4 mL of surfactant solution increased the mean (SD) inspiratory resistance by 
16.2 (8.0)% from the pre-administration values, (time = 0 minutes).  The compliance 
changed -1.4 (2.5)%, meaning the compliance decreased as the inspiratory resistance 
increased (time = 0 minutes). The mass of SDS delivered to the lung during instillation was 
69.12 mg, to produce 12 mL of a 20 mM SDS.  These values were recorded 1 breath after 
being reconnected to the ventilation circuit after administration.  As noted earlier, 
increasing the volume of liquid in the lung is expected to increase resistance and 
compliance.  This increase is also magnified due to the presence of the bolus in the upper 
airways as it distributes to the lungs.  Resistance and compliance of the BIL were also 
recorded after 20 minutes of ventilation with heated air, resulting in a reduction in mean 
(SD) inspiratory resistance [-1.0(1.8)%] as compared to pre-administration values and a 
relative reduction of -14.5 (7.2)% compared to conditions measured just after 1 breath.  
Similarly, the mean(SD) compliance improved, increasing from the pre-administration 
values by 3.1(2.7)% and increasing from conditions at breath 1 by 4.6 (0.1)%. 
The other conventional method of administration evaluated was the delivery of SDS 
using a commercial (CM) vibrating mesh nebulizer.  The CM aerosol system produced an 
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increase in inspiratory resistance of 7.6 (1.3)% immediately after 1 minute of nebulization 
during ventilation.  CM administration of surfactant did not change the compliance [0.0 
(8.7)%] in three replicate experiments.  After 20 minutes of ventilation therapy, the mean 
inspiratory resistance decreased, -7.4(6.8)% and the mean compliance increased by 
1.7(7.5)% compared with pre-administration conditions.  The mean (SD) mass of SDS 
aerosolized during 1 minute was 2.96 (0.09) mg.  Preliminary results from Chapter 6 
indicated that only 0.36% of the nebulized dose would be deposited in the lung, or 10.67 µg 
SDS.  This value seems very low compared with the expected surfactant pool (DPPC) in 
healthy lungs 4 mg/kg (Rebello et al., 1996); however, it is plausible that these 
improvements are related to the small amount of surfactant (synthetic) delivered 
considering the large effect that small amounts of surfactant can have on physiological 
response (Lewis et al., 1993). 
The M-C aerosol system was utilized to produce a charged aerosol with a reduced 
mass median aerodynamic diameter to reduce losses in the ventilator circuitry and 
enhance deposition within the lung by allowing for improved deep lung penetration and 
reducing the exhaled fraction.  This modified system aerosolized 0.23 (0.03) mg of 
surfactant during the 20 minute duration of the therapy.  Preliminary results from Chapter 
6 indicated that 21.3% of the nebulized dose would be deposited in the lung, or 49.5 µg 
SDS.  The M-C system had visibly fewer bubbles in the nebulizer’s reservoir after 20 
minutes of administration than the commercial signal displayed after 1 minute.  The M-C 
administration of SDS to the BIL model resulted in a 7.4 (1.7)% decrease in inspiratory 
resistance after the 20 minute therapy duration.  This decreased resistance was 
accompanied by an increased compliance, 1.9 (3.2)%.  The inspiratory resistance and 
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compliance response results are summarized in Table 5.2 and the responses of the BIL 
model to the administration techniques across equal ventilation times are summarized in 
Table 5.3.   
5.4 Discussion 
The novel BIL model was conceptualized, prototyped, and implemented in the 
ventilation circuit tested in Chapter 4 to produce realistic infant pressure-volume curves 
and increase the scope and usefulness of in vitro testing methods.  The P-V curves shown in 
Figure 5.4 are a basic measure of model realism and demonstrate a typical in vivo 
functionality generated by an in vitro system.  The inhalation and exhalation response 
occurred in the BIL model as expected with forced ventilation, are noted by the arrows of 
inhalation and exhalation in Figure 5.4.  The comparison against clinical data in Figure 5.5 
shows that the BIL model can be used to evaluate breathing conditions that result in 
normal distention.  Furthermore, the response of the BIL model to instilled and aerosolized 
surfactant administration was evaluated and compared to pre-treatment values of 
compliance and inspiratory resistance.  The inspiratory resistance increased after 
administration for both conventional systems, but decreased after 20 minutes of 
ventilation (Figure 5.6), presumably distributing the surfactant in the BIL model.  Finally, 
the low flow-induction charger developed in Chapter 3 and improved in Chapter 4 was 
compared with conventional surfactant administration techniques in the newly developed 
BIL model and a difference was demonstrated between inhaled and instilled surfactant 
administration techniques. 
 
 
117 
5.4.1 BIL Model Accuracy 
The primary source (80%) of inspiratory resistance is the upper conducting airways 
(trachea to generation 7), so if a change is observed in this model of the pleural cavities, the 
model must do an adequate job of capturing the effect of surface tension on the expansion 
of the spheres, simulating the alveolar space expansion’s dependence on surface tension 
(West 2012).  The administration of surfactant through instillation was not shown to 
improve the inspiratory resistance as compared in Figure 5.7 after 20 minutes of 
ventilation because of the airway obstruction presented by the bolus in the upper airways 
before and while it is distributed to the lungs.  The sigmoidal shape (or the breathing curve 
of multiple inflection points) described by Brochard (2006) is demonstrated by the BIL 
model in Figure 5.4.  An initial period of high stiffness (low compliance) changes at the first 
inflection point, approximately 10 mL, to a nearly linear section of increased compliance 
until max inhalation. The hysteresis of the P-V curve shown in Figure 5.4 also demonstrates 
higher lung volumes during exhalation for any given pressure as is typically found in the 
lung.  Not clearly demonstrated is the increased lung stiffness at high expanding pressures 
due to the lung protective values selected in this study; therefore, it is recommended that 
the peak inspiratory pressure of the model be increased to explore this trait.  As the human 
lung expands, geometrical arrangement of elastin and collagen changes, allowing the size of 
the airways to increase without changing the dimension of the individual fibers (West 
2012).   The BIL model is not expected to replicate this complex geometrical arrangement, 
rather the surface tension of the liquid layer between the airway fluid resists the expansion 
of the air gaps between them by acting as an elastic membrane holding the spheres 
together.  As a result, we expect the model to accurately capture aerosol deposition (based 
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on airway dimensions and correct ventilation rate) and mechanical properties related to P-
V curves and the application of surfactants in cases of surfactant deficient airways. 
5.4.2 Similarity of Model Predictions to In Vivo studies 
As mentioned in the Introduction, measurement of compliance and resistance was 
made of the BIL model during instilled and aerosolized administration of surfactant.  The 
improvement in lung properties due to surfactant deposition and dispersion was expected 
for all considered cases, but was only consistently observed with the M-C system.  In spite 
of the small amount of surfactant delivered (49.5 µg), the modified system outperformed 
the instilled and CM system likely due to the obstruction of the artificial airway with 
depositing or instilled liquid.  This obstruction is documented in multiple clinical surfactant 
instillation studies (Tarawneh et al., 2012; Wheeler et al., 2009), but not in aerosol delivery. 
The amount of liquid administered in the M-C case was reduced to 74 µL from 944 µL in the 
CM case and 4 mL in the instilled case.  The increased inspiratory resistance of the instilled 
case is likely a result of the large volume of instilled liquid.  The increased resistance of the 
CM aerosol case is likely a result of the aerosolized liquid collecting in the ETT.  The lack of 
increase in the M-C case indicates that the 74 µL is not obstructing the ETT, but is mostly 
humidifying the air through evaporation as the surfactant is being delivered.  It is known 
that small amounts of aerosolized surfactant can have effects equivalent to 1000-fold doses 
of instilled surfactant, likely due to improved distribution of the nebulized surfactant 
(Willson 2015).  The change in compliance was highly variable (SD > mean) in all cases, but 
the trend of the mean values indicate more compliant lung response in the M-C aerosol 
system.  Factors other than an increased compliance, such as better capillary stability and 
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decreased leakage of fluid into alveoli, have been suggested to explain the immediate 
improvement in oxygenation resulting from surfactant administration in clinical studies 
(Bhat et al., 1990). 
Pre-surfactant administration compliance was measured in a clinical study and 
ranged from 0.2 to 0.7 mL/cm H2O/kg in newborn infants before surfactant replacement 
therapy (Kelly et al., 1993).  This is compared with the pre-administration specific 
compliance of the BIL of 0.52 mL/cm H2O/kg, which results from dividing the quasi-static 
compliance of the model with 12 mL of liquid (1.85 mL/cm H2O) by the mass of the infant 
(3.55 kg).  The post-administration compliance values for infants with pre-adminstration 
compliance of approximately 0.52 mL/cm H2O/kg ranged from 0.45 mL/cm H2O/kg to 0.95 
mL/cm H2O/kg (Kelly et al., 1993), which is equivalent to a percentage change of between -
10% and 90% using the %InitialC equation previously defined.  In another study of instilled 
surfactant on 6 preterm neonates, the mean (SE) inspiratory resistance of the patient was 
96.5 (23.9) cm H2O / L ∙ sec before treatment, and decreased to 54.2 (7.7) cm H2O / L ∙ sec 
after instillation (3.3 mL/kg) of surfactant (Bhat et al., 1990). 
5.4.3 Conclusions and Model Refinement 
Using smaller spheres to more closely approximate the alveolar region may increase 
the realism of the model by reducing the amount that the pleural space needs to be scaled 
and allowing for greater fluid/surface interactions between the injected water and the 
spheres.  Using the method previously established requires a 2.38 mm sphere to produce a 
0.54 mm characteristic gap.  16 spheres of diameter 2.38 mm have the same volume as one 
6 mm sphere.  The surface area of the 16 smaller spheres is 2.52 fold higher than the single 
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sphere.  This leads to a larger contribution of surface forces, such as surface tension, 
overcoming issues of differentiating the flexible membrane compliance from the 
compliance of the expanding spheres.  Experimentally, 2.0 and 2.5 mm spheres are more 
likely to be used due to manufacturing constraints.  The 2.0 and 2.5 mm spheres result in 
characteristic diameters of 0.45 mm and 0.57 mm respectively.  All of these calculations are 
not considering the reduction in area due to the lung volume of liquid.  In future studies, It 
is recommended that the area be recalculated assuming a radius of curvature between the 
spheres to represent the dispersed liquid between the spherical contact points.  This will 
increase the difficulty in finding an analytical solution to the question of sphere size in the 
BIL, but provide a more realistic characteristic area for studies utilizing in vitro and in silico 
methods. 
The critical micelle concentration (CMC) of SDS in a water solution with 0.25%(w/v) 
NaCl was calculated to be 0.071%(w/v) (Dutkiewicz and Jakubowska 2002).  This is the 
concentration of SDS above which the SDS will form micelles (aggregates) due to the 
hydrophobic and hydrophilic nature of surfactants.  Micelle formation needs to be 
minimized in the aerosol administration of surfactant to prevent clogging of the vibrating 
mesh nebulizer.  The amount of SDS present during instilled administration is not critical 
because the SDS will spread into the fluid in the BIL model after administration.  The SDS 
concentration, 1.73%(w/v) is above the CMC, as is the aerosolized concentration, 
0.31%(w/v).  However, the LF-IC and the commercial nebulizer were still able to spray the 
SDS solution in spite of having a concentration higher than the CMC.  A decreased amount 
of NaCl in the formulation is suggested for future experiments (0.05% w/v) to increase the 
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SDS CMC to 0.147%(w/v) and maintain a conductive solution (approximately 5 mS/m) for 
effective induction charging with reduced micelle formation. 
The novel LF-IC developed in Chapter 4 was used with the newly developed BIL model 
to simulate the response to surfactant administration in an in vitro model for the first time.  
Optimization of administration techniques in the BIL model could increase understanding 
of surfactant therapies by determining the lung response for various nebulizer – surfactant 
combinations without endangering infants already suffering from RDS.  There are so many 
administration techniques to choose from and so many new drug formulations that 
improved in vitro testing moves from being an asset to a necessity to ensure patient safety 
and to reduce the number of failed clinical trials.  For instance, the BIL model had a lower 
inspiratory resistance after CM aerosol administration of SDS than M-C aerosol 
administration, and both were lower than after instilled administration, Figure 5.8.  These 
initial results exhibit realistic characteristics of an infant lung, but future modifications to 
the BIL can include: 
1. Reduced sphere diameter (6 mm to 2.5 mm) to more closely model the alveolar 
diameter;  
2. Reduced scaling of the BIL model for FRCs of healthy and distressed newborn lungs; 
and 
3. Extension of the upper airways geometry of model D from generation three to 
generation five to capture more of the upper airway resistance in the model and 
distribute the therapy in the middle of the spheres instead of near the pleural cavity 
wall.   
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In conclusion, an infant model capable of capturing the lung’s response to an 
administered surfactant under realistic in vitro ventilation conditions was developed and 
tested with instilled and aerosolized surfactant therapy.  The physiological properties 
measured, inspiratory resistance and quasi-static compliance, showed a realistic response 
to surfactant therapy and general agreement with published values from the literature.  
The aerosol therapy was shown to deliver approximately 1/1000th of the mass to the 
model, and yet the response of the model to the aerosol therapy was superior to the 
instilled therapy as is also the case in some clinical studies.  Further experimentation with 
the BIL model will determine the exhaled losses in a breathing model and test the ability of 
the previously developed LF-IC (Chapter 4) to increase the lung dose in a more realistic 
model.  
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Table 5.1 Lung physiological characteristics measured in the breathing infant lung 
(BIL) in a completely dry system and a wet system without surfactant. 
BIL Liquid Volume 
Inspiratory Resistance 
(cm H₂0 / L ∙ sec) 
Quasi-Static Compliance 
(mL / cm H₂0) 
0 mL 0.05% NaCl 25 (0%) 1.75 (3.3%) 
12 mL 0.05% NaCl 31 (5.9%) 1.85 (3.1%) 
N = 4 replicates of each measurement 
Value is reported as average (CV) 
BIL, Breathing Infant Lung; CV, Coefficient of Variation 
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Table 5.2 The effect of instilled, commercial (CM) aerosol, and modified and charged 
(M-C) aerosol administration of SDS on inspiratory resistance and quasi-static compliance.  
%Resistance and %Compliance are the change in resistance or compliance normalized by 
the pre-administration resistance or compliance. Decreasing resistance (-) is beneficial and 
increasing compliance (+) is beneficial. 
SDS Administration Technique %Resistance %Compliance 
Instilled 16.2 (8.0)% -1.4 (2.5)% 
CM Aerosol (1 min) 7.6 (1.3)% 0.0 (8.7)% 
M-C Aerosol (1 min) -1.0 (1.7)% 1.9 (3.2)% 
CM Aerosol (20 min) -7.4 (6.8)% 1.7 (7.5)% 
M-C Aerosol (20 min) -7.4 (1.7)% 1.9 (3.2)% 
N = 3 replicates of Instilled, Modified & Charged (M-C) and Commercial (CM) measurements 
Charged refers to the use of a 0.5 kV induction charger 
Value is reported as mean (SD) 
SDS, Sodium Dodecyl Sulphate 
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Table 5.3 The effect of instilled, CM aerosol, and M-C aerosol administration of SDS on 
inspiratory resistance and quasi-static compliance after 20 minutes of ventilation for each 
method.  The instilled system had 20 minutes of ventilation after administration, the CM 
system had 19 minutes of ventilation after 1 minute of administration, and the M-C system 
had 0 minutes of ventilation after 20 minutes of administration.  Decreasing resistance (-) 
is beneficial and increasing compliance (+) is beneficial. 
SDS Administration Technique %Resistance %Compliance 
Instilled -1.0 (1.8)% 3.1 (2.7)% 
CM Aerosol -7.4 (6.8)% 1.7 (7.5)% 
M-C Aerosol -7.4 (1.7)% 1.9 (3.2)% 
N = 3 replicates of Instilled, Modified & Charged (M-C) and Commercial (CM) measurements 
Value is reported as mean (SD) 
SDS, Sodium Dodecyl Sulphate 
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Figure 5.1 Drawing view of a.) Front and b.) Side of the mouth-throat model used 
to construct the upper airways of the BIL model. 
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Figure 5.2 Features of the BIL model highlighting a.) the interior of the pleural 
cavity, b.) the front view of the BIL, and c.) one of the two outlet covers prototyped to 
prevent bulk motion of the spheres in the pleural cavity. 
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Figure 5.3 Determination of characteristic diameter between 6 mm spheres.  An 
effective alveolar diameter is calculated by determining the area of a triangle 
between three tangential circles of equal diameter.  This triangle is an equilateral 
triangle with side length 6 mm.  The area of intersection between the triangle and a 
single circle is calculated by the equilateral angle, 60° of a 360° circle of radius 3 mm.  
This area is the same in all three circles, and can thus be multiplied by 3.  The area of 
intersection is subtracted from the area of the triangle to calculate the area between 
three tangential circles.  This area is then assumed to be circular to calculate an 
effective diameter, resulting in a characteristic diameter of 1.36 mm. 
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Figure 5.4 Pressure vs. Volume curves for a.) the BIL model without airway liquid 
and b.) the BIL model with 12 mL of airway liquid instilled without surfactant. 
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Figure 5.5 P-V curve determined from BIL model and compared with data for 
infants between 1 and 31 days old from Fisher et al. (1988). 
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Figure 5.6 Change in inspiratory resistance during the course of treatment. 
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Figure 5.7 The effect of increasing liquid volume in the BIL model on mean 
inspiratory resistance and comparison with instilled surfactant model after 20 
minutes of ventilation (error bars are ± 1 standard deviation). 
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Figure 5.8 Comparison of surfactant administration techniques considered (t = 20 
minutes; error bars represent ± 1 standard deviation). 
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6.1 Introduction 
In vitro experiments are important to establish parameters for the safe delivery of 
aerosol therapies before commencing in vivo studies (Byron et al., 2010; Carrigy et al., 
2014; Martin and Finlay 2014).  For instance, in the study of Finer et al. (2010), an in vitro 
infant model was used to determine the maximum possible delivered dose using an 
vibrating mesh nebulizer and a 2% synthetic surfactant solution, assuming that none of the 
aerosol that reaches the patient was exhaled.  These types of studies provide exposure 
limits for protecting patients during in vivo studies but are not representative of the actual 
dose delivered to the lung because they do not currently account for drug exhalation and 
often do not include realistic upper airway anatomies and breathing physiology.  In vitro 
testing of mean, small, and large models of the mouth and upper airways has been used to 
produce an in vitro-in vivo correlation to predict in vivo aerosol drug deposition using an in 
vitro test method for dry powder inhalers (Delvadia et al., 2013; Delvadia et al., 2012).  
However, most in vitro models do not account for the drug distribution within the lungs.  It 
is well known that drug distribution within the lungs can have a significant impact on 
therapeutic benefit (Usmani et al., 2003). 
Chapter 6 Evaluation of Aerosol Delivery to a Novel 
Breathing Infant Lung (BIL) Model 
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An in vitro model of an infant capable of realistically capturing the lung dose of an 
administered pharmaceutical aerosol under actual ventilation conditions would clearly be 
a beneficial tool.  In designing this breathing infant lung (BIL) model for testing inhaled 
therapies, drugs with high cost and significant side effects were primarily considered.  
Development of inhaled therapies for infants has been hindered by low delivery efficiency 
(high waste) and high variability (uncontrolled dose) (Mazela and Polin 2011; Shah et al., 
2007).  Surfactants are very expensive, steroids need low variability because of adverse 
side effects, and antibiotics need to be delivered in high and consistent doses to prevent 
resistant strains of bacteria from surviving (Lehne and Rosenthal 2014).  Bronchodilators 
such as Albuterol Sulfate (AS) are typically inexpensive, have low side effects, and don't 
require a large dose.  AS was used as a marker to determine the depositional loss and 
delivery efficiency of the LF-IC in the novel BIL model.  Implementation of the BIL model 
will quantify the depositional reduction due to aerosol exhalation using an in vitro 
experiment. 
A realistic breathing model of the infant lung was designed and constructed in 
Chapter 5.  It was then evaluated using ventilator measurements of compliance and 
inspiratory resistance during instilled surfactant therapy.  A model of a full term neonate 
respiratory system was developed using an infant patient CT scan of the pleural space and 
digitally assembled with a previously constructed trachea model, Model D (Walenga et al., 
2013).  This assembled model was rapid prototyped and filled with solid spheres to 
simulate the packed expansion of the alveolar region.  The expected alveolar outer 
diameter of 0.54 mm (Khajeh-Hosseini-Dalasm and Longest 2014) was approximated by 
the gaps formed between the spheres.  Instillation of a liquid produced a surface tension 
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between the spheres and created a compliance and resistance in the model that was more 
than just the elasticity of the flexible membrane. 
Development of aerosol delivery protocols often rely on in vitro studies to determine 
the mass of drug delivered to the lung.  However, these in vitro studies are not able to 
account for the reduction in lung deposition caused by exhalation.  In vitro models over 
estimate the dose to a patient because they use an absolute filter which cannot simulate 
drug loss due to exhalation (Dhand 2008; Fink and Ari 2013; Fink 2004; Guerin et al., 
2008), as was applied in Chapter 4.  For example, in the recent study of Mazela et al. (2014), 
a novel connector was used to bypass the bias-flow and increase delivery of a jet nebulized 
aerosol.  The lung delivery efficiency of approximately 2–7% was a significant 
improvement over the less than 1% efficiency achieved with standard care, but this was 
measured before the endotracheal tube (ETT), without an inline flow meter, and not 
considering exhalation (Mazela et al., 2014).  Large particles are often filtered out by 
ventilation circuitry such that the aerosol mass median aerodynamic diameter (MMAD) 
after an infant ventilation circuit and a 3 mm ETT was measured as 1.4 µm for a vibrating 
mesh and a jet nebulizer which generated aerosols with MMADs of 4.6 and 4.8 µm, 
respectively (Dubus et al., 2005).  Inefficient delivery and exhalation of inhaled aerosol 
therapy has been addressed by reducing aerosol MMAD to < 1.8 µm, as suggested by 
Longest et al. (2014b), and inducing a charge on the aerosol to increase deposition in the 
lung (Chapter 4).   
Delivery of aerosol therapy to infants using a metered dose inhaler (MDI), jet 
nebulizer, or a vibrating mesh nebulizer result in low lung delivery efficiencies ranging 
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from <1-14%, with the greatest efficiency coming from the vibrating mesh nebulizer 
(Dubus et al., 2005; Fink 2004; Fok et al., 1996; Mazela and Polin 2011; Sidler-Moix et al., 
2013).  The research and development of aerosol therapies such as vaccines, gene therapy, 
cancer treatment, and diabetes management were recently reviewed in clinical and in vitro 
studies (Rubin and Williams 2014).  The high variability and low delivery efficiency of 
aerosolized medications need to be improved for the development of next generation 
medications and more efficient implementation of current inhaled therapies (Brion et al., 
2006; Cole et al., 1999; Fink 2004; Rubin and Williams 2014; Shah et al., 2007). 
In this chapter, depositional losses and delivery efficiency were determined in the 
BIL model using the same techniques described in Chapter 4.  A modified signal was 
supplied to a vibrating mesh nebulizer (Aeroneb Lab; Aerogen, Galway, Ireland) to reduce 
the output rate and initial momentum of the generated aerosol (described in Chapter 3).  
This modified output was sprayed into a streamlined induction charger that has been 
previously optimized (Chapter 4) to deliver aerosol efficiently under cyclic ventilation 
conditions in an infant ventilation circuit.  The experiments of Chapter 4 demonstrated a 
dramatic 26-fold increase in delivery efficiency, but a reduction in the rate of delivered 
mass to the inhalation filter.  However, these in vitro tests were conducted assuming zero 
exhalation of the aerosol from the lung.  The systems designed and implemented in 
Chapters 3, 4, and 5 will be applied to a test case of aerosolized albuterol sulfate (Spectrum 
Chemicals, New Brunswick, NJ; a model drug commonly used as a bronchodilator) to 
determine the impact of charging on the exhalation of an aerosol < 1.8 µm (MMAD) and test 
the ability of the BIL model to simulate the exhalation of inhaled aerosol.  The lung 
deposition in this study is expected to be lower than the filter data collected in Chapter 4 
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(34%), but the difference between the commercial system and the modified and charged 
delivery system is expected to be greater than the 26-fold increase demonstrated in 
Chapter 4. 
The object of this study was to compare the performance of the previously 
implemented LF-IC with a commercially available nebulizer under realistic flow conditions 
in a BIL model (Chapter 5) designed to capture both deposited and exhaled dose.  
Conventional and modified aerosol delivery techniques with a vibrating mesh nebulizer 
were considered and suggestions are given for method of administration based on: 
1. Cost; 
2. Adverse side effects; 
3. Dosage; and 
4. Speed of delivery. 
After creating an in vitro method of testing lung deposition of aerosol therapy without 
assuming perfect capture within the lungs, the LF-IC is suggested for use with drugs that 
have a high cost and significant side effects such as surfactants, antibiotics, and steroids 
because the emphasis of the LF-IC design was on maximizing delivery efficiency rather 
than maximizing the rate of mass delivery.  Still, mass delivery rate appears acceptable for 
many high dose medications considering that continuous long-term delivery is possible 
during mechanical ventilation and may be preferred from a clinical standpoint in some 
cases. 
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6.2 Methods 
The BIL model was composed of two regions: the upper airways through the third 
tracheobronchial bifurcation (B3), which were derived from CT scan data, and the lower 
airways, which were experimentally modeled using packed spheres within a pleural shell 
built from CT data.  Functional residual capacity (FRC) is defined as the volume of air 
within the lung after passive exhalation and was used in the scaling of the pleural model.  
The scaled model was rapid prototyped and is shown in Figure 6.1.   Full details on the 
construction and properties of the BIL model can be found in Chapter 5.  The BIL model 
was tested under the same cyclic ventilation conditions as Chapter 5 and using the same 
aerosol generators developed in Chapter 4, with commercial (CM), modified - uncharged 
(M-UC) and modified - charged (M-C) systems defined in Table 6.1.  CM, M-UC, and M-C 
components are summarized in the system schematics, Figure 6.2.  
The systems were evaluated using three metrics: lung delivery efficiency (η), mass 
of drug delivered per 4 mL loading (Mass4mL [μg]), and the mass of drug delivered to the 
lung in one minute (Mass1min [μg]).  The delivery efficiency, η, was defined as the lung dose 
(μg) divided by the recovered dose (μg) multiplied by 100.  The drug formulation (0.25% 
albuterol sulfate, 0.25% sodium chloride) and the process of recovering the drug (washing 
and HPLC analysis) were unchanged from Chapter 4.   
6.2.1 Model Design and Construction 
Two thousand two hundred fifty spheres at a random packing density of 0.641 with 
a 6 mm diameter and a mass of 0.12 grams per sphere were used to model the alveolar 
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region in a 3.55 kg infant.  The pleural space that housed the spheres was digitally 
constructed from an infant CT scan and combined with an adult mouth throat model, Model 
D, (Walenga et al., 2013) which was scaled to infant dimensions (using a length scale factor 
of 0.377).  The spheres used (Crosman Corporation; Bloomfield, NY) were 6 mm, light 
weight (density is approximately equal to water), plastic  and the characteristic dimension 
between the spheres was 1.36 mm (Figure 6.3 ), which is an approximation of the expected 
alveolar airway outer diameter of 0.54 mm (Khajeh-Hosseini-Dalasm and Longest 2014).  
The characteristic dimension between the spheres was calculated based on the area 
between three adjacent 6 mm (diameter) circles on a plane.  Chapter 5 confirmed realistic 
response of the BIL model to instilled surfactants without visible pooling of the 12 mL of 
injected solution to represent airway surface liquid. 
6.2.2 Implementation in Ventilation Circuit 
After construction with a stereolithography rapid prototyper from 3D Systems, each 
pleural cavity was loaded with the appropriate number of spheres to achieve the desired 
FRC. The pleural cavity was not filled completely, this allowed for expansion between the 
spheres during inhalation.  The number of spheres added was determined gravimetrically 
using a mass balance.  A rapid prototyped mesh was fixed to the pleural outlets to prevent 
bulk motion of the packed spheres and a flexible membrane was attached after the mesh.  
The ventilator circuit was connected to a 3 mm infant ETT as outlined in Chapter 4.  This 
ETT was inserted past the glottis and near the first bifurcation of the breathing lung model 
(Figure 6.1).   
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6.2.3 Experimental Parameters and Analysis 
As described in chapters three and four, washing with deionized water and analysis 
using validated High Performance Liquid Chromatography (HPLC) method followed each 
experiment.  Three replicate experiments were conducted using the CM system, three using 
M-UC, and three using M-C.  The system was disassembled for washing, the spheres and the 
BIL shell were washed together as one part, and the 6 mm spheres were discarded after 
one use.  The ETT was separated from the LF-IC and removed from the BIL model before 
washing.  As in previous chapters, nominal dose was calculated by weighing the nebulizer 
before and after an experimental run on a mass balance and multiplying by the 
concentration of the solution.  Total mass recovery of greater than 90% of the nominal dose 
indicated a high quality experiment.  Additional information on the nebulizer 
synchronization, ventilation parameters, and analysis techniques were presented in 
Chapter 4 and are clarified for the CM, M-UC, and M-C systems in Table 6.1. 
6.3 Results 
 CM, M-C, and M-UC delivery of aerosolized AS was evaluated in an infant lung model 
designed to simulate both realistic airway deposition and exhalation of inhaled drug using 
an in vitro approach.  The results of CM, M-C, and M-UC delivery in the BIL model are shown 
in Figure 6.4.  The modified delivery was accomplished using the LF-IC developed in 
Chapter 3 and Chapter 4, with and without an induction charging voltage.  The lung 
efficiency, η, is defined as the mass of drug depositing in the lungs divided by the total 
deposited mass.  The expected dose to the lung was also reported as the amount (µg) of 
drug deposited in the lung normalized by a typically administered volume of solution, 4 mL 
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(Mass4mL).  Finally, the delivery rate over one minute of the CM and modified systems was 
calculated, Mass1min.  In addition to the lung delivery values, the depositional loss in the 
ventilation circuit was reported in this new in vitro BIL model. 
6.3.1 CM System 
 Depositional loss and drug delivery to the lung was assessed in the BIL model using 
a commercially available vibrating mesh nebulizer for comparison with clinical studies of 
aerosol delivery to ventilated infant patients.  Results are summarized in Figure 6.4 as 
mean (SD) % deposition, which is calculated based on the drug mass in each section 
divided by the total recovered dose and expressed as a percentage.  The nebulizer and T-
connector had a high depositional loss of 68.4 (2.8)% of the aerosol.  The fraction of drug 
deposited in the exhalation filter was 18.7 (1.5)%.  A large portion, 7.4 (0.6)% of the 
aerosol deposited in the Y-connector and 4.1 (2.0)% deposited in the flow meter.  Only 1.0 
(0.1)% of the aerosol deposited in the ETT, due to high upstream losses.  The patient 
received 0.36 (0.1)% of the total recovered dose in the lungs.  This low lung delivery 
efficiency (η = 0.36%) was also demonstrated in the amount of drug delivered to the 
patient for a typical 4 mL loading, which was 36 µg (Table 6.2).  However, the delivery rate 
of the commercial vibrating mesh nebulizer was 7.15 µg/min to the lungs under the 
specified parameters with the previously characterized system.  The percentage of 
aerosolized AS recovered within the experimental system was  90% of the nominal dose 
in all CM experiments. 
 
 
143 
6.3.2 Modified aerosol delivery to the BIL model 
6.3.2.1 M-UC System 
To provide a reference value for the effect of inducing a charge on the aerosolized 
AS, the depositional loss and delivery efficiency was first examined without the high 
voltage power supply (M-UC), as summarized in Figure 6.4.  The depositional loss on the 
nebulizer and the T-connector was 23.7 (6.5)% of the total recovered mass.  In the 
modified delivery system, the nebulizer and T-connector were directly connected to the 
ETT.  The depositional loss in the ETT was 24.2 (4.2)%, leaving 52.1% of the nebulized AS 
to potentially deposit in the BIL model.  Of this, the majority was exhaled and only 20.6 
(6.8)% deposited in the lung (but with 57-fold improvement in delivery efficiency over CM 
delivery).  This exhaled dose deposited in the flow meter [4.8 (1.0)%], Y-connector [1.0 
(0.5)%], and eventually in the exhalation filter [25.8 (8.7)%].  Excellent mass balance was 
achieved during uncharged delivery as 98.2 (5.3)% of the nominal mass was recovered in 
the three experiments.  The increased lung delivery efficiency (η = 20.6%) was reflected in 
the mass of drug delivered to a patient in a typical 4 mL loading, which was 2,056.9 µg.  The 
delivery rate of the uncharged and modified delivery system decreased to 2.87 µg/min in 
the BIL (2.5-fold decrease compared with the CM system).  In the uncharged system, 60.5% 
of the aerosol that reached the lung was exhaled. 
6.3.2.2 M-C System 
The M-C delivery system was evaluated with an induction charging voltage of 500 
volts and compared with the CM and M-UC system in terms of depositional loss and drug 
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delivery efficiency to the lungs (Figure 6.4).  The charging field present in the nebulizer and 
T-connector caused the depositional losses to increase to 32.2 (6.2)%.  The charged aerosol 
also experiences greater deposition in the 3 mm ETT, 26.5 (4.3)%.  These losses left 41.4% 
of the nebulized aerosol to potentially deposit in the BIL model before exhalation.  
However, only 21.3 (2.4)% of the aerosol deposited in the lungs, with the remaining 
fraction exhaled from the lungs.  This exhaled fraction deposited first in the flow meter 
[3.42 (0.4)%], then in the Y-connector [0.76 (0.1)%], and finally in the exhalation filter 
[15.9 (0.5)%].  Normalizing the exhalation by the amount of drug entering the BIL, 48.6% 
of the aerosol that reached the lung was exhaled.  The depositional efficiency (η = 21.3%) 
found in the lung was reflected as the dose to the lung per 4 mL solution loading, which was 
2,127 µg.  The lung delivery rate decreased in the charged and modified delivery system 
from the CM rate of 7.15 µg/min to 2.65 µg/min [2.7-fold decrease], but the delivery 
efficiency, η, increased 59-fold compared to the CM system. 
6.4 Discussion 
This chapter evaluated the low flow induction charger (developed in Chapters 3 and 
4) together with other techniques to optimize aerosol delivery η outlined in Table 6.1 using 
the BIL model of Chapter 5.  Previous in vitro models cannot simulate drug loss due to 
exhalation (Fink and Ari 2013).  The importance of accounting for exhalation when 
measuring lung dose was demonstrated and the impact of aerosol charge on the reduction 
of exhalation in a realistic model was quantified.  The LF-IC implementation in the BIL 
model was evaluated in terms of lung delivery efficiency, lung delivery rate, and lung 
delivery per 4 mL solution loading of the nebulizer.  Based on these criteria, the LF-IC is 
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recommended for further optimization and implementation in animal models for inhaled 
therapies that require efficient delivery over long treatment times. 
Comparing performance of the CM case evaluated in Chapter 4 and now evaluated 
with the BIL model illustrated the impact of exhalation on deposition in two key areas, the 
nebulizer and T-connector as well as the inhalation filter or the BIL model.  As expected, the 
exhaled fraction did not have considerable effect on the depositional losses in the nebulizer 
and T-connector.  The results from Chapter 4 and the BIL model results showed very high 
deposition of approximately 68%.  Unlike the depositional losses near the nebulizer, the 
already low lung delivery efficiency of 1.6% decreased 4-fold to 0.36% when exhalation 
was modeled in vitro.  This efficiency was similar to many observed nebulization therapies 
in vivo, but much lower than the vibrating mesh nebulizer delivery in the animal model of 
Dubus et al. (2005), for reasons described in Chapter 4. 
The drug delivery rate was also calculated and compared against the inhaled dose 
established in Chapter 4.  The CM delivery rate to the inhalation filter was reported to be 
25.6 µg/min using a 0.25% AS solution.  Replacing the inhalation filter with a breathing 
model of an infant lung reduced the delivery rate 3.6-fold to 7.15 µg/min.  Based on this 
finding, studies such as Finer et al. (2010), which used an in vitro system to determine the 
delivery rate of the aerosol and in turn the patient’s treatment time, may need to increase 
delivery duration approximately 3.5-fold to account for the reduction in delivery due to 
exhaled dose.  It is recommended that this in vitro determination of in vivo delivery 
duration be conducted with a more realistic breathing model.  The modified system also 
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experienced a decreased delivery rate under exhalation conditions, but instead of a 3.6-fold 
decrease it was a 1.3-fold decrease of Mass1min from 3.5 to 2.7 µg/min.   
The CM system delivered more drug to the lung in a fixed amount of time because of 
two factors: the reduced mass output resulting from the modified signal and the reduced 
nebulization time resulting from the synchronized delivery of aerosol.  The CM system was 
continuously operated, whereas the modified system was running for 0.11 seconds of every 
2 second breath (1/18th) and 1/10th of the drug was produced from the nebulizer when it 
was operated using the modified signal.  Considering both of these aspects, there was 
1/180 of the drug in the circuit.  The charged system was about 60x more efficient (21.3% 
/ 0.36%), which means that approximately 60/180 of the CM delivery (2.38 µg/min) was 
expected to reach the infant lung. 
As mentioned in the Introduction, the improvement in lung deposition due to 
modified delivery and induction charging was expected to be even greater than the 26-fold 
improvement of inhaled dose from Chapter 4.  The CM system provided an inefficient 
delivery of 0.36% to the BIL model.  The modified system, used a 500 Volt induction 
charger improved the lung delivery efficiency to 21.3%.  As expected, this 21.3% efficiency 
was less than the inhaled efficiency determined in Chapter 4, of 34% (Figure 6.5).  
However, the improvement over CM delivery was greater than the Chapter 4 26-fold 
improvement of inhaled dose, achieving a 59-fold improvement in delivery efficiency to the 
BIL model. 
To consider the impact the induction charger had on the exhaled fraction, the 
modified system was run without and with the high voltage source in the induction 
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charger.  The deposition in the LF-IC and the ETT was increased when the charger was 
operational; meaning that less drug reached the lung model to be deposited or exhaled.  To 
examine the effect of charging on exhaled dose, the exhaled dose was normalized by the 
amount entering the BIL model.  Using this normalization technique, the mean(SD) exhaled 
fraction of drug that entered the BIL model was 65.7 (12)% in the uncharged case.  
Applying an induction charging voltage of 500 Volts decreased the exhaled fraction to 48.5 
(9)%, a 17.2% increase.  However, conducting a two tailed Student’s t-test resulted in a p 
value of 0.112 which means that the effect of induction charging on improving lung 
deposition is not significant at p<0.05 but does provide a weak correlation with the current 
sample size of 3 replicates per experiment.   Increasing the number of replicate 
experiments in future revisions of the LF-IC and the BIL model is expected to provide a 
stronger correlation due to a lowered variability and a higher signal to noise ratio. 
The commercial mesh nebulizer (Aeroneb Lab) that was used for all experiments had a 
capacity of 10 mL, but many nebulizer ampules are in 4 ml quantities. To demonstrate the 
increased efficiency of the modified system, the dose (in µg) delivered for a typical 4 mL 
solution loading was determined (Table 6.2). This produced an estimate of the total 
amount of drug that could be administered to a patient with a typical single nebulizer 
loading. In the case of the CM system, this would mean that a care provider would need to 
refill the nebulizer (10 mL) about every 15 minutes to deliver more than 90 µg (the amount 
delivered to the lung in 10 mL of solution) of drug at the concentration used (0.25%).  This 
was in contrast to the modified system's ability to spray for approximately 30 hours 
without needing to be refilled by a care provider.  In some instances, like delivery of 
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Illoprost for pulmonary hypertension, long delivery times are preferred.  The total dose 
that could be delivered to a patient in the 10 ml loading was 5,142 µg.   
The novel infant lung model developed in Chapter 5 was used with the low flow 
induction charger improved in Chapter 4 to simulate the exhalation of an inhaled aerosol in 
an in vitro model for the first time.  Optimization in the LF-IC using the BIL model could 
increase the drug delivery rate by determining the best timing and duration of 
nebulization.  In addition, the BIL model could be used to optimize the induction charging 
voltage to minimize depositional losses and the exhaled fraction.  Furthermore, the LF-IC 
design could still be improved to reduce depositional loss in the device.  The CM system is 
acceptable when quick delivery is needed with an inexpensive drug that has low side 
effects and does not require a high dose for a clinical response.  A 59-fold improvement in 
lung delivery efficiency was seen in the LF-IC over the CM vibrating mesh nebulizer and a 
reduction in exhaled aerosol was the result of induction charging a 1.6 um aerosol under 
infant ventilation conditions in the novel BIL model. 
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Table 6.1 Naming convention and parameters for the commercial (CM), modified and 
uncharged (M-UC), and the modified and charged (M-C) systems. 
 
Mass output 
reduced 
Breath 
Synchronized 
0.5 kV 
charging 
Streamlined 
Components 
Nebulizer 
located after 
Y-connector 
CM No No No No No 
M-UC Yes Yes No Yes Yes 
M-C Yes Yes Yes Yes Yes 
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Table 6.2 Lung delivery efficiency (η), mass of AS (µg) delivered to BIL model per 4 mL 
loading (Mass4mL), and mass of AS (µg) per minute (Mass1min). 
 
Lung delivery 
efficiency (η) 
Mass of AS (µg) 
delivered to BIL 
model per 4 mL 
loading (Mass4mL) 
Mass of AS (µg) 
delivered to BIL 
model per minute 
(Mass1min) 
CM 0.36 (0.1)% 36.09 (8.34) 7.15 (1.88) 
M-UC 20.57 (6.8)% 2056.85 (684.5) 2.87 (1.01) 
M-C 21.27 (2.4)% 2127.27 (239.3) 2.65 (0.72) 
Mean (SD) BIL model results for 0.25%  AS, 0.25%  NaCl (N=3) 
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Figure 6.1 Breathing infant lung model digitally constructed from patient CT scans 
and rapid prototyped to estimate the exhaled fraction in an in vitro study of 
mechanical ventilation through a 3 mm endotracheal tube.  
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Figure 6.2 Connection configuration for (a) Commercial aerosol delivery (CM) and 
(b) Modified aerosol delivery (M-UC & M-C). 
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Figure 6.3 6 mm spheres arranged to show approximate average area between the 
spheres. 
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Figure 6.4 Comparison of drug (AS) delivery efficiency in a commercial vibrating 
mesh nebulizer (CM), the uncharged vibrating mesh nebulizer with a reduced mass 
output (M-UC), and the vibrating mesh nebulizer with an induced charge and a 
reduced mass output(M-C). 
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Figure 6.5 Modified and charged (M-C) albuterol sulfate deposition in the in vitro 
breathing infant lung model as compared to a mechanically ventilated filter model 
system capturing modified and charged (500 V) albuterol sulfate from Chapter 4. 
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 As described in Chapter 1, the specific aims are divided into two objectives and 
seven tasks.  Each of these objectives has been met and each task will be briefly 
summarized.  In Task 1.1 an electrospray device was designed and prototyped for the 
generation of a highly charged submicrometer aerosol with no moving parts, but the mass 
output of the device was not high enough for delivery of pharmaceutically relevant 
concentrations of aerosol.  Task 1.2 consisted of the development of a condensational vapor 
device designed to generate a submicrometer aerosol through heated phase change in a 
thin walled metal capillary followed by condensation after ejection from the heated region.  
The completion of Task 1.2 resulted in a very small aerosol that was not charged due to 
unsuccessful radial gradient charging, necessitating a third device.  Task 1.3 utilized a 
commercial vibrating mesh nebulizer with a modified electrical input signal to produce less 
aerosol (by mass) and a smaller initial aerosol momentum coupled with induction charging 
that was measured for the polydisperse aerosol.  Task 1.4 made use of the low flow 
induction charger (LF-IC) to evaluate the depositional loss in an infant ventilation circuit 
under steady state flow conditions.  Having determined the appropriate runtime in Task 
1.4, Task 1.5 considered implementation of the LF-IC in a ventilation circuit within realistic 
cyclic flow conditions, which made necessary a movement of the nebulizer location from 
before the Y-connector to after for the reduction of depositional losses in the flow-meter 
Chapter 7  Conclusions and Future Work 
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and a redesign of the LF-IC to reduce the dead volume for patient safety in the new 
nebulizer location.  In Task 2.1 a novel breathing infant lung (BIL) model was developed 
from a previously constructed mouth throat model and CT scan reconstruction of an infant 
pleural cavity.  This model was filled with 6 mm spheres to represent the alveolar region 
and used to test lung response and surfactant administration techniques.  The developed 
model from Task 2.1 was then used in Task 2.2 to quantify the exhaled fraction from a 
vibrating mesh nebulizer and the refined delivery system from Task 1.5 under realistic 
ventilation parameters.  Conclusions are drawn from these tasks and summarized under 
each objective below with an identification of future study areas.  
Objective 1: Development of an effective method for generating charged 
pharmaceutical aerosols with low depositional loss for use with invasive 
mechanical ventilation. 
 An electrospray device was developed and considered for infant delivery, but the 
chosen wick material was not substantial enough to spray the chosen drug formulation 
without degrading the wick material and causing the spray to end after approximately 20 
minutes.  The rate of delivery of the electrospray device would have required more than 8 
hours of therapy to achieve a pharmaceutically meaningful dose, which is acceptable for 
some drugs.  However, the electrospray device is not capable of spraying for long periods of 
time in the tested system configuration.  For the purpose of this work, electrospray was not 
selected due to the sensitivity of the process to the drug solution and the low output rate of 
the tested system.  Future work could be conducted to implement the electrospray using a 
metal capillary and a syringe pump to simplify the solution selection process and then 
implemented in a superior wicking material that will not degrade or dry out over an 8 hour 
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run.  If an electrospray system is designed that can deliver a pharmaceutically relevant 
aerosol over the course of an 8 hour run, then the charge level will need to be assessed to 
determine if it is too high for delivery through the ventilator circuit. 
 A modified control signal was used to reduce the mass output of a commercially 
available vibrating mesh nebulizer and allow for effective size reduction of the generated 
aerosol with an infant flow rate.  The droplet size distributions given by the impactors 
operating at 2 and 30 LPM (1.57 µm and 0.88 µm) demonstrate the importance of the 
volumetric flow rate of sampling air for the evaporation of an aerosol.  It is important for 
ventilated patients to have a humidified supply line that is will not dry the lungs (Fink and 
Ari 2013). The difference between DSDs demonstrates the remaining water content of the 
aerosol at realistic infant flow rates that will enable delivery to the infant lungs without an 
additional humidity generator to prevent drying of the airways.  Future characterization 
work should be done on multiple vibrating mesh nebulizers (VMN) of the same type as the 
work done here has been completed using a single unit.  Consideration of the ventilation 
parameters and ETT on droplet MMAD and charge distribution would be beneficial for 
future CFD studies and comparison to clinical results (Dubus et al., 2005; Longest et al., 
2013a).  The impact of synchronized delivery on MMAD and charge distribution should 
also be determined after the 3mm ETT.  Additional experiments determining the charge 
per particle with induction charging voltages varying from 0 to 2000 volts in 250 volt 
increments would better characterize the charging capabilities of the LF-IC. 
 The streamlined LF-IC was 5-fold more efficient at delivering aerosol to a filter than 
the commercial VMN in a commercial T under steady-state infant ventilator conditions.  
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This improvement resulted from the reduced momentum in the modified system causing 
less impaction in the LF-IC than in the commercial T as well as the reduced mass output 
system having a smaller MMAD and less deposition in components due to superior drying.  
The LF-IC was then modified for implementation in a different location of the ventilator 
circuit due to the presence of bias-flow and a built in flow meter (not previously 
considered) that is not removable from the Galileo ventilator [like many other ventilators 
(Schena et al., 2015)].  A reduction of LF-IC device volume was necessary to minimize the 
ventilator dead volume and potential re-breathing of exhaled gas.  To reduce the exhaled 
drug, the nebulizer was breath synchronized to generate an aerosol that would be 
delivered to a lung filter instead of an exhalation filter. The redesigned LF-IC delivered 26-
fold more aerosol to the inhalation filter as compared to the commercial VMN.  Future 
studies are needed to optimize the timing and duration of synchronization.  The current 
system generates aerosol during the last 0.11 seconds of exhalation, but it is suggested by 
the author that aerosol be generated during the last 0.1 seconds of exhalation and the first 
0.1 seconds of inhalation as a starting point to determine the most efficient timing. Most 
importantly, optimization of the redesigned LF-IC is recommended to reduce the 
depositional loss in the device and increase the filter delivery to the potential fraction 
determined by CFD, approximately 60% (Longest et al., 2014a).  In conclusion, an effective 
method was developed for generating a pharmaceutical aerosol for use with mechanical 
ventilation.  
 
 
160 
Objective 2: Use of charged aerosols for targeted deposition in infant 
airways. 
 A novel model of the infant lung was developed based on physiological data to allow 
testing of surfactant administration and the highly efficient LF-IC developed for the 
previous objective.  This model provides a unique opportunity for realistic testing of 
inhaled aerosols and instilled therapies without the ethical considerations or high costs 
associated with clinical research in infants.  The BIL simulates the deposition of an aerosol 
within the lung unlike any known model and allows for a more realistic measurement of 
delivered and exhaled dose.  This is particularly helpful when developing a method to 
reduce the exhaled fraction of inhaled aerosol.  Characteristic traits of the lung are 
exhibited in the pressure-volume curve, which was recorded during invasive mechanical 
ventilations using infant ventilations parameters.  The specific compliance of the BIL was 
shown to fall within a range of values observed in a clinical study of surfactant deficient 
infants before treatment with surfactant (Kelly et al., 1993).  The model also demonstrated 
an increase in inspiratory resistance immediately following instillation of surfactant.  This 
is thought to reflect the airway obstruction that has been observed in multiple studies of 
instilled surfactants in infants, with harmful consequences (Tarawneh et al., 2012; Wheeler 
et al., 2009).   The BIL model could be very useful to the American Academy of Pediatrics as 
a tool to assess methods of administration and evaluate the harm that can be inflicted by 
instillation and the benefit of aerosol administration.  A small amount of aerosol (49.5 μg) 
delivered to the BIL was shown to improve physiological lung function in the BIL model as 
was also described in the study of Lewis et al. (1993) considering deposition of 0.5 mg/kg.  
The next study with the BIL should consider an increased dose of surfactant 
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(approximately 10 to 100 times more) by some combination of an increased solution 
concentration, improved delivery efficiency, and increased runtime.  Additional 
experimentation needs to be conducted in parallel with Mr. Karl Bass’ CFD work to 
determine the sphere size that should be used in future versions of the BIL model, the 
initial recommendation of this researcher is a 2-2.5mm sphere instead of the 6mm sphere 
to more closely mimic the alveolar diameter of 0.54mm (Khajeh-Hosseini-Dalasm and 
Longest 2014). The BIL model can also be digitally reconstructed with a functional residual 
capacity of 110mL, which is more representative of newborn infants (Lumb 2012).  With 
this rescaled model that utilizes smaller spheres, the appropriate volume of fluid will need 
to be reconsidered using the same method described in Chapter 5.  Finally, even without 
modifying the BIL it could prove informative to consider the physiological response of the 
model to a bovine derived surfactant such as Survanta (Abbvie; North Chicago, IL), which is 
approved for clinical use by the United States FDA. 
 Another application of the BIL which was evaluated is the use of the developed LF-
IC to target delivery in the lung.  As determined in the previous objective, the output 
aerosol size of the LF-IC was less than 1.8μm, which should greatly reduce the losses in the 
ventilator circuit, but is also expected to reach the alveolar region and have reduced 
deposition in the upper airways.  The delivery efficiency of the LF-IC is compared with the 
commercial vibrating mesh nebulizer and is found to increase from 0.36% to 21.3%. This 
59-fold improvement over commercial delivery demonstrates the importance of 
minimizing depositional losses in the device due to impaction, losses due to bias-flow, 
losses due to the built in flow meter, and depositional losses in the ETT due to an initially 
large MMAD.  The primary purpose of this device was to increase the delivery efficiency, 
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but the trade-off for 59-fold increased efficiency was a 2.6-fold decreased delivery rate 
from 7.15μg/min to 2.7μg/min.  Induction charging of the aerosol increased the 
depositional loss on the LF-IC, but considering the fraction of drug entering the BIL, 
charging the aerosol decreased the exhaled fraction by 17% (not statistically significant).  
The BIL enables additional considerations to be evaluated in future studies.  In cases when 
increased delivery rate is more desirable than efficiency, it will be important to increase 
the duration of nebulization from the current 0.11 seconds to 0.33 seconds.  This is 
expected to directly increase the delivery rate, but may decrease the delivery efficiency.  It 
is recommended that the beginning of nebulization remain 0.11 seconds before inhalation, 
but the nebulization period extend 0.22 seconds into inspiration.  This is still less than the 
first half of inspiration used in the study of Longest et al. (2014a).  The LF-IC can also be 
used to deliver medicines that are expensive or have adverse secondary effects in an in vivo 
rat study comparing invasive and non-invasive delivery of aerosol generated by the LF-IC 
and by the commercial VMN as well as an additional conventional method, such as instilled.  
This in vivo study can be used as another benchmark for the BIL model by aerosolizing a 
radio labeled dose and comparing the regional deposition in the animal model and the BIL 
model using gamma scintigraphy (Biddiscombe et al., 2011).  
 The BIL model also provides a way of evaluating additional administration 
techniques such as dry powder inhalers, metered dose inhalers, and jet nebulizers.  The 
same study of albuterol sulfate should be considered again after the BIL model has been 
modified with refined sphere size (2.5 mm), additional morphology in the upper airways 
(to generation 7), and potentially altered ventilation parameters such as inspiratory time 
and positive end expiratory pressure.  Finally, the development of a breathing adult lung 
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(BAL) model to accompany the BIL model could be useful for testing adult therapies which 
have a larger amount of clinical data for validation 
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Academic Tutor, Spring 2007- Spring 2009 
Led individual and group teaching sessions for Engineering Statics 
Held weekly appointments tutoring Math and Physics at the Campus Learning Center 
Math – Algebra, Pre-Calculus, Calculus, Differential Equations 
Physics –University Physics I and II, Modern Physics  
 
SERVICE 
 
Engineering Ministries International Internship, 2008. –Danja, Niger 
Assisted with survey and design of surgical clinic in Niger 
Drafted design report in Calgary, Canada 
 
Makunda Christian Hospital Mission Trip, 2013. –Assam, India 
Assessed design of structural components of operating theater  
Surveyed and mapped the boundaries of the land. 
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Engineers Without Borders Assessment Trip, 2011. –Virginia, USA 
Provided consult to director of Allegheny Mountain School 
Designed composting latrine 
Investigated water quality at source and possible contamination site 
 
Participation in Hiring committee for new faculty, 2013 – Virginia, USA 
VCU Mechanical and Nuclear Engineering - Supathorn Phongikaroon 
 
Peer reviewer for “Respiratory Care”, 2015. –Virginia, USA 
Science journal with impact factor 1.84 
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PROFESSIONAL SOCIETIES 
American Society of Engineering Education (ASEE) 
American Association for the Advancement of Science (AAAS) 
American Society of Mechanical Engineers (ASME) 
Engineers without Borders (EWB) 
Phi Kappa Phi Honor Society 
 
HONORS AND AWARDS 
 School of Engineering Phi Kappa Phi Scholarship 2014- 2015 
 Graduate Assistance in Areas of National Need (GAANN) Fellowship, 2010 – 2013 
 “Important Contributions to the Internationalization of the University Community”, 
VCU Global Education Office 2011 
 Scholarship for Graduate and Professional Students, VCU Business Services 2010 
 VCU School of Engineering, Excellence in Design Senior Design Expo, 2009 
 VCU University Honors Summers Undergraduate Research Program, Holbrook, L. 
“Development of a respiratory tract model from the female visible human data set,” 
Summer 2007. 
 Rocheleau Scholarship 2008-2009 
 Sandgren Scholarship 2008-2009 
 Carl Burlock Scholarship 2005-2008 
 Electro Technologies Scholarship 2005-2008 
